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“When I was a boy of fourteen, my father was so ignorant I could hardly stand 
to have the old man around. But when I got to be twenty-one, I was astonished 
at how much the old man had learned in seven years.” 
Ambiguous source 
 
 
 
 
 
“知之为知之 不知为不知 是知也.” 
“Sei dir bewusst, was du weißt. Was du hingegen nicht weißt, das gib zu.  
Das ist das richtige Verhältnis zum Wissen.” 
Konfuzius (551 v. Chr. – 479 v. Chr.) 
 
 
 
 
 
 
“As you think, so shall you become.” 
Bruce Lee (1940 – 1973) 
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Abstract 
The aim of this thesis was to investigate the applicability of the human liver cell line HepaRG in 
toxicological long-term studies. For this purpose, cells were 1) characterized on metabolic level 
2) optimized for long-term cultivation and 3) applied in relevant scenarios. 
Metabolic characterization allows for comprehensive and meaningful phenotyping of cells. The 
HepaRG cell line was characterized in an untreated state, as well as upon treatment with drugs. 
Several commonalities with primary reference cells supported application of the cells in further 
toxicological studies. Next, optimization of HepaRG cells was investigated, using three-dimensional 
cultivation systems and adapting the composition of the culture medium. Increased activities in pivotal 
parameters and a 30-day duration were ensured with the tested approaches. In two concluding and 
comprehensive long-term studies, the potential hazard of drugs upon oral administration was 
estimated, and effects of drugs on the different cellular layers were assessed. The latter allowed for a 
holistic view and deep understanding of processes underlying drug-induced toxicity. Taken together, 
in this thesis, important steps and generally applicable techniques were illustrated that may help in 
reducing the number of animal testing in toxicological studies. 
Zusammenfassung 
Das Ziel der vorliegenden Arbeit bestand darin die Anwendbarkeit der humanen Leberzelllinie 
HepaRG in toxikologischen Langzeitstudien zu untersuchen. Für diesen Zweck wurden die Zellen 
1) auf metabolischer Ebene charakterisiert 2) für die Langzeitkultivierung optimiert und 3) in 
praxisrelevanten Studien eingesetzt. 
Die metabolische Charakterisierung erlaubt eine aussagekräftige Phänotypisierung von Zellen. Die 
HepaRG Zellen wurden hierfür sowohl unbehandelt, als auch unter Zugabe von Medikamenten 
untersucht. Zahlreiche Gemeinsamkeiten zu primären Referenzzellen unterstützten die Verwendung in 
weiteren toxikologischen Studien. Daraufhin wurde untersucht, inwieweit sich die Eigenschaften von 
HepaRG Zellen in 3D-Kultivierungssystemen und durch Anpassungen des Kulturmediums optimieren 
lassen. Mit den getesteten Verfahren konnten erhöhte Aktivitäten in zentralen Parametern sowie eine 
30-tägige Studiendauer erzielt werden. In zwei abschließenden Langzeitstudien wurde die 
Gefährlichkeit von Medikamenten bei oraler Applikation abgeschätzt, und die Auswirkungen von 
Medikamenten auf den verschiedenen zellulären Ebenen untersucht. Letzteres ermöglichte eine 
ganzheitliche Abbildung und damit ein tiefgreifendes Verständnis der Prozesse die 
wirkstoffinduzierten toxischen Effekten zugrunde liegen. Insgesamt konnten in dieser Arbeit wichtige 
Schritte und generell anwendbare Techniken aufgezeigt werden, die mittelfristig zu einer Reduktion 
von Tierversuchen in Toxizitätsstudien führen können. 
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Chapter 1 General introduction 
1.1 Drug development and the problem of drug discontinuation 
Between 6 to 13% of all hospital admissions are related to adverse drug effects (Alexopoulou et al., 
2008; Brvar et al., 2009; Pirmohamed et al., 2004) and even though in the past only 2.3% of these 
cases were lethal, the resulting costs are tremendous (Pirmohamed et al., 2004). Even more, further 
economic loss is caused by adverse drug reactions occurring while patients are treated in hospitals, 
resulting in prolongation of hospitalization (Bates et al., 1997; Classen, 1997; Moura et al., 2009). 
Assessment of drug safety is an essential part of drug development in pharmaceutical companies to 
ensure a reasonable risk-benefit ratio. Safety assessment spans over the whole lifetime of a drug, 
starting with drug discovery and continuing in the preclinical, clinical and post-marketing phase. To 
understand why adverse drug effects still account for such a striking number of hospital admissions, 
the safety assessment process is critically examined in the following. 
1.1.1 Overview on the drug development process 
In the preclinical phase, drug candidates are tested for their therapeutic efficacy, as well as for their 
toxicological potential upon single and repeated dosing. Furthermore, the kinetics of the candidates are 
investigated, i.e. their absorption, distribution, metabolism and excretion (ADME) in the body (Dunne 
et al., 2013; Greaves et al., 2004). Additionally, data obtained in the preclinical phase is used to 
estimate a first-in-human dose. Low efficacy, intolerable toxicity and unfavorable ADME properties 
lead to discontinuation of the candidates (Kubinyi, 2003; Vuppala et al., 2013). Many of the 
experiments during the preclinical phase are conducted in animals, yet some parameters are estimated 
using in vitro test systems (figure 1.1) (Greaves et al., 2004). When drug candidates qualify for the 
clinical phase, first studies are performed in humans – initially only in few healthy individuals and 
eventually in several thousand patients in the third phase. Afterwards, promising drug candidates are 
subjected to evaluation and, if successful, approval by the regulating authorities (Dunne et al., 2013). 
1.1.2 Discontinuation of drugs during drug development and beyond 
In the USA, from originally 5,000 to 10,000 compounds in drug discovery only 1 to 2 drugs are 
eventually approved by the Food and Drug Administration (FDA), in a process that takes 10 to 15 
years and costs 0.8 to 2 billion dollars (figure 1.1) (Dunne et al., 2013).  
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Figure 1.1 Overview on the drug development process in the USA. Current drug development procedure 
(adapted from Dunne et al, 2013), highlighting the number of drug candidates in the different phases and the 
type of test systems used. (+) and (-) indicate that tests are either conducted in healthy test subjects or in patients 
with target disease. Subjects highlighted in red are representative for adverse drug effects leading to 
discontinuation of drug development. 
 
One third of failures in drug development result from adverse effects in humans or animals and around 
half the substances lack efficacy (Kubinyi, 2003) (figure 1.2). Cardiovascular and liver toxicity are the 
two main causes for adverse events with 27 and 15% of toxic events encountered respectively 
(Guengerich, 2011). But not all harmful substances are identified before entering the market. In some 
cases, severe adverse events, in particular those related to idiosyncratic drug hepatotoxicity, are not 
detected until the drug is available on the market. According to FDA reports, 32% of drugs withdrawn 
in the post-marketing phase were related to a hepatotoxic potential (Stevens and Baker, 2009). This 
not only causes unnecessary suffering of patients, but subsequent withdrawal of drugs additionally 
results in tremendous financial losses for the releasing companies. As each phase of the drug 
development involves expensive tools and manpower, early detection of toxicity is highly desired to 
avoid unnecessary expenses on hazardous compounds. 
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Figure 1.2 Reasons for drug candidate failure in drug development. Data is based on 121 new chemical 
entities taken from large UK companies between 1964 and 1985. Anti-infectives were excluded due to generally 
poor bioavailability. Redrawn from Kubinyi, 2003. 
 
Reasons for late identification of hazardous properties of drug candidates will be discussed in the 
following paragraphs. 
Idiosyncratic drug-induced liver injury 
Despite its relevance in drug development, idiosyncratic drug-induced liver injury (iDILI) remains 
poorly understood. Per definition, iDILI only occurs in few individuals in a population, for which it is 
usually only discovered in large populations, resulting in being the most frequent cause of post-
marketing warnings and withdrawals. It is generally suggested that formation of reactive metabolites 
resulting from bioactivation in the liver and the adaptive immune system may have major contribution 
to the development of iDILI (Gómez-Lechón et al., 2015; Kaplowitz, 2005). 
Animal experiments in drug development 
Additionally, almost all attempts to show idiosyncratic toxicity in animal models were doomed to 
failure. Yet, poor correlation of animal experiments to humans is not limited to iDILI, but is a general 
problem in toxicity assessment. Extensive reviewing of pharmacological studies has shown that 
sensitivity for the identification of toxic compounds during the preclinical phase is around 70% using 
a combination of rodent and non-rodent animal species. Looking at the prediction potential of the 
species individually, sensitivity is reduced to 43 and 63% respectively (Olson et al., 2000). 
Apart from the low potential of reliably predicting human-relevant toxicity (Blaauboer and Andersen, 
2007), and the ethical issue, which is inherent to experiments conducted in animals, animal studies are 
notably more costly, time consuming and throughput is low compared to in vitro studies (Shukla et al., 
2010; Xia et al., 2008). 
But what are the causes leading to poor animal/human concordance in toxicity studies? Firstly, 
animals and humans differ in cytochrome P450 (CYP450) enzyme concentrations, substrate specificity 
and the potential of the CYP450 enzymes for being induced or inhibited. The CYP450 superfamily 
contains a large set of enzymes responsible for metabolization of xenobiotics and endogenous 
molecules, making the substances more hydrophilic and facilitating their secretion (Martignoni et al., 
2006). Therefore, the CYP450 superfamily plays a central role in detoxification and sometimes also 
Lack of efficacy
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Animal toxicity
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bioactivation of drugs. Secondly, concentrations of endogenous metabolites may differ drastically 
between species. For example, bile salt composition in humans and rats differ substantially from one 
another and as a result, only in humans toxicity elicited by the cholestasis-inducing compound 
bosentan is observed (Fattinger et al., 2001; Setchell et al., 1997). Thirdly, while animals used in these 
studies are healthy and handled under uniform conditions, e.g. in terms of housing and nutrition, the 
opposite is the case in humans (Olson et al., 2000). 
Duration of studies and repeated dosing  
Another aspect to consider is that it may take several weeks of treatment before manifestation of drug-
induced injuries. Olson et al. reviewed that 94% of toxicity occurs within the first month; 
consequently 6% of adverse events develop not before at least one month of treatment. The time 
before manifestation also depends on the type of toxicity observed. E.g. in case of liver, toxicity was 
not observed after single doses, but always required repeated dosing (Olson et al., 2000). As a 
conclusion, it is obligatory to include repeated dosing and ensure sufficiently long experiments in the 
study design. 
 
1.2 The human liver and its central role in the body 
1.2.1 General liver functions 
The liver plays a unique role within the human body in terms of metabolization of endogenous and 
exogenous metabolites, as well as regulation of metabolism. It is responsible for formation, 
degradation and storage of several endogenous metabolites, thereby maintaining homeostatic 
conditions in the system. One example is the storage of glucose as glycogen in the liver after a meal, 
and the process of glycogenolysis in fasting conditions to keep up constant glucose levels in blood and 
cells (figure 1.3). Another example is the synthesis of cholesterol. The liver is the main site of 
cholesterol synthesis, a molecule which is an integral part of all membranes in mammalian cells and 
precursor of steroid hormones, oxysterols and bile acids, central regulators of a multitude of essential 
functions in the human body. Bile acids recently moved back into focus of current research as they 
have been associated with various diseases such as Alzheimer’s disease and diabetes (Quinn et al., 
2014; Ramalho et al., 2008; Thomas et al., 2008) as well as due to the discovery of novel functions. 
Like their precursors, the majority of bile acids are synthesized in the liver from where they are 
transported into the gall bladder, which releases them when required. Historically, bile acids were 
described as mere solubilizing molecules, which aid in the digestion of lipid-rich diets. However, it 
was shown in recent studies that bile acids also act as hormones via the farnesoid X receptor (FXR) 
and G-protein coupled bile acid receptor 1 (GPBAR1, TGR5) (Makishima et al., 1999; Parks et al., 
1999), exhibiting regulatory functions on cholesterol, glucose and triacylglyceride metabolism as well 
as on energy homeostasis and inflammation (Lefebvre et al., 2009; Staels and Fonseca, 2009). 
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Figure 1.3 Metabolic functions of the liver. Nutrients and xenobiotics that are resorbed from the stomach and 
small intestine enter the liver via the blood stream. In the liver, nutrients and xenobiotics may undergo 
metabolization; such as postprandial glucose, which is stored inside the cells as glycogen and used when 
nutrients are limited (orange = pathway of gluconeogenesis, glycogenesis and glycogenolysis). Xenobiotics can 
be subject to phase I and phase II metabolism (green), which generally facilitates excretion of lipophilic 
compounds. Furthermore, the liver produces oxysterols and bile acids from cholesterol (blue). Bile acids are 
stored in the gallbladder and aid the digestion of lipophilic compounds. Lipoproteins (LP) are produced by the 
liver for transport of cholesterol and other lipids from and to the liver. 
 
Even more, through production and secretion of lipoproteins of different density and the transport 
protein albumin, the liver is also involved in the transport of cholesterol and other lipids to different 
parts of the body and back to the liver (Nelson and Cox, 2008). 
1.2.2 Metabolization of xenobiotics 
The central role of the liver is further strengthened by the fact that stomach and intestine are connected 
to the blood stream via the hepatic portal vein which collects and transports blood to the liver before it 
is further distributed to the rest of the body (Abdel-Misih and Bloomston, 2010). I.e., nutrients from a 
meal and xenobiotics, resorbed in the stomach or intestine, first pass through the liver and may 
undergo metabolization, prior of being supplied to other organs. In case of drugs, this effect is called 
first-pass effect and depending on the compound may greatly reduce the amount of active drug 
reaching the organ of interest. Therefore, parenteral drug application is inevitable for certain 
compounds (Pond and Tozer, 1984). On the other hand, in case of so called prodrugs, the desired, 
pharmacologically active compound only emerges after the parent compound underwent 
metabolization (Grant, 1991). It is also worth mentioning that oral administration is not a prerequisite 
for metabolization in the liver, but compounds applied to the skin, e.g. cosmetics, or drugs that are 
administered intravenously eventually reach the liver via the blood stream (Sandanger et al., 2011). 
Therefore, not only orally administered compounds, but basically all compounds that man is exposed 
to, require investigation of potential toxicity upon metabolization in liver. 
Chapter 1          General introduction 
14 
 
The liver, more precisely the parenchymal cells or hepatocytes are the main site of drug metabolism, 
however, other organs such as kidney and lungs also contribute (Lu and Kacew, 2002). Drug 
metabolism can be divided into different phases. Uptake of the compound into the cells sometimes is 
referred to as phase 0. Depending on the compound, uptake may occur either via passive diffusion or 
active transport – or both ways (Sugano et al., 2010). In phase I, non-polar and hydrophobic 
xenobiotics are modified by introduction of a polar group, most commonly in an oxidation reaction 
catalyzed by the CYP450 enzyme superfamily. Other modifications include reduction or hydrolysis of 
the compound. In phase II, xenobiotics are conjugated with hydrophilic molecules, such as sulfate, 
glucuronic acid or glutathione at the site where the first modification was introduced. The resulting 
molecules are more hydrophilic and excretion via the renal pathway is facilitated (Grant, 1991). 
Before xenobiotics can be excreted via urine, they first need to be secreted from the liver cells into the 
blood, also referred to as phase III of drug metabolism. Excretion from the liver cells is mainly 
dependent on two protein families, multidrug resistance-related proteins (MRP) and multidrug 
resistance proteins (MDR), both are members of ATP-binding cassette (ABC) transporters (Borst et 
al., 2000; Ferreira et al., 2015). 
In many cases, drugs affect the cells such that their own metabolization, as well as metabolization of 
other compounds are either induced or repressed. This phenomenon is referred to as drug-drug 
interaction and is of high relevance when two or more drugs are applied in combination. These 
alterations can have unforeseeable consequences and may lead to detrimental responses, e.g. caused by 
increased production of reactive metabolites or impaired inactivation of the pharmacologically active 
drug. Due to its central role in clearance and metabolization of drugs, the liver is a particular target for 
drug-induced toxicity and it becomes evident that the liver has to be in the focus of toxicological and 
pharmacological testing (Kaplowitz, 2004; Soldatow et al., 2013). 
 
1.3 Drug-induced liver injury 
Given the multiple central functions of the liver, it is not surprising that imbalances in its regulation 
may result in severe and even fatal conditions. In the following, selected mechanisms will be 
discussed, by which drugs induce such imbalances and thereby exert toxic effects. 
For further discussion, the term toxicity, though it may seem clear at first glance, will be briefly 
reflected. Already in the 16
th
 century, Philippus Theophrastus Aureolus Bombastus von Hohenheim, 
also known as Paracelsus, stated that all substances were toxic and nothing was without toxicity, and 
only the dose would determine that a substance was not toxic (Borzelleca, 2000). Therefore, toxicity 
quantitatively describes the potency of a compound to exert harmful effects, but also the mechanism 
by which adverse events are triggered. As a consequence, no-observed-adverse-effect levels 
(NOAELs) or similar margins are commonly defined for each substance tested in the context of 
toxicology (Liebler and Guengerich, 2005). 
1.3.1 Mechanisms of drug-induced toxicity 
Drugs and drug metabolites binding to their target receptor may not only elicit the intended responses, 
but in some instances can be accompanied by a weak toxic reaction that only becomes evident upon 
overdosing or accumulation of the drug during repeated dosing (on-target or mechanism-based 
toxicity) (figure 1.4). For other drugs, binding properties may be insufficiently specific and binding to 
another then the intended target can lead to adverse events (off-target toxicity). The third mechanism 
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is based on the covalent-binding theory, which states that reactive metabolites formed during 
metabolization in the liver eventually impair cellular functions (Liebler and Guengerich, 2005). 
These three initial events of adverse reactions are commonly associated with oxidative stress, 
mitochondrial dysfunction and endoplasmic reticulum (ER) stress as downstream effects (Foufelle and 
Fromenty, 2016). Oxidative stress is characterized by an imbalance in the formation of reactive 
oxygen species (ROS) and antioxidant defenses (Betteridge, 2000). As a result, ROS prevail and 
extensively form adducts with DNA and proteins, and produce lipoperoxides, such as 4-
hydroxynonenal (HNE). HNE is considered a second messenger of oxidative stress and has been 
associated with the induction of apoptosis upon accumulation (Barrera, 2012). The mechanisms by 
which ROS cause cell damage are manifold and not yet fully elucidated. ROS binding to proteins may 
on the one side impair the function of important regulatory proteins, disturbing normal cell function 
and eventually causing necrotic or apoptotic cell death. Another theory is that binding of reactive 
species to proteins leads to formation of neoantigens, structures foreign to the body, with the potential 
of activating the immune system and triggering a cytotoxic immune response. When reacting with 
DNA, ROS may cause mutations in the DNA sequence, leading to carcinogenesis and genotoxicity 
(Gómez-Lechón et al., 2015; Guengerich, 2011). 
Oxidative stress can be the source as well as one of the outcomes of mitochondrial dysfunction. 
Mitochondrial dysfunction is a collective term and comprises damage of mitochondrial components as 
well as changes in metabolic pathways related to mitochondria. Potential consequences of 
mitochondrial dysfunction comprise oxidative stress, energy shortage, accumulation of 
triacylglycerides, cell death as well as ER stress (Begriche et al., 2011). Lastly, ER stress describes a 
cellular state in which mis- or unfolded proteins accumulate within the cell, triggering the so called 
unfolded protein response (UPR). The UPR initiates processes to remove incorrectly folded proteins to 
reestablish fully functional folding. When a cell fails to restore normal conditions, pathways for 
programmed cell death are triggered (Sano and Reed, 2013). 
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Figure 1.4 Scheme of mechanisms in drug-induced toxicity. In an ideal scenario, drugs or its metabolites 
(light grey boxes) bind selectively to the desired receptor and fulfil their purpose, while phase I and II enzymes 
lead to their inactivation over time (receptors and enzymes highlighted as green boxes). However, in case of 
overdose or drug accumulation, binding to the receptor may lead to a detrimental response. Alternatively, the 
parent compound or the metabolites may also bind to other receptors, which may likewise result in adverse 
effects. As a third mechanism, reactive metabolites may directly bind to DNA or proteins and cause cellular 
damage, or indirectly cause cellular damage by triggering oxidative stress. Oxidative stress, together with 
endoplasmic reticulum (ER) stress and mitochondrial dysfunction, are central events in the majority of drug-
induced liver injuries (red boxes). Affected molecules and adverse outcomes are highlighted in dark grey and 
blue respectively. ROS = Reactive oxygen species. The figure is based on Liebler and Guengerich 2005 and 
Gómez-Lechón 2015. 
 
Finally, there is iDILI, for which mechanisms leading to toxicity remain to be elucidated. According to 
current hypotheses, mechanisms in many cases are identical to those mentioned above, but only occur 
in few individuals due to the presence of one or more additional risk factors like inflammatory stress 
or genetic variability in the human leukocyte antigens (HLA), CYP450 enzymes or other proteins 
involved in drug biokinetics (figure 1.5) (Gómez-Lechón et al., 2015). The rare occurrence of 
detrimental mutations in these genes may explain the low incidence of iDILI of around 10
-4
 to 10
-5
 
(Gómez-Lechón et al., 2015; Vinken, 2015). 
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Figure 1.5 Scheme of response in idiosyncratic toxicity. Under normal conditions, application of a drug at its 
recommended dose does not evoke severe adverse reactions, if any at all. In a normal situation, response to the 
drug varies slightly between individuals, but remains in a safe range. In rare occasions, the dose response curve 
is shifted towards notably lower concentrations, eliciting toxicity at the recommended dose. 
 
1.3.2 Patterns of drug-induced liver injury 
While the mechanisms of drug-induced toxicity described above take place on molecular and cellular 
level, prolonged duration eventually affects organs and finally the whole organism, with several 
different outcomes depending on the initial perturbation. The 5 most common patterns of DILI are 
acute and chronic hepatitis, as well as acute and chronic cholestasis and a combination of the two 
patterns, cholestatic hepatitis. In total, these patterns make up for around 83% of observed DILI cases 
(Kleiner, 2014). Drug-induced hepatitis is characterized by the infiltration of inflammatory cells into 
the tissue together with the occurrence of hepatocellular necrosis (figure 1.6). The term cholestasis on 
the other hand describes the accumulation of bile acids within the liver due to intra- or extrahepatic 
obstruction of bile flow from the liver to the gall bladder. Beyond a certain threshold, bile acid 
accumulation leads to toxic reactions as a result of their detergent nature. 
Another important pattern of DILI is the aberrant retention of lipids within hepatocytes, in particular 
triacylglycerides either in the form of small or large lipid droplets, referred to as micro- or 
macrovesicular steatosis respectively (Vinken, 2015). Steatosis results from mitochondrial 
dysfunction, leading to intrahepatic accumulation of fatty acids, which are partially converted into 
triacylglycerides to avoid toxicity caused by free fatty acids (Listenberger et al., 2003). Traditionally, 
steatosis is considered as the first step in the spectrum of the non-alcoholic fatty liver disease 
(NAFLD) and goes along with reversible enlargement of liver volume. In more severe cases of 
NAFLD, steatosis is accompanied by inflammation of the liver, an indication referred to as non-
alcoholic steatohepatitis (NASH). Further progression of NAFLD causes fibrosis, i.e. scarring of the 
tissue and eventually hardening of the liver and permanent liver damage, called cirrhosis. In rare cases, 
drugs cause development of hepatocellular carcinoma (HCC) as the final stage of the NAFLD 
spectrum (Farrell and Larter, 2005; Yilmaz, 2012). However, fibrosis, cirrhosis and HCC not only 
occur in the context of NAFLD, but also as a result of other patterns, such as cholestasis (Bataller and 
Brenner, 2005). 
Steatosis is a frequent disease in the general population (Browning et al., 2004), yet it is the 
predominant pattern in DILI in less than 2% of cases. However, it was also observed that around 
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27% of DILI showed at least some degree of steatosis (Kleiner et al., 2014; Rabinowich and Shibolet, 
2015). 
 
 
Figure 1.6 Patterns of drug-induced liver injury (DILI). The most relevant DILI patterns and progression 
towards severe liver damage including the characteristics of each step. NASH = Non-alcoholic steatohepatitis. 
HCC = Hepatocellular carcinoma. 
 
Acute hepatic necrosis is yet another type of DILI pattern, which is usually caused by direct 
hepatotoxins such as acetaminophen. 
In most of the cases of DILI, injuries eventually resolve completely. However, rare complications may 
occur during which the injury progresses towards acute liver failure, cirrhosis or ductopenia, i.e. the 
gradual loss of bile ducts. Due to their severity, these rare complications may be lethal and require 
liver transplantation (www.livertox.nih.gov, accessed 2016-03-26).(NIH, n.d.) 
 
1.4 Test systems for the study of hepatotoxicity 
1.4.1 Traditional test systems in in vitro toxicity assessment 
For the study of liver functions and effects of compounds on these liver functions, several different 
test systems are available, ranging from simple enzyme expression systems and co-cultures of 
mammalian cells to xenograft animal models and eventually humans themselves. Depending on the 
question that is raised, simpler systems are sufficient or more complex systems may be required.  
For the screening of drug- and chemical-induced hepatotoxicity and investigations on the underlying 
mechanisms, subcellular fractions, cell lines, primary hepatocytes, liver slices and perfused organs are 
the most commonly used in vitro systems (Guillouzo, 1998), with transgenic cell lines and stem cells 
slowly emerging into the field. These studies are traditionally complemented by in vivo experiments 
conducted in animals and ultimately, experiments directly conducted in humans during the clinical 
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phases. A summary of the different test systems used in toxicity assessment is given in table 1.1, 
highlighting their advantages and disadvantages. 
Table 1.1 Overview on the different test systems for assessment of hepatotoxicity. The different test systems 
used in toxicity assessment are listed according to their complexity. Their characteristics are graded from non-
existing (-) to optimal (+++). PHH = primary human hepatocytes; iPSC = induced pluripotent stem cells; hESC 
= human embryonic stem cells. Table was adapted from literature and expanded (Brandon et al., 2003; Fasinu et 
al., 2012). 
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Subcellular fractions 
Subcellular fractions are the simplest systems applied in the study of hepatotoxicity. Different types of 
fractions are available, including recombinant enzymes, cytosolic fractions, microsomes and S9 
fractions. Recombinant enzymes are used to study the activity of single enzymes related to the 
metabolization or transport of a given drug. Enzymes can be recombinantly expressed in transgenic 
cell lines, bacteria, yeast or insect cells. Depending on the system, this technique allows isozyme-
specific drug biotransformation studies (Brandon et al., 2003). The cytosolic fraction only contains 
soluble phase II enzymes and is rarely used in drug biotransformation studies (Brandon et al., 2003). 
Liver microsomes on the other hand consist of ER vesicles and therefore are suitable to study drug 
metabolism via CYP450 enzymes and uridine diphosphoglucuronosyl transferases (UGT) in the 
context of drug metabolite profiling and for the comparison of metabolic activity in different groups, 
such as different species or effects based on the gender (Fasinu et al., 2012). S9 fractions combine 
cytosolic and microsomal fractions and allow assessing both, phase I and phase II metabolism of 
compounds. Compared to the cytosolic and microsomal fractions, enzyme levels are lower and 
consequently overall activity is lower. This may result in certain metabolic products being 
underrepresented and not being quantifiable or even detectable (Brandon et al., 2003). 
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Subcellular fractions are well established, affordable and easily applicable. Fractions from different 
origin are commonly pooled to overcome interindividual differences and increase reproducibility. 
Studying fractions originating from different individuals separately on the other hand offers the 
possibility to investigate differences in the xenobiotic metabolism within a population (Brandon et al., 
2003). 
Unlike whole cells, subcellular fractions do not possess all required cofactors and cofactor-
regenerating systems necessary to perform all phase I and II reactions, even in case the enzymes are 
present. Thus, missing cofactors and enzymes need to be supplied depending on the reactions of 
interest, such as adenosine-3’-phosphate 5’-phosphosulfate (PAPS) in case of sulfotransferases 
(Fasinu et al., 2012). The limited set of reactions and the artificial conditions in these systems, e.g. the 
absence of drug transport, prevent a holistic and representative image of a drug’s metabolism and lead 
to a poor correlation with in vivo (Brandon et al., 2003). 
Hepatic cell lines 
With cell lines, the complexity of the investigated systems increases notably. Several different human 
tumor-derived hepatic cell lines are used in toxicity studies. At least theoretically, cell lines are 
capable to conduct the complete set of drug metabolizing reactions as well as to provide all required 
non-essential cofactors. Most of them however lack a reasonable expression of major liver specific 
molecules, such as the CYP450 enzymes, phase II enzymes, membrane transporters and nuclear 
receptors. This also applies to the most widely used human hepatoma cell line, the HepG2 cell line 
(Donato et al., 2013; Soldatow et al., 2013). The HepG2 cell line was first established in 1979 by 
Barbara Knowles. It was derived from a male patient suffering from a hepatoblastoma (López-Terrada 
et al., 2009). Despite its shortcomings, the cell line may still yield accurate results when investigating 
parent compound toxicity or resistance to chemotherapy (Mueller et al., 2013; Niklas et al., 2009; Ong 
et al., 2008). 
Another promising human hepatic cell line was established in 2002, where it was isolated from a 
female patient with hepatocarcinoma and hepatitis C infection (Gripon et al., 2002). Unlike other 
hepatic cell lines, the so called HepaRG cell line expresses liver specific enzymes in an amount that is 
comparable to that of primary human hepatocytes (PHH) (Lübberstedt et al., 2011). Furthermore, it is 
amenable to prolonged cultivation, while maintaining a differentiated state for several weeks (Josse et 
al., 2008). Contrary to other hepatic cell lines, it consists of two different cell types; hepatocyte-like 
(HLC) and biliary epithelial-like cells (BLC) (Cerec et al., 2007). 
Hepatic cell lines generally allow well reproducible results, but on the other hand, they are not capable 
of representing a large population as each of the cell lines only has a single genotype (Soldatow et al., 
2013). In this context, it is worth noting that polymorphisms, e.g. in the CYP450 enzymes may have a 
major impact on the fate of therapeutic compounds (Zhou et al., 2009). Contrary to subcellular 
fractions, cell lines allow induction studies, which necessitate functional transcription and translation 
of genes involved in drug metabolism (Castell et al., 2006). 
Primary hepatocytes 
The introduction of the collagenase perfusion method for isolation of hepatocytes from liver tissue 
paved way for the broad use of primary hepatocytes (Guillouzo, 1998; Howard et al., 1967). PHH are 
considered the gold standard in the assessment of hepatotoxicity as expression of liver specific 
enzymes is close to humans in vivo. Contrary to cell lines and primary rodent hepatocytes, the 
diversity of their origin yields a good representation of the human population and enables to assess 
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effects of genetic variation to a toxic response. This however goes along with sometimes poor 
reproducibility of results. Since the development of techniques for cryopreservation of hepatocytes 
(Diener et al., 1993), availability of PHH greatly improved. Still, PHH are often freshly isolated and 
used either in adherent cultures or in suspension. Compared to hepatic cell lines, cultivation of PHH 
generally requires more complex techniques to avoid dedifferentiation and maintain liver specific 
functions (Brandon et al., 2003). Under standard cultivation conditions, PHH retain liver specific 
activities for around 24 to 72 h (Godoy et al., 2009), and after 1 week, around 50% of the initial 
CYP450 amount still remains. The upkeep of functionality in PHH was found to be substantially 
better, compared to rodent-derived hepatocytes (Guillouzo, 1998; Guillouzo et al., 1985). With special 
media, viability and functionality of PHH can even be extended to several weeks (Mueller et al., 
2012). 
Liver slices 
Liver slices resemble the in vivo situation even closer. They retain liver structure including periportal 
and pericentral zone specificity and functional bile canaliculi. Furthermore, they include all different 
cell types present in the liver. Studies involving liver slices usually run between few minutes and up to 
120 h. Comparable with the previously mentioned systems, upkeep of liver functionality and viability 
is strictly limited. After 6 h to 72 h, CYP450 enzyme levels decrease quickly and cellular necrosis 
occurs after 48 h to 72 h (Soldatow et al., 2013), though in some studies viability was maintained until 
96 h (Klassen et al., 2008). 
Liver slices are usually prepared from animal liver, but can also be prepared from human liver, e.g. 
from liver biopsies. Standard slices have a thickness of approximately 250 µm (Guillouzo, 1998). Due 
to the dimensions, nutrient supply and exposure to xenobiotics is limited to a large extent to diffusion 
and gradients build up across the slices. Liver slices provide a good correlation to in vivo (Soldatow et 
al., 2013) and allow reducing the number of animals needed for an experiment as several slices can be 
prepared from a single animal. 
Isolated perfused liver 
Isolated perfused livers are the most complex in vitro tool for toxicity assessment and it is also the 
system closest to the in vivo situation. Its 3D architecture is preserved, including cell-cell contacts and 
intact bile canaliculi. Unlike for liver slices, not to mention more basic systems, bile can be collected 
and studied separately (Guillouzo, 1998). Despite its close resemblance to in vivo, the drawbacks of 
the system are overwhelming. The system is generally difficult to handle and only allows studies for 
few hours after which functional integrity is compromised. The complexity of the system brings along 
low throughput and limited reproducibility (Fasinu et al., 2012). Animals are the only source of 
perfused livers. From an ethical point of view, perfused livers do not harbor many advantages as each 
animal only yields a single liver (Brandon et al., 2003). 
In summary, it is evident that the main advantage of more complex systems is the increased 
correlation to in vivo, while forfeiting throughput, technical simplicity, commercial availability, 
reproducibility and ethical acceptance. Thus, at least at the moment, the decision on one of the systems 
is always a compromise between these two sides. 
1.4.2 Novel strategies and tools in toxicity assessment 
To date, one of the biggest needs in toxicology is for methods to assess repeated dose toxicity in a 
human-relevant context. As in vitro systems either lack stable viability and functionality or human in 
vivo correlation, hopes rest on the improvement of current techniques or development of new 
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techniques, combining the advantages of both sides without hampering the one or the other. The 
ultimate goal is to provide a validated system that yields reliable data for prediction of adverse effects 
in humans (Soldatow et al., 2013). 
The loss of functionality and induction of cell death that is observed during cultivation of primary 
hepatocytes, and to some extent in cell lines, is attributed to A) two-dimensional (2D) cultivation of 
cells, B) processes triggered during isolation and C) exogenous soluble factors (Guguen-Guillouzo, 
2002; Guillouzo, 1998; Guillouzo et al., 1990) 
Different strategies that have been applied to tackle these problems will be described in the following 
(figure 1.7). 
 
 
Figure 1.7 Summary on options available for improving in vitro cultivation. The approaches used to improve 
in vitro cultivations in order to allow them a more in vivo-like behavior were divided into three groups: 1) 
developing and introducing new cells, 2) optimizing cellular environment and 3) optimizing nutritional 
environment. The approaches can be used as a stand-alone version, but are readily combined in many studies for 
further improvement. 
 
2D versus 3D cultivation 
The first strategy aims at reestablishing an in vivo-like cellular morphology by cultivating cells in an 
environment that allows their three-dimensional (3D) spreading (3D cultivation). The idea to cultivate 
cells in a 3D environment has already been applied several decades ago, e.g. in producing spheroids of 
Chinese hamster V79 cells to develop an in vitro tumor model for investigation of effects of radiation 
(Sutherland et al., 1970). Differences between 2D and 3D cultivation are manifold. Baker and Chen 
summarized the dissimilarities that cells have to cope with in the traditional but artificial environment 
of a 2D cultivation, compared to 3D cultivation. Their main cues are depicted in figure 1.8. A major 
difference between cells in a 2D and 3D environment is their morphology. Cells in 2D monolayer 
cultures are flat and elongated and can freely spread on the surface they are growing on. Hepatocytes 
in vivo on the other hand have a cuboidal shape and their spreading is limited sterically. Also, in vivo, 
hepatocytes are mostly surrounded by other cells, whereas in 2D cultures, cells are almost exclusively 
in contact to the medium and the culture device. This has several implications. E.g., cellular nutrient or 
xenobiotic gradients are absent within 2D cultures. Furthermore, in a 2D environment adhesion is 
restricted to the surface of the culture device and therefore apical-basal polarity is forced upon the 
cells, whereas polarity is not prescribed in a 3D environment (Baker and Chen, 2012). This is 
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particularly of concern for hepatocytes, which have a special type of polarity. Unlike other epithelial 
cells, hepatocytes possess two basolateral surfaces as well as apical surfaces, which are connected to 
the lumen of bile canaliculi (Dunn et al., 1989). 
 
Figure 1.8 Differential factors in cell cultures in 2D and 3D environment influencing cellular behavior. A 
summary of the adhesive, topographical, mechanical and soluble factors that potentially determine cellular 
behavior in the two different cultivation setups. The figure was adapted from Baker and Chen, 2012. 
 
3D cultivation systems 
A variety of different systems for 3D cultivation is commercially available. Spheroid cultures for 
example are a scaffold-free system making use of the self-aggregation of cells upon establishing cell-
cell contacts. There are various ways to form spheroids. Next to shaking cells in spinner flasks as in 
the example mentioned above (Sutherland et al., 1970), spheroids can also be formed in hanging drop 
cultures as well as on non-adhesive surfaces (Chen et al., 2012; Kelm and Fussenegger, 2004). To 
demonstrate the potential of spheroid cultures in toxicity assessment, our group has shown that the 
CYP450 activity as the crucial factor in studying toxicity, was significantly higher in HepaRG 
spheroids compared to 2D cultures (Mueller et al., 2014). Going along with elevated CYP450 activity, 
we were showing significant changes in the EC50 values upon exposure to 4 different compounds 
when HepaRG cells were cultivated as spheroids, compared to conventional 2D cultivation (Mueller et 
al., 2014). 
CSW cultures are another type of 3D cultivation system where cells are embedded in between two 
layers of collagen matrix to favor formation of in vivo-like cellular geometry. Dunn et al. were the first 
to apply this technique to hepatic cells and could show that rat hepatocytes cultivated in a CSW 
retained morphology and albumin secretion for 6 weeks. 2D cultures on the other hand ceased albumin 
secretion completely within a week (Dunn et al., 1989). The CSW technique is applied in studies that 
essentially require in vivo-like polarity, e.g. in transporter studies (Liu et al., 1999), whereas 
application in toxicity studies (Hrach et al., 2011) is less common.  
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Continuous cultivation systems 
More recently, systems have been developed combining 3D cultivation and a continuous media flow, 
mimicking in vivo-like morphology and blood flow. Unlike static cultures, this allows continuous 
supply of nutrients and removal of metabolic waste products resulting from metabolization of endo- 
and exogenous compounds, as well as establishing an extracellular steady state. Flow of medium also 
helps in preventing oxygen limitation, a major concern in 3D cultures (Dash et al., 2009). Realization 
of this principle was shown using different approaches, e.g. in the form of 3D hollow-fiber bioreactors 
(Mueller et al., 2011) and microfluidic hanging drop spheroid cultures (Frey et al., 2014). Cultivating 
PHH in hollow-fiber bioreactors allowed maintenance of the cells and upkeep of hepatic functions for 
at least two weeks, offering great improvement over 2D cultures of PHH (Mueller et al., 2011). Major 
drawbacks of this system are the tremendous amount of cells required (10
8
 PHH per bioreactor) and 
incompatibility with high-throughput approaches. The afore-mentioned microfluidic hanging drop 
cultures are one solution to overcome these problems by reducing the number of cells per organotypic 
culture to around 10
3
 and enabling the study of 16 cultures in parallel (Frey et al., 2014). 
Medium supplements 
In vivo, hepatocytes are not only embedded in an extracellular matrix (ECM) and engaged in cell-cell 
contacts with other hepatocytes, but they are also exposed to a multitude of molecules secreted by 
other cells that may potentially modulate their behavior, including hormones and growth factors 
(Guillouzo, 1998). To account for a lack of these exogenous factors, hepatocyte cultivation media are 
supplemented with various compounds with the goal to maintain and improve hepatic functions and 
longevity. Corticosteroids and insulin are traditional supplements in media for cultivation of 
hepatocytes, yet supplements are not limited to molecules of biological origin, but also include non-
physiologic compounds such as dimethyl sulfoxide (DMSO), one of the most effective supplements to 
maintain hepatocytes in a differentiated state (Guillouzo, 1998; Isom et al., 1985). Optimization of 
media is a classical approach in bioprocessing to improve production yields (Subathra Devi et al., 
2015), but is also applied in other fields of research, such as in the optimization of culture conditions 
for hepatic cell lines and primary hepatocytes (Dong et al., 2008).  
Hepatocyte co-cultures 
Another very effective way to improve maintenance of hepatic functionality in an in vitro setup is the 
co-cultivation of hepatocytes with other cell types, in many cases other liver cells (Begue et al., 1984; 
Krause et al., 2009). In animals, cells and organs fulfill specific functions and only their interactions 
eventually form a fully functional system. Therefore, in vitro models generally represent only a 
fraction of the processes that occur in vivo, which at the same time is the biggest drawback of in vitro 
systems. At least to some extent, co-cultivation allows cell-cell interaction as observed in vivo, 
yielding systems more reliably representing the in vivo situation (Kostadinova et al., 2013). 
Consequently, co-cultivation with primitive biliary cells extended survival of hepatocytes for several 
weeks while maintaining specific hepatic functions (Guguen-Gouillouzo et al., 1983). Superiority of 
the HepaRG cell line, which is an inherent co-culture of HLC and BLC is likely to be partially based 
on the same principles (Aninat et al., 2006). 
In another study investigating the longevity and behavior of co-cultures upon exposure to several 
toxicants, it was shown that co-cultures of PHH with non-parenchymal cells, such as stellate and 
Kupffer cells, maintained liver-specific functions for up to 3 months. Furthermore, these cultures more 
accurately captured in vivo toxicity when exposed to drugs eliciting idiosyncratic toxicity, including 
trovafloxacin. The authors hypothesized that activation of Kupffer or stellate cells results in the release 
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of pro-inflammatory signaling molecules, eventually eliciting a toxic response (Kostadinova et al., 
2013). 
Another focus of current research deals with a more sophisticated version of co-cultivation where the 
different cell types are spatially separated and connected to each other only via channels in a 
microfluidic setup. These multi-organ-chip platforms, also referred to as body-on-a-chip or human-on-
a-chip, allow co-cultivation of cells from different origins, e.g. hepatic, myocardial and skin cells 
combined with a blood stream-like medium flow to study their interactions in an in vivo-like 
environment (Maschmeyer et al., 2015). Several cellular functions and processes can be monitored 
using biosensors (Perestrelo et al., 2015) or simple sample collection and subsequent analysis. The 
body-on-a-chip approach currently is the best available way to close up to animal models in respect to 
their systemic nature. 
Stem cells 
Considered as promising alternatives to hepatic cell lines and primary hepatocytes, stem cells are 
slowly emerging as useful tools in drug development. Induced pluripotent stem cells (iPSC) and 
human embryonic stem cells (hESC) currently attract most attention, even though both systems still 
struggle with teething problems. 
iPSC were originally derived from somatic cells using viral vectors for reprogramming by introduction 
of key transcription factors like OCT3/4 and C-MYC (Ko and Gelb, 2014; Takahashi et al., 2007; 
Takahashi and Yamanaka, 2006). Later on, an approach without the use of viral vectors was developed 
(Okita et al., 2008). While cells are in an embryonic-like state, they can be passaged indefinitely. After 
upscaling, iPSC can be differentiated into a wide range of different cell types, e.g. neurons, 
hepatocytes, cardiomyocytes, and hematopoietic cells (Ko and Gelb, 2014). Since iPSC are derived 
from somatic cells and still possess the genetic background of the individual they originate from, they 
may serve as an indispensable tool in personalized medicine in the future. iPSC can also be used to 
generate cell banks that can be used to study toxicity in a large in vitro population during early drug 
development. Even more, they allow predicting the effect of a compound in patients suffering from 
rare diseases (Knudsen et al., 2015; Ko and Gelb, 2014). One of the hurdles of this approach yet to 
overcome is the inconsistency and low efficacy of current protocols for reprogramming of cells. In 
case of protocols for iPSC differentiation into hepatocytes, populations of different liver cell types and 
different stages of hepatocyte-like maturity have been observed. Consequently, activity of liver 
specific enzymes was reported below activity in PHH (Baxter et al., 2010), and thus, protocols require 
further fine-tuning for the approach to be applied more broadly. 
Sharing many advantages and disadvantages, few things differ between iPSC and hESC. For example, 
hESC are derived from blastocysts (Thomson et al., 1998) and unlike iPSC do not rely on previous 
reprogramming. Due to their origin, hESC are tainted with ethical concerns, which drastically limits 
their use. Furthermore, while iPSC are specific for patients and diseases as stated above, hESC are not 
(Ko and Gelb, 2014). Similar to iPSC, protocols for differentiation yield cell populations with highly 
variable and generally low functionality and additionally, both types of stem cells share one of the 
major disadvantages of primary hepatocytes, which is loss of functionality after few days in culture 
(Soldatow et al., 2013). 
Genetically modified primary hepatocytes 
Another very recent approach is based on the generation of proliferating hepatocytes from PHH by 
introduction of genetic modifications. The goal is to combine advantages of hepatic cell lines, i.e. 
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unlimited availability, easy handling and cost efficiency with the advantages of PHH, i.e. high, in vivo-
like drug metabolizing capacity and the option to study interindividual differences using cells derived 
from different donors. Hepatocytes generated with this method are referred to as upcyte hepatocytes 
(Burkard et al., 2012). In a comparison with PHH and HepG2 cells, upcyte hepatocytes were found to 
be closer to PHH than the HepG2 cell line in terms of their gene expression profile. Furthermore, 
upcytes were shown to be readily applicable in toxicity studies with repeated dose regiment (Tolosa et 
al., 2016). 
Chimeric animal models 
At this point, an approach shall be briefly mentioned that takes another direction, which is the 
humanization of animal models, i.e. the production of chimeric animals. Unlike previously stated 
methods, the goal here is not to reduce the use of animal models, but to make use of the systemic view 
they provide and improving their reliability by introducing human-derived liver cells. For that 
purpose, immunodeficient animals, commonly mice, e.g. TK-NOG mice, undergo hepatectomy and 
human liver cells are transplanted into the animal (Nishimura et al., 2013). Interestingly, in a recent 
study, HepaRG cells have been used as a source of human liver cells (Higuchi et al., 2014). This 
approach generally allows the study of human xenobiotic metabolism in a systemic environment, but it 
also comes along with several disadvantages. One of them is the inherent immunodeficiency of these 
mice, which prevents them from being used in studies that involve immune-mediated adverse drug 
effects. Furthermore, chimeric mice harbor uncertainties in terms of extrahepatic influences and the 
degree of humanization of the biliary tract which is important, e.g. for hepatobiliary clearance 
(Nishimura et al., 2013). Additionally, inter-species differences in telomerase regulation and in 
cytokines put the approach on a shaky foundation (Griffith and Swartz, 2006). 
 
1.5 In silico tools for risk assessment and implementation of in vitro methods 
Considerable progress is made in providing more and more reliable in vitro tools. The question that 
now arises is how these tools can be implemented to assist the assessment of toxicity in a regulatory 
environment. One way these systems can be used is to replace animals in assessing parameters 
required for the evaluation of toxicity of a compound of interest, thereby reducing the number of 
animal tests and yielding results more relevant to the human organism. In another way, in vitro tools 
can be used to gain mechanistic understanding of toxicological processes, which may drastically help 
in prediction of DILI. The steps involved in risk assessment and how the in vitro tools can be 
employed will be discussed in more detail in the following. 
1.5.1 Toxicological risk assessment 
The risk of a substance to cause harmful effects is evaluated in a process called toxicological risk 
assessment, which comprises 4 steps (Kleinjans, 2003; Leeuwen and Vermeire, 2007):  
1. Hazard identification  
Identification of the inherent adverse effects of a substance. 
2. Hazard characterization 
Quantitative relation between dose and incidence and severity of an effect. 
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3. Exposure assessment  
Specification of the population potentially exposed to the compound of interest and 
identification of exposure routes, magnitude and duration.  
4. Risk characterization  
Integration of the three previous steps, i.e. qualitative or quantitative estimation of the 
likelihood that hazards will be realized upon exposure. 
 
In summary, the aim is to characterize the type, magnitude and probability of the hazard for a given 
substance and population (Kleinjans, 2003). The first two steps, hazard identification and 
characterization will be in the focus of the following discussion. 
 
 
Figure 1.9 Overview on in silico tools and the –omics approach for risk assessment. Each tool is represented 
by a comb, and neighboring combs represent a potential interaction between the different tools. E.g., grouping of 
chemicals via quantitative structure-activity relationship can be used to find similar compounds to apply in the 
read-across approach. 
 
1.5.2 Threshold of toxicological concern 
An increasingly popular method applied in risk assessment of unknown substances is to determine the 
threshold of toxicological concern (TTC), i.e. the threshold below which the probability of harmful 
effects to human health is low (figure 1.9). The TTC is based on the distribution of the NOAEL of 
compounds with known toxicity. It further requires structural information on the unknown compound 
and reliable information on human exposure (EFSA, 2014). It is used as a screening method for less 
well-characterized compounds to prioritize toxicity testing (Felter et al., 2009) 
1.5.3 Read-across and structure-activity relationships 
The read-across approach is employed to predict results of an endpoint assay for the substance of 
interest, using one or more biologically or chemically similar compound(s) (source substance(s)) with 
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available endpoint information. Similarities can be of physicochemical nature or based on sharing a 
functional group related to adverse effects, or similarities in metabolization (EFSA, 2014; Low et al., 
2013; Worth et al., 2011). Other in silico tools, such as the quantitative structure-activity relationship 
(QSAR) models can be used to automatically group substances according to predefined criteria, which 
can then be used as source substances for other compounds within the same group to estimate missing 
parameters. QSAR models relate molecular descriptors to biological activities via mathematical 
models. In general, molecular descriptors are the intrinsic physicochemical properties of the 
investigated substance, e.g. its atomic composition, structure, volume and hydrophobicity (EFSA, 
2014). The approach implies that the biological activity of a chemical is based on these molecular 
descriptors and therefore, activity can be directly predicted from descriptors and further, that the 
activity for unknown substances can be inferred from compounds with similar traits and known 
activities.  
Besides its use in grouping chemicals, the QSAR approach is also applied to quickly decide on the 
safety of a chemical when no toxicological data is present (Worth et al., 2011), as well as to predict 
physicochemical properties of a substance (Leeuwen and Vermeire, 2007) 
Both, the QSAR and read-across method require considerable expert knowledge as reliability of the 
approaches heavily depends on the choice of analogue compounds as well on reliability of the 
underlying experimental data (EFSA, 2014; Leeuwen and Vermeire, 2007; Worth et al., 2011). Unlike 
QSAR, read-across is a non-formalized approach and therefore the data selection step is even more 
critical (EFSA, 2014). In vitro experiments are a viable source of data for such approaches, hence, to 
ensure reliability, appropriate in vitro tools have to be used for data generation. 
1.5.4 In vitro to in vivo extrapolation and physiologically-based models 
The approach of in vitro to in vivo extrapolation (IVIVE) refers to the use of in vitro data to infer in 
vivo parameters reflecting human physiology and metabolism. When variability in humans is 
considered, the approach is termed quantitative IVIVE (QIVIVE) (EFSA, 2014). To yield in vivo 
relevant parameters, adjustments need to be made, e.g. taking into account plastic binding in the in 
vitro scenario and differences in protein binding, as well as in drug metabolism compared to in vivo 
(Hamon et al., 2015). 
IVIVE is commonly incorporated into physiologically-based pharmacokinetic (PBPK) or 
physiologically-based toxicokinetic (PBTK) models. The models describe the relation of external dose 
and the resulting internal organ-specific concentrations over time under consideration of ADME 
processes (EFSA, 2014). Though PBTK models are mostly applied to estimate the resulting internal 
concentration upon application of a drug (Bois et al., 2010), they can also be used in a reversed 
manner, i.e. to estimate the dose of a compound needed to be taken up orally, in order to achieve a 
steady-state blood concentration, equivalent to a given effective concentration (EC), e.g. EC50 (Rotroff 
et al., 2010). PBTK models may also be applied to simulate and study inter- and intraindividual 
differences in a compound’s kinetics (Bois et al., 2010), and even to predict pharmacokinetic 
parameters between different species (Sharma and McNeill, 2009). Missing information on 
physicochemical parameters are typically estimated from QSAR (EFSA, 2014). 
PBTK models can furthermore be extended by their toxicodynamic counterpart, mathematically 
describing the tissue response to a biologically effective dose of a given substance. Such models are 
generally applicable to compounds with well-known toxicokinetic and toxicodynamic parameters and 
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allow estimation of internal levels of the parent compound and its metabolites and the resulting effects 
on the organism (EFSA, 2014). 
Setting up a PBTK or even PBTK-TD model requires substantial knowledge and data, including drug-
specific information, biochemical and physiological information and considerations on the ideal model 
structure (Bois et al., 2010); information which can be partially generated using in vitro models or 
taken from databases.  
1.5.5 Adverse outcome pathways 
The use of the adverse outcome pathway (AOP) framework is one approach to gain mechanistic 
understanding and compile knowledge on events occurring during toxicity. Thus, it facilitates the 
generation of models such as PBTK-TD by highlighting structures and pathways that are of crucial 
importance. AOP are characterized by a molecular initiating event (MIE) which is connected to an 
adverse outcome via a sequence of key events (KE), which may occur on different organism levels 
(Wittwehr et al., 2017). MIE can be processes such as inhibition of the bile salt export pump (BSEP) 
or activation of the liver X receptor (LXR), leading to cholestasis and steatosis respectively. Under the 
premise that compounds triggering the same MIE will cause the same adverse outcome, substances 
need to be grouped according to their MIE in order to predict toxic outcomes. Again, grouping can be 
conducted using approaches like QSAR (Vinken, 2015). Vinken has described the AOP for a number 
of toxicological endpoints related to DILI, such as liver fibrosis, steatosis and cholestasis (Vinken, 
2015). 
1.5.6 -omics approach 
The -omics techniques are the predestined approach to gather the vast amount of information that is 
underlying an AOP. -omics is a collective term comprising various fields of study; in its traditional 
form representing the different levels of cellular hierarchy in a holistic manner, contrary to focusing on 
single genes, proteins or metabolites: The genome, epigenome, transcriptome, proteome, metabolome 
and fluxome (figure 1.10). The genome represents the genetic material of a cell, in case of mammalian 
cells including coding and non-coding regions of the DNA strands, as well as the genetic material 
inside of the organelles. The epigenome includes the whole set of modifications of histones and DNA 
with exception of mutations in the sequence. Epigenetic modifications serve the regulation of gene 
expression and are the cause for differential gene expression in distinct cell types in an organism 
despite identical genotype throughout the body. Methylation of DNA bases and histones and 
deacetylation of histones are classical examples for epigenetic modifications (Jaenisch and Bird, 
2003). The next level of cellular hierarchy is represented by the entirety of DNA transcripts, i.e. 
mRNA, rRNA, tRNA and non-coding RNA molecules. mRNA is subsequently translated into proteins 
by the enzymatic activity of ribosomes. The complete set of proteins in or outside of a cell is termed 
proteome. Proteins, which have a multitude of different functions such as stabilization of cellular 
structure or regulation of transcription, may also catalyze biochemical reactions. Substrate and product 
of such biochemical reactions are usually molecules of low molecular weight also referred to as 
metabolites. The sum of all metabolites in or outside of a cell is called metabolome. The aim of 
metabolism is to gain energy and to form macromolecules, signaling or regulatory molecules as well 
as the temporary storage of molecules. On the apogee of cellular hierarchy is the fluxome which refers 
to reaction rates or fluxes as a whole, including rates for the conversion of one molecule into another, 
but also rates describing the transport of molecules across membranes. The fluxome integrates the 
effects of all hierarchical levels below and therefore, flux analysis is the best indicator for the actual 
cellular phenotype (Klein and Heinzle, 2012). Independent on the investigated cellular level, cells are 
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dynamic in nature, depending on environmental factors and therefore, -omics can only represent a 
snapshot of cellular status. 
 
 
Figure 1.10 Overview on the different levels of cellular hierarchy and regulatory processes. The central 
dogma of molecular biology describes the flow of information from genes to proteins. Proteins in turn affect 
metabolite levels via enzymatically catalyzed reactions, while the concentrations of metabolites have an impact 
on the reaction and transport rates (fluxes). Possible regulatory actions are indicated by light red arrows. 
 
In summary, the –omics approach yields information on all possible events occurring within a cell and 
therefore potentially allows full deciphering of DILI. Yet, this again emphasizes the need for an ideal 
model system, in detail reflecting the human in vivo situation. 
 
In the light of current legislation, such as the European Union initiative on registration, evaluation, 
authorization and restriction of chemicals (REACH), the need for methods facilitating prediction of 
toxicity is more urgent than ever. The initiative requires safety assessment of chemicals in general, 
including cleaning products, cosmetic ingredients, dyes, and so on in order to minimize risks for 
human health and environment. In total, around 30,000 chemicals might require testing (Prieto et al., 
2006). The overall goal of the tools described above is to avoid unnecessary toxicity testing either 
because human intake is appreciably below the TTC, or due to the fact that missing parameters can be 
estimated reliably from already existing data. Avoiding unnecessary experiments allows to focus 
limited resources on substances likely to be harmful and reducing the number of experiments 
performed on animals (Kroes et al., 2004). Besides their application in risk assessment, approaches 
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may also be used for estimation of ADME parameters during the screening of new drug candidates to 
aid in the selection of compounds with potentially favorable ADME properties (Rowland et al., 2004). 
 
1.6 Metabolomics in detail 
Metabolomics refers to the impartial analysis of the entirety of small molecules in a given 
compartment such as a cell, tissue or blood. Metabolites from different pathways may vary drastically 
in concentrations, size and a multitude of chemical properties such as lipophilicity and stability. As a 
result, covering the whole diversity of metabolites in an impartial or complete manner is currently 
restricted by technical limitations. To give an example, nitric oxide (NO), a signaling molecule in the 
human body, has a molar mass of 30 g/mol, is gaseous, hydrophilic and found in human blood in 
concentrations notably below 1 nM, whereas the liquid and lipophilic molecule docosahexaenoic acid, 
a source of anti-inflammatory eicosanoids, has a molar mass of 328.5 g/mol and is found in human 
blood in concentrations well above 1 µM (www.hmdb.ca, accessed 2016-06-18). 
1.6.1 Targeted versus untargeted metabolomics 
Metabolomics is commonly divided into a targeted and an untargeted branch. In targeted 
metabolomics, extraction protocols and quantification methods are optimized for a predefined set of 
metabolites with known identity. The data is either of quantitative or semi-quantitative nature (Roberts 
et al., 2012). Owing to its focus on a subset of metabolites, targeted metabolomics is commonly 
considered as a hypothesis-driven approach (Sévin et al., 2015). 
Untargeted metabolomics is also known as global metabolite profiling. It aims at maximum 
comprehensiveness and may include metabolites with known as well as unknown identity. Data is 
mostly reported as signal intensities and rarely yield absolute concentrations. The method is applicable 
in hypothesis-generating but also in hypothesis-driven studies, with a tendency towards the former. 
More than targeted metabolomics, it aims at the discovery of pathways previously not known to be 
affected by a certain disease, drug or other condition. Untargeted metabolomics commonly comes 
along with the generation of huge amounts of data which poses challenges in respect to data 
processing and management, as well as data interpretation (Sévin et al., 2015) The untargeted 
approach can be further divided into metabolic finger- and footprinting, referring to the global high-
throughput analysis of intra- and extracellular samples respectively (Dunn et al., 2005). 
1.6.2 Analytical tools in metabolomics 
From an analytical point of view, metabolomics is particularly challenging due to the tremendous 
variety in the objects of investigation. In terms of popularity, two analytical approaches notably stand 
out within the field of metabolomics, namely mass spectrometry (MS) on the one hand, and nuclear 
magnetic resonance (NMR) spectroscopy on the other hand. Several factors have to be considered 
when selecting the best method for analysis, such as available sample volume, chemical nature of the 
metabolites of interest, budget, applicability to high-throughput and data output (Klein and Heinzle, 
2012). 
Mass spectrometers determine ion signals depending on mass-to-charge ratios, which can be specified 
for particular metabolites or metabolite classes. Mass spectrometers are usually coupled to a 
chromatographic system to compensate for the lack of separation in case of low resolution systems 
and to reduce so called matrix effects (Fuhrer and Zamboni, 2015). Depending on the compounds of 
interest, hyphenation to gas chromatography (GC) or liquid chromatography (LC) is used. In case of 
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high resolution systems, chromatographic separation can be omitted, which allows drastic reduction of 
the run time, and analysis of more than 1,000 samples per day. Flow injection is one approach for 
injection of liquid samples without prior chromatography, in which case samples are injected into a 
continuous eluent stream (Fuhrer and Zamboni, 2015). 
NMR spectroscopy is a non-destructive method for identification and quantification of metabolites, 
which allows analysis in an unbiased manner with highly reproducible results. On the downside, the 
methodology is incompatible with high-throughput setups and acquisition costs of the equipment are 
high. Further, the sample volume requirements and limit of detection for NMR spectroscopy are 
notably above those of MS systems. Regarding the latter two points however, recent advances in 
technology led to an approximation of the two technologies (Cuperlović-Culf et al., 2010; Klein and 
Heinzle, 2012; Wishart, 2008). 
1.6.3 Applications of metabolomics 
Applications of metabolomics can be roughly divided into two sections. First, biomarker discovery 
and second, understanding of cellular processes, e.g. those underlying toxicological, pathological, and 
homeostatic responses, as well as the production of certain molecules. Both applications are 
intertwined but differ in focus. Biomarkers are quantifiable parameters, e.g. metabolites that can be 
used as indicators for a variety of biological processes. Such processes may include the assessment of 
drug efficacy or adverse reactions upon drug exposure during drug development. In a clinical 
environment, biomarkers may be used for diagnostic or prognostic purposes (Puchades-Carrasco and 
Pineda-Lucena, 2015). The newborn screening is a well-known example for the application of 
metabolic biomarkers. It allows screening of infants for a number of conditions related to inborn errors 
of metabolism such as phenylketonuria and severe combined immunodeficiency via the quantification 
of key metabolites. 
Apart from the application in the context of biomarkers, metabolomics is used to gain better 
understanding of biological processes, both, as part of basic research as well as applied sciences. One 
example is a study on the interplay between lactic acid bacteria, acetic acid bacteria and yeast on a 
metabolic level during cocoa fermentation. Using 
13
C labeled substrate, metabolomics was applied to 
derive the fluxes in different lactic acid bacteria strains and acetic acid bacteria. Comprehensive 
knowledge of the interaction of the metabolism of the different species allows selection of an ideal co-
culture composition during fermentation for optimization of the ongoing reactions and eventually the 
taste of the resulting cocoa itself. Furthermore, it allows to veer the cocoa production away from an 
uncontrolled process towards a streamlined process including defined starter cultures (Adler et al., 
2014, 2013). 
One example related to drug discovery is the finding of the metabolite trimethylamine N-oxide 
(TMAO) and its association with the formation of atherosclerotic plaques (Wishart, 2016). In several 
studies, TMAO was shown to promote atherosclerotic plaques by a mechanism yet to be fully 
elucidated (Gregory et al., 2015; Organ et al., 2016). It is produced from trimethylamine (TMA) in the 
liver via the enzyme flavin monooxygenase 3 (FMO3). TMA in turn originates from several dietary 
sources such as choline, betaine or carnitine, i.e. largely from the consumption of meat. The formation 
of TMA is catalyzed by the TMA lyase, an enzyme found in the gut microbiota. This led to the 
hypothesis that the two enzymes FMO3 and TMA lyase may serve as targets for the prevention of 
atherosclerotic plaques (Wang et al., 2011; Wishart, 2016). FMO3 however is an important regulator 
of cholesterol metabolism and its knockdown was shown to promote hepatic inflammation and other 
adverse reactions (Warrier et al., 2015). Regarding the enzyme TMA lyase, 3,3-dimethyl-1-butanol, 
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which is a choline analogue and an ingredient in olive oil, was found to be an effective inhibitor of the 
enzyme and is currently tested for its use as a drug in atherosclerosis treatment (Wang et al., 2015, 
2011; Wishart, 2016). Another molecule that was shown to reduce TMAO levels is resveratrol. 
Resveratrol is particularly abundant in red wine and is suggested to act via remodeling of the gut 
microbiota (Chen et al., 2016). 
We described more applications related to metabolomics and fluxomics, technical considerations 
during the design of experiments and theoretical basics in a separate review in more detail (Klein and 
Heinzle, 2012). Yet, the theoretical background shall be briefly touched in the following. 
1.6.4 Theoretical background on the calculation of metabolic fluxes 
The aim of metabolic flux analysis (MFA) is to quantify intracellular reaction rates. In its simplest 
form, metabolic fluxes can be calculated using metabolite balancing. This requires quantitative 
information on uptake and secretion rates, biomass formation, as well as a stoichiometric network 
model of the organism of interest. Additionally, the presence of metabolic steady state or at least 
pseudo steady state is implied, i.e. intracellular metabolite concentrations are assumed to be constant 
over time. Though sufficient for less complex networks, metabolite balancing reaches its limits when 
cyclic pathways, reversible reactions or compartmentalization are to be considered. In case of 
underdetermined networks, additional constraints can be set to limit the space of possible solutions 
(Niklas and Heinzle, 2011). 
One approach to increase the resolution and reliability of metabolite balancing is the addition of 
labeled substrates - in most cases 
13
C-substrates. Therefore, this approach is also referred to as 
13
C MFA. It uses the information residing in the pathway-specific rearrangement of the carbon atoms 
to gain deeper insight into the cellular metabolism (Niklas and Heinzle, 2011). Hence, this approach 
requires data on mass or positional isotopomers, which can be acquired using NMR or MS (Klein and 
Heinzle, 2012). Subsequently, data on isotopomers is combined with metabolite balancing, and 
iterative algorithms are applied to minimize the deviation between measured and simulated labeling 
patterns. This approach yields more accurate results compared to mere balancing approaches and 
allows to estimate fluxes in more complex pathways including split ratios between pathways (Niklas 
and Heinzle, 2011). 
 
1.7 Objective of the thesis 
The thesis was prepared in the context of the NOTOX project, a project funded by the European Union 
and cosmetics industry. The project in turn was part of the SEURAT (safety evaluation ultimately 
replacing animal testing) cluster which was brought into being to aid in the reduction, replacement and 
refinement of animal testing. The particular aim of NOTOX was to provide systems biological tools to 
predict toxic events; i.e. tools of experimental as well as computational nature. A particular focus was 
put on organotypic cultures, long-term toxicity and pathways related to toxicological outcomes. 
In this work, the human hepatic cell line HepaRG will be put in context as to its applicability in single 
and repeated dose long-term in vitro toxicity setups, assisted by the use computational methods. 
Reliable and human-relevant toxicity assessment and prediction incontrovertibly require a test system 
adequately reflecting the situation in vivo. Therefore, a first comparison was performed using HepG2 
cells and PHH, the current gold standard in in vitro toxicity, as a benchmark for HepaRG cells 
(chapter 2). The focus of this comparison was two-fold. First, metabolic competence and basal carbon 
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metabolism was contrasted, and secondly, behavior upon drug exposure was investigated on in terms 
of viability as well as alterations in the central carbon metabolism. 
Next, different cultivation techniques and medium compositions for HepaRG cells were investigated 
as to their potential to improve hepatic functionality and long-term stability of the cell line. The 
assessment of repeated dose toxicity is still one of the most pressing issues and alternative in vitro 
approaches allowing reliable assessment of toxicity are not available. Using a set of different 3D 
cultivation techniques as well as a 2D cultivation, we were investigating hepatic functionality in 
HepaRG cells by quantification of biokinetics parameters such as drug uptake, CYP450 activity and 
induction, as well as excretion of the glucuronidated drug (chapter 3). Additionally, we studied the 
effect of single and repeated dosing (three days) of bosentan, chlorpromazine and valproic acid on the 
viability of the cells, cultivated using different 3D and a 2D setup. 
To further extend the cultivation period of HepaRG cells as well as to facilitate –omics analyses, we 
tested several different serum-free compositions for the cultivation medium (chapter 4). The study 
was conducted for 30 days, which is in accordance with the Organization for Economic Cooperation 
and Development (OECD) guideline 407 for long-term repeated dose toxicity studies. As an addition, 
we studied the differences in the metabolism of HepaRG cells maintained in the different media to 
gain better understanding of the processes occurring in the cells. Subsequently, as a proof of principle, 
we tested the medium in a repeated dose toxicity study using valproic acid as a hepatotoxic compound 
and investigated the toxic effects of two-week drug application. 
Applying the previously obtained knowledge on long-term cultivation of HepaRG cells, we performed 
two in-depth repeated dose toxicity studies. In the first case, we exposed HepaRG cells to valproic 
acid and bosentan for one month and applied an IVIVE approach to estimate human-relevant toxicity 
and determined metabolic fluxes to obtain more information on the underlying pathways (chapter 5). 
In the second study, we exposed HepaRG cells to valproic acid for two weeks while collecting 
samples for a multi-omics analysis, including epigenetics, transcriptomics, proteomics, metabolomics 
and fluxomics (chapter 6). The focus will be on the analysis of the metabololomics data, but selected 
results obtained from other –omics technologies will also be briefly highlighted. 
A final overall summary on the findings gathered during the work on this thesis, as well as a critical 
reflection of results in the context of current research is given in chapter 7. The chapter further 
provides an outlook with potential applications of the approaches elaborated in this thesis. 
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Chapter 2 Carbon metabolism in HepaRG cells and its alterations upon 
drug exposure in a comparative study with primary human hepatocytes 
and HepG2 cells 
2.1 Abstract 
Replacement of animal studies with in vitro tools in the field of toxicology is fueled by ethical, legal 
and monetary incentives, but essentially requires alternative approaches that are sufficiently reliable in 
predicting toxicity relevant for humans. Therefore, major effort is put into improving current in vitro 
technologies and developing new cell lines for better prediction of toxic events. Herein, we compare 
the recently introduced HepaRG cell line to the well-established HepG2 cells and primary human 
hepatocytes in terms of their central carbon metabolism as a representation of the overall cellular 
phenotype. In addition to the basal cellular metabolism, we investigated alterations therein when cells 
were exposed to the two hepatotoxic compounds acetaminophen and diclofenac, in order to compare 
the response in the different systems, using metabolomics as an easy-to-perform method for indirect 
quantification of the integrated underlying regulatory processes. We observed that for many 
metabolites, the HepaRG cell line closely resembled the metabolism in primary hepatocytes, whereas 
HepG2 cells were hallmarked by a typical cancer metabolism. When cells were exposed to the 
hepatotoxic compounds, both cell lines appropriately covered the majority of the metabolic features 
observed in primary hepatocytes. However, HepaRG cells more closely resembled the situation in 
primary cells, particularly in respect to glucose metabolism. As a conclusion, HepaRG cells are more 
suitable when studying the carbon metabolism and its alterations when exposed to external stimuli 
than HepG2 cells, and may play an important role in future in vitro toxicological studies. 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in preparation for submission as  
Klein S, Beshr G, Shevchenko V, Mueller D, Noor F, Heinzle E. Carbon metabolism in HepaRG cells 
and its alterations upon drug exposure in a comparative study with primary human hepatocytes and 
HepG2 cells 
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2.2 Introduction 
Strengthening the use of in vitro tools in pharmaceutical and cosmetic research and abandoning 
traditional animal studies is a major step towards modern toxicity assessment. Ethical issues associated 
with animal studies, high costs and poor transferability of results to humans in some cases (Blaauboer 
and Andersen, 2007; Olson et al., 2000; Shukla et al., 2010), make this step inevitable. 
Primary human hepatocytes (PHH) are the current gold standard in in vitro toxicity testing as they best 
mimic the human in vivo situation and therefore allow for most reliably predicting human toxicity. 
Dozens of alternative test systems have been tested and development of new cell lines and cultivation 
conditions is currently being pushed by the government and industry to overcome the shortcomings of 
PHH, which include scarce availability and a strictly limited lifespan.  
The human liver cell line HepG2 is a well-established cell line for the application in toxicity studies 
(Donato et al., 1992; Niklas et al., 2009). However, HepG2 cells lack many liver specific functions 
and only possess a basal expression of most cytochrome P450 (CYP450) isoforms compared to PHH 
(Aninat et al., 2006; Sumida et al., 2000; Wilkening et al., 2003). Yet, activity of these enzymes is a 
decisive parameter for the outcome of toxicological studies, as they are in involved in the 
detoxification of a vast amount of chemicals and in some cases produce reactive species causing 
cytotoxicity (Lammert et al., 2010; Leung et al., 2012). More recently, a human hepatic cell line with 
superior performance has been introduced (Gripon et al., 2002; Lübberstedt et al., 2011). The so called 
HepaRG cell line has been isolated from a female patient suffering from hepatocarcinoma and a 
hepatitis C infection (Gripon et al., 2002). Unlike in HepG2 cells, in HepaRG cells, expression levels 
of genes encoding for xenobiotics metabolizing enzymes and transporters were in a similar range as in 
PHH (Gerets et al., 2012) and, at the same time, HepaRG cells are available on demand without 
restrictions to cell number. Even more, in first studies the suitability of HepaRG cells in long-term 
studies has been demonstrated (Josse et al., 2008; Klein et al., 2014), making the cell line ideal for 
toxicity studies.  
A multitude of drugs are known to elicit hepatotoxicity in humans and in many cases, poor 
concordance of animal and human toxicity contributed to its late discovery, not before the drugs 
entered the post-marketing phase. Many drugs have been withdrawn from the market due to their 
hepatotoxic potential, but in some cases, hepatotoxic drugs are still out on the markets. Two examples 
for such compounds are acetaminophen and diclofenac. Acetaminophen is one of the most commonly 
applied drugs worldwide, making use of its analgesic and anti-pyretic effects. At the same time, 
acetaminophen accounts for more than 50% of acute liver failure cases resulting from overdosing of 
the drug (Larson et al., 2005; Yoon et al., 2016). At therapeutic doses, acetaminophen is mainly 
metabolized by glucuronidation and sulfation, followed by its excretion from the body. Only few 
percent of the drug are oxidized via the CYP450 system, producing the reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI), which is promptly detoxified by conjugation to glutathione (McGill et 
al., 2011; Nelson, 1990). However, upon overdosing glucuronidation and sulfation pathways are 
saturated and metabolization via the CYP450 system, in particular via the isoforms CYP2E1 and 
CYP3A4 (Laine et al., 2009; Snawder et al., 1994), becomes more prominent. NAPQI binds to 
mitochondrial proteins, leading to mitochondrial dysfunction, formation of reactive oxygen and 
nitrogen species (ROS and RNS) and ATP depletion (Burcham and Harman, 1990; Cohen et al., 1997; 
Jaeschke, 1990). This in turn results in fragmentation of DNA and eventually cell death via necrosis 
(Cover et al., 2005; Gujral et al., 2002). Only recently, acetaminophen has additionally been associated 
with endoplasmic reticulum (ER) stress, which was suggested to play a crucial role in acetaminophen-
induced toxicity (Uzi et al., 2013). 
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Similar to acetaminophen, toxicity of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac 
was shown to involve oxidative stress, ER stress and mitochondrial dysfunction (Begriche et al., 2011; 
Boelsterli, 2003; Gómez-Lechón et al., 2003; Kretzrommel and Boelsterli, 1993; Tsutsumi et al., 
2004). Diclofenac is metabolized via the CYP450 system, with 4’-OH, 5’OH and N,5-(OH)2 
diclofenac as the main metabolites, which can also potentially be oxidized to a p-benzoquinone imine, 
capable of binding to cellular structures (Boelsterli, 2003; Bort et al., 1999, 1998). Furthermore, 
reactive arene oxides of diclofenac have been detected after exposing human microsomes to diclofenac 
(Yan et al., 2005). Main CYP450 isoforms involved in the oxidation of diclofenac belong to the 
CYP2C family, however at high drug concentrations, CYP1A2, CYP2B6 and CYP3A4 can also 
contribute to its metabolization (Bort et al., 1999). In addition to reactive diclofenac metabolites 
disturbing metabolic homeostasis, severe immune mediated responses have been described upon 
diclofenac treatment (Boelsterli, 2003; Gutting et al., 2002; Jürgensen et al., 2001). 
Besides its pivotal role in the metabolism of xenobiotics, the liver essentially contributes to various 
metabolic pathways and transport of molecules across the body. Examples include glucose, neutral 
lipid and cholesterol metabolism and the detoxification of ammonia via the urea cycle. Next to direct 
modulation of enzyme activity, nuclear receptors are a crucial factor in the regulation of metabolism. 
The terms metabolomics and fluxomics refer to approaches unbiasedly assessing the complete set of 
small molecules within a cell, tissue, organ and biological fluids, and their changes over time 
respectively. As metabolites and fluxes are situated downstream of genes, transcripts and proteins, 
they contain the integrated information of the processes occurring on these levels (Klein and Heinzle, 
2012), and can be used as an easy-to-perform readout for regulatory processes, e.g. induced by drugs 
or diseases. In several studies, metabolomics and fluxomics have been applied to HepG2 cells to gain 
insight into the underlying mechanisms of drug-induced hepatotoxicity and to identify biomarkers for 
toxicological outcomes which will help in screening and classification of hepatotoxic compounds 
(García-Cañaveras et al., 2016, 2015; Niklas et al., 2009). 
In this study, we address the question to which extent the hepatic cell line HepaRG is capable of 
replacing PHH in the context of in vitro toxicology, focusing on the central carbon metabolism and its 
perturbation upon exposure to the two hepatotoxic compounds, acetaminophen and diclofenac. Cancer 
cells, such as the hepatoblastoma-derived cell line HepG2, are well known to differ in carbon 
metabolism compared to normal tissue, as their environment in situ and demands differ considerably 
(Iyer et al., 2010; Zhou et al., 2012), arising the question whether they and other tumor-derived cell 
lines can be used for reliable predictions in toxicity studies. 
 
2.3 Methods 
2.3.1 Cell culture 
HepG2 cells were obtained from DSMZ (Brunswick, Germany). HepaRG cells and cryopreserved 
PHH were supplied by Biopredic International (Saint-Grégoire, France). Detailed information on the 
donors is given in table S2.1. 
For HepaRG and PHH cultures, before seeding, 96-well plates (Greiner Bio One, Frickenhausen, 
Germany) were coated with type I rat collagen (Roche Applied Sciences, Penzberg, Germany) by 
adding 100 µl of a solution of 50 µg collagen/ml in DMEM (AMIMED BioConcept, Allschwil, 
Switzerland), followed by a 1 h incubation at 37°C. Afterwards, wells were washed once with 100 µl 
phosphate buffered saline (PBS) (Gibco Invitrogen, Darmstadt, Germany) and equilibrated for 1 h 
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with Williams Medium E (Pan Biotec, Aidenbach, Germany) at room temperature. Medium was 
removed and cells were seeded into the 96-well plates (n = 3 for each condition and time point), 
suspended in 100 µl Williams Medium E supplemented with 10% fetal bovine serum (FBS) (PAA 
Laboratories, Pasching, Austria), 100 U/ml penicillin and 100 µg/ml streptomycin (c.c. pro, Oberdorla, 
Germany). In case of PHH, seeding medium was additionally supplemented with 50 µM 
hydrocortisone 21-hemisuccinate and 5 µg/ml human insulin. In addition to supplements for PHH, 
1.8% DMSO (v/v) were added for HepaRG cells. Supplements, if not noted differently, were obtained 
from Sigma Aldrich, Steinheim, Germany. Numbers of seeded cells were 50,000 for PHH and HepG2 
cells, and 72,000 for HepaRG cells. Seeding was done one day before beginning of analyses for PHH 
and HepG2 cells and a week before in case of HepaRG cells. Two days after seeding, medium for 
HepaRG cells was replaced by fresh medium with a reduced DMSO concentration of 0.5% (v/v). 12 h 
before beginning of analyses, medium was renewed using the same medium for all cells. The medium 
was supplemented with penicillin, streptomycin, hydrocortisone 21-hemisuccinate and insulin, without 
FBS and DMSO (hepatocyte culture medium). Cultivation was conducted in a cell culture incubator 
(Memmert, Schwabach, Germany) at 37°C with 95% relative humidity and 5% CO2 supply. 
2.3.2 Quantification of glucose, organic acids and urea 
Glucose, pyruvate and lactate were quantified using a Kontron HPLC (Kontron Instruments, 
Neufahrn, Germany) as described previously in detail (Hans et al., 2003). Amino acids and urea were 
quantified in an Agilent 1100 HPLC system (Agilent, Waldbronn, Germany). Technicalities on the 
methods were elaborated on before (Clark et al., 2007; Klein et al., 2014; Krömer et al., 2005). 
2.3.3 Calculation of secretion rates 
From measured metabolite concentrations, secretion rates ri were calculated using equation 2.1. 
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       [2.1] 
Ci is the concentration of a metabolite i at time point 1 (t1, 24 h) or time point 0 (t0, 0 h). X represents 
the mean cell number during the 24 h cultivation and V is the culture volume. 
2.3.4 Labeling studies for estimation of pathways contributing to formation of lactate 
11.11 mM [1,2-
13
C] glucose (99%, Cambridge Isotope Laboratories, MA, USA) and 2 mM [U-
13
C] 
glutamine (99%, Cambridge Isotope Laboratories, MA, USA) were added to glucose- and glutamine-
free Williams Medium E (Pan Biotec, Aidenbach, Germany) with otherwise identical composition as 
the hepatocyte culture medium. Cells were incubated with the tracers for 24 h and medium was 
collected after 2 h, 10 h, 18 h and 24 h from different wells. 
2.3.5 Sample preparation for measurement of mass isotopomers in GC-MS 
The procedure for sample preparation and measurement in a mass spectrometer coupled to a gas 
chromatograph (GC-MS) was adapted from literature (Strigun et al., 2011a) as follows. 25 μl of 
collected supernatants were frozen and lyophilized. Afterwards, 40 μl of N,N-dimethylformamide 
(Carl Roth, Karlsruhe, Germany) containing 0.1% pyridine (v/v) (Sigma Aldrich, Steinheim, 
Germany) and 40 μl N-methyl-N-tert-butyldimethylsilyl-trifluoroacetamide (MBDSTFA) (Machery-
Nagel, Dueren, Germany) were added. Samples were then incubated for 30 min at 80°C, followed by 
centrifugation at 12,100 g for 5 min at 4°C. The supernatants were transferred into new glass vials 
with 0.2 ml inserts (Machery-Nagel, Dueren, Germany) for GC-MS analysis. 
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2.3.6 Measurement of mass isotopomers in GC-MS 
For measurement of mass isotopomers, 1 µl of the derivatized sample was injected into a GC (HP 
6890, Hewlett Packard, Palo Alto, CA, USA) equipped with a HP-5 MS column (5% phenyl-methyl-
siloxanediphenylpolysiloxane, 30 m × 0.25 mm × 0.25 µm, Agilent, Waldbronn, Germany) and 
coupled to a quadrupole MS (MS 5973, Agilent, Waldbronn, Germany). The flow rate for separation 
was 1.1 ml/min with helium as carrier gas, and the following temperature gradient was applied: 135°C 
for 7 min, 10°C/min increase until 160°C, 7°C/min until 170°C and 10 °C/min until 325°C which was 
held for 2.5 min. Ionization was done with electron ionization at 70 eV. 
2.3.7 Processing of GC-MS spectra and estimation of pathways contributing to formation of 
lactate 
From the mass spectra of MBDSTFA derivatized lactate, carbon mass isotopomer distributions were 
computed using a described method (Yang et al., 2009). Corrected mass isotopomer distributions were 
used for the estimation of the pathways contributing to the formation of lactate, using equations 2.2 to 
2.5, with M0 to M3 representing the different carbon mass isotopomer fractions of lactate (figure S2.1). 
Pathways include glycolysis, pentose phosphate pathway (PPP), gluconeogenesis from glutamine, and 
other sources, which comprise glycogenolysis as well as gluconeogenesis from molecules other than 
glutamine. Degradation of [1,2-
13
C] glucose via glycolysis results in one lactate molecule labeled at 
two positions (M2) and another one without labeling (M0). M2 is specific for this pathway, while M0 is 
produced by two more sources. Hence, M2 is used for the calculation of glycolytic contribution by 
doubling its value to account for the production of two molecules of lactate per molecule glucose 
(eq. 2.2). During degradation of [1,2-
13
C] glucose via PPP, the labeled C1 atom is lost, resulting in a 
lactate molecule labeled only at one position (M1) and one without labeling (M0). In this case, M1 is 
specific for the PPP and hence, it applied to estimate the pathway’s contribution. The loss of the C1 
atom during the oxidative phase of the PPP was considered in the calculations by multiplying M1 by 
5/3 (instead of 2 as it is the case for glycolysis) (eq. 2.3). In case of lactate formation from [U-
13
C] 
glutamine, two carbon atoms are lost as CO2 and the remaining labeled carbon atoms build the carbon 
backbone of lactate (M3) (eq. 2.4). To calculate the contribution of other sources to the formation of 
lactate, unlabeled lactate molecules formed via the glycolytic pathway and PPP have to be subtracted 
from M0 in the calculation (eq. 2.5). It was assumed that the interconversion of the different sources, 
e.g. glycogenesis from labeled glutamine, was negligible within the 24 h period. 
       [2.2] 
        [2.3] 
     [2.4] 
      [2.5] 
2.3.8 Quantification of CYP450 activity 
For determination of the CYP450 activity in the different hepatic cells, these were incubated with a 
substrate cocktail, and product formation was quantified using an LC-MS method. Incubation of the 
cells with the cocktail of CYP450 substrates was conducted in 100 µl hepatocyte culture medium for 
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1 h. In case of CYP2D6, CYP1A2, CYP2B6 and CYP3A4, further details on the substrates and the 
LC-MS method used for quantification of CYP450 products have been described previously (Klein et 
al., 2014). CYP2E1 activity was assessed using chlorzoxazone (Sigma Aldrich, St. Louis, MO, USA) 
as a substrate with a final concentration of 300 µM in hepatocyte culture medium. Thorough 
information on the quantification of the CYP2E1 product OH-chlorzoxazone via LC-MS is given in 
literature (Gunness et al., 2013). 
2.3.9 Dose response curves for acetaminophen and diclofenac in hepatic cells 
First, acetaminophen (Sigma Aldrich, Steinheim, Germany) and diclofenac sodium salt (Sigma 
Aldrich, Steinheim, Germany) were dissolved in hepatocyte culture medium with concentrations of 
80 mM and 5 mM respectively. From these stock solutions, drug concentrations ranging from 80 mM 
to 5 × 10
-2
 mM (acetaminophen) and 5 mM to 2.5 × 10
-3
 mM (diclofenac) were prepared in hepatocyte 
culture medium and subsequently applied to the cells in a volume of 100 µl for 24 h. 
2.3.10 Viability assessment 
To determine the number of adhered cells after seeding, first a sulforhodamine B (SRB) assay was 
conducted as described in literature (Skehan et al., 1990) and results were compared to calibration 
curves for each cell type individually. To assess viability, a resazurin-based assay was applied 
(CellTiter-Blue® cell viability assay, Promega, Mannheim, Germany). The resazurin solution was 
mixed with medium in a ratio of 1:5. The mixture was prewarmed and a volume of 100 µl was given 
to the cells which were then incubated for 3 h at 37°C. Fluorescence of the product resorufin was 
detected using a Fluoroskan Ascent CF fluorescence reader (Thermo Labsystems, Vantaa, Finland), 
measuring emission at 590 nm upon excitation at 540 nm. A mixture without cells served to assess the 
background signal. The fluorescence signals from treated samples were then normalized to the signal 
of the untreated control. 
2.3.11 Curve fitting and calculation of confidence intervals  
Boltzmann equation (eq. 2.6) was used for curve fitting to the experimental dose response data. 
       [2.6] 
ymin and ymax are defined as the lowest and highest y-value in the data set, and xc represents the applied 
drug concentration. An evolutionary algorithm within Excel 2010 (Microsoft, Redmond, WA, USA) 
was used to find the maximum value for the coefficient of determination (r
2
), varying EC50 and the 
slope (sl) of the curve. The 90% Confidence interval (CI) at each concentration c was calculated 
according to equation 2.7, 
     [2.7] 
where tα;n-2 is the critical t-value for degrees of freedom reduced by two and σest indicates the standard 
error of the estimate. The number of data points is given by n and SSXX is the sum of squared 
deviations of x-values from the mean of x. 
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2.3.12 Detailed metabolic characterization of hepatic cells upon drug exposure 
Three concentrations for each drug and hepatic system were chosen for in-depth investigation of the 
metabolism upon drug exposure. These concentrations included the EC10 and a subtoxic concentration, 
which were taken from the dose response curves and the cmax taken from literature (table 2.1). 
Untreated cells were added as a control. Drug preparation and exposure of the cells was identical to 
the procedure described above. Additionally, supernatants were collected for quantification of carbon 
metabolites. 
 
Table 2.1 Drug concentrations applied to cell cultures. List of acetaminophen and diclofenac concentrations 
used during the detailed metabolic characterization of HepG2 and HepaRG cells, as well as primary human 
hepatocytes (PHH1, PHH2, PHH3) upon drug exposure.  
Cell type High drug concentration 
(EC10) [mM]* 
Medium drug concentration 
(subtoxic) [mM]* 
Low drug concentration 
(Cmax) [mM]** 
Acetaminophen Diclofenac Acetaminophen Diclofenac Acetaminophen Diclofenac 
HepG2 6 0.05 
1.25 0.008 0.125 0.002 
HepaRG 3 0.2 
PHH1 2 0.3 
PHH2 3 0.3 
PHH3 1.5 0.3 
* Values were taken from dose response curves acquired prior to the metabolic characterization.  
** Values were taken from literature (Hinz et al., 2005; Sevilla-Tirado et al., 2003). 
 
2.3.13 Principal component analysis 
All calculated secretion rates ri,j were Pareto-scaled, i.e. centered using the mean secretion rate for 
each metabolite and drug, and divided by the square rooted standard deviation, resulting in pretreated 
rates ṙi,j  (eq. 2.8) which were then subjected to a principal component analysis (PCA) to reduce the 
complexity of the data set and visualize results. 
        [2.8] 
Loading coefficients were determined to identify the relevance of the individual secretion rates for 
separation of the different clusters. PCA and 95% confidence intervals were calculated in MatLab 
2007b (MathWorks, Nattick, MA, USA). 
2.3.14 Hierarchical cluster analysis  
Hierarchical cluster analysis (HCA) was applied to determine similarity of metabolic alterations in the 
different hepatic cells upon drug exposure. Before analysis, changes in the secretion rates r (Δri,j,d) 
upon drug exposure (index d) relative to the control (index ctrl) were calculated. To reduce the 
influence of rates with high absolute but low relative changes, and to correct for heteroscedasticity, 
data was normalized as following. The differences in rates from drug-treated to control conditions 
_
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were cube root transformed and subsequently scaled using the standard deviation as described in 
equation 2.9. 
       [2.9] 
Clustering and drawing of the heat map was done in MatLab 2007b using Euclidian distance as a 
measurement for similarity and Ward’s minimum variance method clustering algorithm. 
2.3.15 Student’s t-test 
Unpaired Student’s t-tests were performed using MatLab 2007b. Differences in two measurements are 
considered significant at p < 0.001, p < 0.01 and p < 0.05. 
 
2.4 Results 
2.4.1 Central carbon metabolites in untreated human hepatic cell lines and PHH 
A PCA on the secretion rates of untreated hepatic cells allowed their classification (figure 2.1) and 
identification of metabolites mostly contributing to their differences (figure S2.2). All hepatic cell 
systems were sorted into distinct clusters, while distances between the clusters within the different 
PHH were lowest, followed by the HepaRG cell cluster being close to PHH3 and PHH1. In addition, 
the HepaRG cell cluster was completely enclosed by the combined 95% confidence ellipse of the 
combined PHH cluster. Variance of the replicates was by lowest in HepaRG cells, and highest in 
PHH2. 
 
 
Figure 2.1 Principal component analysis on metabolic rates in untreated hepatic cells. Principal component 
analysis on Pareto-scaled secretion rates of untreated hepatic cells (n = 3). PHH1, PHH2 and PHH3 represent 
cells from 3 distinct donors. Principal components (PC) 1 and 2 are shown and their loadings are depicted in 
figure S2.2. Ellipses represent 95% confidence regions for each cell type individually (full lines) and additionally 
for all three donors of PHH combined (dashed line). 
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Metabolites with major impact on the separation of the clusters in the first principal component (PC1, 
mostly separation of HepG2 cells from other hepatic cells) and the second principal component (PC2, 
mostly separation of HepaRG and the different donors of PHH) were identical (figure S2.2), while 
separation along PC1 was clearly more pronounced than for PC2 (85% vs 11% contribution to total 
difference). Metabolites with highest relevance to cluster separation were glucose, lactate, urea, 
glutamine, glutamate, pyruvate and leucine. Based on the PCA, metabolites were selected and their 
secretion rates in untreated hepatic cells were compared (figure 2.2A). HepG2 cells had a strong 
uptake of glucose, which was 6 times higher than glucose uptake in HepaRG cells. PHH from all 
donors on the other hand secreted low (PHH1 and PHH3) to large quantities of glucose (PHH2). 
Similarly, HepG2 cells had a high demand in glutamine, whereas HepaRG cells only incorporated 
minor amounts. Consumption of glutamine in all PHH donors was slightly higher than in HepaRG 
cells, but notably lower than in HepG2 cells. Lactate secretion in HepG2 cells was more than 30 times 
higher than in HepaRG cultures and 12 to 60 times higher than in PHH. Ratios of lactate secretion to 
glucose uptake were 1.6 and 0.3 in HepG2 and HepaRG cells, respectively. In HepG2 cells, only 
traces of urea could be detected and the formation was around 1% of the average production found in 
PHH. Urea formation in HepaRG cultures was considerably higher compared to HepG2 cells with 4% 
of the average production in PHH. Pyruvate was secreted by both hepatic cell lines, whereas it was 
consumed in primary hepatocytes from all three donors. Alanine was taken up by all hepatic systems 
with a comparable level in HepaRG cells and PHH, and at a slightly lower rate in HepG2 cells. 
Leucine was taken up in the two hepatic cell lines at an identical rate, but secreted in low amounts in 
PHH from the three donors. 
From the mass isotopomer fractional enrichment in lactate (figure S2.3), contributions of pathways to 
the formation of lactate were calculated (figure 2.2B). Mass isotopomer fractions reached steady state 
after around 10 h for all hepatic systems. For HepG2 cells, 79% of lactate formation was based on 
glycolytic pathway activity. The pentose phosphate pathway and other sources were contributing with 
10 and 8%, respectively. In HepaRG cells only 18% of lactate formation was based on glycolysis and 
the major part was originating from other sources, which involve e.g. glycogenolysis. Likewise, in all 
PHH donors, other sources were the main contributors to lactate formation with percentages between 
79% and 87%, and glycolysis only contributing 7 to 11%. For all hepatic systems, gluconeogenesis 
from glutamine only played a minor role (2 to 3%). 
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Figure 2.2 Secretion rates in untreated hepatic systems and pathway contributions to lactate formation. 
Mean secretion rates of selected central metabolites in the metabolism of untreated HepG2 and HepaRG cells, as 
well as for primary human hepatocytes from three different donors (PHH1, PHH2, PHH3). Selection of 
metabolites was based on the metabolites contributing to separation of the clusters in the principal component 
analysis in figure 2.1. Negative secretion is equivalent to uptake. Dashed arrows represent secretion, the 
interconnection between the different metabolites and their role in metabolism is signified by full arrows. Error 
bars indicate standard deviation (n = 3) (A). Percentages of pathways contributing to formation of lactate in the 
different cell types. Pathways include glycolysis, pentose phosphate pathway (PPP), gluconeogenesis from 
glutamine, and other sources, e.g. glycogenolysis and gluconeogenesis from molecules other than glutamine (B). 
 
2.4.2 Metabolic competence in human hepatic cell lines and PHH 
CYP450 activities were assessed in the two human hepatic cell lines HepG2 and HepaRG and in PHH 
from three different donors (figure 2.3). In case of HepG2 cells, no activity was found for any of the 
tested CYP450 isoforms. On the other hand, activity was found for all tested isoforms in HepaRG 
cells. For the isoforms CYP2D6, CYP2B6 and CYP2E1, activity in HepaRG cells was significantly 
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lower than in all the PHH (86%, 68% and 83% lower than average activity in PHH, respectively). In 
case of the isoforms CYP1A2 and CYP3A4, activity was on the same level or slightly higher than for 
donor 1 (PHH1), but significantly lower than for donors 2 and 3 (PHH2, 3).  
 
 
Figure 2.3 Activity of CYP450 enzymes in different hepatic systems. CYP450 activities in HepaRG cells 
(black bars) and primary human hepatocytes from three different donors (PHH1, PHH2, PHH3; light, medium 
and dark grey bars, respectively) for the isoforms CYP2D6, CYP1A2, CYP2B6, CYP3A4 and CYP2E1. In case 
of HepG2 cells, products were not detectable. Error bars indicate standard deviation (n = 3). An unpaired 
Student’s t-test was performed for comparison of PHH to HepaRG cells. *, **, *** indicate a p-value of < 0.05, 
0.01 and 0.001, respectively. Measurements have been performed by Valery Shevchenko at Biopredic 
International, Saint Grégoire. 
 
2.4.3 Effects of acetaminophen and diclofenac treatment on viability of the different hepatic 
systems 
The two human hepatic cell lines HepG2 and HepaRG, and PHH from three different donors were 
exposed to the two hepatotoxic compounds acetaminophen and diclofenac and their effects on 
viability were investigated (figure 2.4). In case of acetaminophen, HepG2 cells were least sensitive 
with an EC50 value of 23.2 mM, followed by HepaRG cells with an EC50 value of 18.4 mM. PHH from 
all three donors were more sensitive to acetaminophen exposure with EC50 values ranging from 6.8 to 
12.7 mM and an average EC50 value of 9.2 mM. For diclofenac, HepG2 cells and PHH from donor 1 
and 2 were affected similarly by the treatment. EC50 values were 0.5, 0.5 and 0.45 mM, respectively. 
HepaRG cells were least sensitive with an EC50 value of 0.73 mM, which was slightly higher than for 
PHH3 (EC50 value 0.63 mM). In average, the EC50 value in PHH upon diclofenac exposure was 
0.53 mM. 
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Figure 2.4 Dose response curves and EC50 values in different hepatic systems upon exposure to 
acetaminophen and diclofenac. Dose response curves for HepG2 (●) and HepaRG cells (■), as well as for 
primary human hepatocytes from three different donors (PHH1 (▲), PHH2 (▼), PHH3 (♦)) exposed to 
acetaminophen (A) and diclofenac (B) for 24 h. Full lines represent curve fits using Boltzmann equation. Error 
bars indicate standard deviation (n = 3). EC50 values in HepG2 and HepaRG cells, as well as PHH1, PHH2 and 
PHH3 upon exposure to acetaminophen (C) and diclofenac (D). EC50 values are given and highlighted by grey 
diamonds. Upper and lower ends of the bars represent boundaries of the 90% confidence intervals. The mean 
EC50 values of the primary hepatocytes from the three donors are indicated by grey dashed lines (N = 3). 
Viability was assessed using the resazurin-based CellTiter-Blue® cell viability assay. 
 
2.4.4 Metabolic alterations in human hepatic cell lines and PHH upon drug exposure 
PCA were performed on the secretion rates in the individual hepatic cell systems treated with 
acetaminophen and diclofenac; together with controls (figure 2.5, figure S2.4). In all systems, 
secretion rates upon acetaminophen and diclofenac treatment could be distinguished from each other 
using a PCA, indicated by non or slightly overlapping confidence ellipses for the respective EC10 
conditions and arrows pointing into different directions, with exception of HepG2 cells. On the other 
side, strongest alterations upon drug exposure were observed for HepG2 cells, while changes in 
PHH1, and particularly PHH2 were less pronounced. 
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Figure 2.5 Principal component analysis on secretion rates in different drug-treated hepatic systems. 
Principal component analyses (PCA) representing all calculated secretion rates in treated (acetaminophen, 
diclofenac) and untreated hepatic cells (n = 3) for each system individually (HepG2 (A); HepaRG (B); PHH1 
(C); PHH2 (D); PHH3 (E)). Data was Pareto-scaled prior to the PCA. Circles and diamonds represent secretion 
rates from cells treated with the highest concentration (EC10) of acetaminophen and diclofenac, respectively. To 
increase clarity, data points for cells treated with lower concentrations are not depicted, but were part of the 
calculations (complete PCA plots in figure S2.3). White squares represent rates in control cells. Dotted, dashed 
and full lines indicate 95% confidence ellipses for acetaminophen-treated, diclofenac-treated and control cells, 
respectively. Red and blue arrows indicate the direction of the change from the control to cells treated with the 
highest concentration of acetaminophen or diclofenac. 
 
To further classify the trends of metabolic alterations in the different hepatic cell systems upon drug 
treatment and visualize their direction, an HCA was carried out and results were plotted in a heat map 
(figure 2.6). 
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Figure 2.6 Hierarchical clustering of secretion rates in hepatic systems exposed to acetaminophen and 
diclofenac. Effects of exposure to acetaminophen (A) and diclofenac (B) on the secretion rates in HepG2 (green 
bars) and HepaRG (red bars) cells, as well as primary human hepatocytes from three different donors (PHH1, 
PHH2, PHH3 (blue, yellow and grey bars, respectively)). The hierarchical clustering analysis is based on drug-
induced changes relative to the control. Drug-induced changes leading towards (increased) secretion or uptake 
are represented by red and blue colors, respectively. The different concentrations EC10, subtoxic concentration 
and cmax are indicated by E, S and C, respectively. 
 
Details on acetaminophen clustering 
Cluster analysis on alterations in the secretion rates upon acetaminophen treatment resulted in two 
main clusters; PHH2 on the one hand, and all other cell systems on the other hand. The latter cluster 
was in turn divided into PHH3 and HepG2 on one side, and PHH1 and HepaRG on the other side. It is 
noteworthy that for PHH1 and PHH2 only 4 of the drug-induced alterations were significant, whereas 
the maximum number of significantly changed rates (a total of 18) was found for HepG2 cells 
(table S2.2). Generally, drug-induced alterations were weaker than differences between the systems 
and individuals. Hence, each system formed an individual cluster, with exception of the EC10-treated 
HepaRG cells clustering together with the EC10-treated PHH1. 
There was a general trend towards (increased) glucose uptake upon high dose acetaminophen 
exposure; however not in case of HepG2 cells. The trend in lactate secretion was inconsistent between 
the different systems. There was a trend towards (increased) secretion for HepaRG cells and PHH1, 
while the opposite was the case for the other systems. Pyruvate metabolism was similarly affected in 
all cell systems with a trend towards (increased) uptake, except for PHH2. Upon treatment with the 
EC10, a trend towards (increased) secretion was observed for 8 amino acids; except for PHH2 – 
amongst others alanine, the branched chain amino acids (BCAA) valine and isoleucine and two 
aromatic amino acids (AAA) tyrosine and phenylalanine. The third AAA tryptophan was the only 
metabolite for which the same trend was observed in all cell systems and under all conditions. 
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Details on diclofenac clustering 
Cluster analysis on diclofenac-treated cells gave rise to two major clusters. HepG2 cells and the EC10-
treated HepaRG cells, PHH2 and PHH3 in one cluster, while their remaining conditions and PHH1 
were grouped into the second cluster. In case of diclofenac treatment, only 9 rates were significantly 
affected for PHH1, while numbers ranged from 14 to 16 for the other cell systems. 
For alanine, uptake was decreased in all systems upon exposure to the EC10, except for HepG2 cells. 
BCAA (valine and isoleucine) and AAA (tryptophan and phenylalanine) uptake at EC10 was lower in 
all systems, except for PHH1, where uptake was increased. For the metabolites glucose, methionine, 
lactate and pyruvate, trends in alterations at the EC10 were identical in all systems. The former two 
metabolites were found to show a trend towards (increased) secretion, while for the latter two, there 
was a trend towards (increased) uptake. 
 
2.5 Discussion 
To draw conclusions from in vitro toxicity data, relevant for preclinical drug development and risk 
assessment in other industries, the experimental conditions, including the model cell system, have to 
reflect the in vivo situation as closely as possible. This implies that the model cell system reacts to 
stimuli as it happens in vivo. So far, PHH are the gold standard in toxicity assessment, but many 
studies have shown that HepaRG cells could be a suitable surrogate with unlimited availability and 
superior long-term stability. Yet, up to now, these studies had a strong focus on mRNA level and 
neglected other cellular levels (Aninat et al., 2006; Gerets et al., 2012; Hart et al., 2010; Jennen et al., 
2010). In the present study, we first investigated key metabolites in the central carbon metabolism as 
well as metabolic competence in untreated hepatic cell lines HepG2 and HepaRG and compared it to 
PHH. Subsequently, the hepatic cell systems were exposed to two pharmaceutical compounds, 
acetaminophen and diclofenac, and their effects on viability and metabolism of the cells were 
evaluated. 
2.5.1 Central carbon metabolites in untreated human hepatic cell lines and PHH 
When investigating key metabolites of the central carbon metabolism in the different hepatic systems, 
we found that glucose uptake in HepG2 cells was significantly higher than in all other tested systems. 
The additional glucose molecules can be used for the generation of energy and for integration into 
cellular constituents, both of which is required as HepG2 cells were the only tested cells capable of 
proliferation. The majority of glucose (around 80%) was converted into lactate, which was mostly 
derived from glycolysis, and subsequently secreted into the medium. In previous studies, high 
glycolytic activity in cancer cells has been associated to compensate for the lower ATP formation due 
to reduced tricarboxylic acid (TCA) cycle activity (Kim et al., 2006), triggered by inherently increased 
ROS levels. ROS upregulate the hypoxia-inducible factor 1α (HIF-1α) (Jung et al., 2008; Shi et al., 
2009) which leads to inactivation of the pyruvate dehydrogenase (Kim et al., 2006) and transcription 
of glucose transporters and the complete set of enzymes involved in glycolysis (Denko, 2008; Lee et 
al., 2004). To recover NAD
+
 from NADH, which is produced during glycolysis and normally reverted 
to NAD
+
 through oxidative phosphorylation, expression levels of L-lactate dehydrogenase B (LDH-B) 
are elevated likewise (Zhou et al., 2012, 2011), resulting in notably higher lactate secretion. This 
process of aerobic glycolysis is also known as the Warburg effect (Ferreira, 2010). We observed that 
relative contribution of the PPP to lactate formation in HepG2 cells was slightly higher than in the 
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other cell systems, which is likely to be related to the higher demand in nucleic acid building blocks as 
well as NADPH in proliferating cells. 
Though the HepaRG cell line is also derived from a tumor, more precisely from a hepatocarcinoma 
(Gripon et al., 2002), glucose uptake was significantly lower compared to HepG2 cells and lactate 
secretion was in the range of PHH. We hypothesize that there are two main factors contributing to the 
differences in glucose metabolism in HepG2 and HepaRG cells. 1) Energy metabolism is more 
efficient, i.e. based on energy formation via oxidative phosphorylation instead of glycolysis. This 
hypothesis is supported by a notably lower lactate secretion to glucose uptake ratio in HepaRG cells 
(1.6 in HepG2 vs 0.3 in HepaRG cells), indicating that the majority of glycolytic products was 
channeled into the TCA cycle. This may be a result of lower HIF-1α mRNA levels in HepaRG 
compared to HepG2 cells, shown by data from previous whole genome gene expression level studies 
(Hart et al., 2010; Jennen et al., 2010). 2) HepaRG cells are not proliferating and therefore require less 
energy for the production and upkeep of macromolecules. 
Contrary to the cell lines and against our expectations, for all donors of PHH we observed secretion of 
glucose, which may partially also be related to HIF-1α, for which mRNA levels in PHH are even 
lower than in HepaRG cells (Hart et al., 2010). Considering that the culture medium used in this study 
contains high concentrations of glucose and insulin, the medium may be compared to a postprandial 
situation in vivo. Both, glucose and insulin levels play a critical role in the regulation of glucose 
metabolism in healthy humans and high levels result in inhibition of gluconeogenesis and stimulation 
of glucose and amino acid uptake into the liver (Edgerton, 2006; Moore et al., 2012). For comparison, 
postprandial hyperglycemia starts at blood glucose levels of 2 g/l (Giugliano et al., 2008), which is the 
same concentration used in the culture medium. In addition, insulin levels in the culture medium are 
around 2,000 times higher than the maximum levels postprandially found in the blood of healthy 
individuals (Kelley et al., 1994). Winnike et al. have described similar observations in PHH in a 
previous study and related these to a stress response to injury and surgery, resulting in release of 
epinephrine, cortisol and glucagon leading to glucose intolerance, glycogenolysis and gluconeogenesis 
(Winnike et al., 2012). Further, we found very similar relative contributions to lactate formation in 
HepaRG cells and PHH, with a slightly higher contribution from glycolysis in HepaRG cells, which 
probably resulted from the net uptake of glucose, not observed in PHH. 
Similar to glucose, we observed that pyruvate metabolism differed notably between cell lines and 
PHH. Contrary to the two cell lines secreting pyruvate, PHH ingested notable amounts of pyruvate 
which may serve as alternative fuel for the TCA cycle as PHH did not rely on extracellular glucose. 
Other than that, it was shown in previous studies that pyruvate does not only serve as a carbon source 
in central metabolism, but has also been related to maintenance of CYP450 (Tomita et al., 1995) and 
glutathione S-transferase (GST) activity in primary hepatocytes (Vanhaecke et al., 2001). As PHH 
readily dedifferentiate in 2D in vitro cultures (Godoy et al., 2009), increased uptake of pyruvate might 
act as a measure to counteract the dedifferentiation process.  
Demand in glutamine in HepG2 cells was significantly higher than in the other systems. This could on 
the one hand again be attributed to the proliferating nature of the cell line and thus, a higher demand in 
nucleic acid and protein building blocks, but also to fulfilling some of the many additional biological 
functions previously described for glutamine. These functions include serving as a carbon source for 
de novo lipogenesis (Metallo et al., 2011), as source for pyruvate and TCA intermediates (Yang et al., 
2014), as well as supporting glutathione synthesis (DeBerardinis and Cheng, 2010). Even more, 
studies have shown a regulatory role of amino acids, in particular glutamine and leucine, on the 
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mammalian target of rapamycin complex 1 (mTORC1). mTORC1 is a master regulator of protein 
translation and cell growth and plays an important role in cancer cells (Wise and Thompson, 2010). 
Besides its role in regulation of mTORC1, leucine in the human liver is mainly used as a building 
block for macromolecules and not for production of energy. Redundant leucine is secreted by the liver 
and taken up by muscle tissue where it is used for both, protein synthesis and energy production 
(Brosnan and Brosnan, 2006). We found minor secretion of leucine in PHH, whereas it was taken up 
by both cell lines, which we expected for all our in vitro cultures based on the amino acid’s essential 
nature. Though leucine secretion is a typical function of the liver in vivo, the question arises as to 
where it is originating from in in vitro cultures. One hypothesis is that secreted leucine is related to 
cell death and resulting proteolysis. As a first step, the rationality of the hypothesis can be checked by 
balancing the amount of secreted leucine against the amount of leucine within the cell, estimated from 
literature data. Accounting for more than 10% of the mole fraction of amino acids in human liver 
microsomes, leucine, together with glutamate, is the most abundant amino acid (Benga and Ferdinand, 
1995). Using previously described data on the protein content in PHH (Richert et al., 2006) for an 
estimation, secretion of leucine is equivalent to less than 5% of the total protein mass. Thus, from a 
balancing point of view, proteolysis is a valid hypothesis for the secretion of leucine, however, looking 
at viability data (not shown), there is no evidence for major cell loss.  
In vivo, alanine is secreted by muscle cells in exchange for glucose and taken up in the liver, where it 
can be converted into pyruvate in a one-step transamination reaction via the alanine aminotransferase, 
which then serves as a substrate for gluconeogenesis. This cycle, also referred to as Cahill cycle, on 
the one hand serves the purpose of carbohydrate regeneration, and on the other hand the transport of 
ammonia from muscles to liver for detoxification via the urea cycle. In tumor cells, secretion of 
alanine has been reported, resulting from a surplus in glycolysis and glutaminolysis pathways 
(DeBerardinis and Cheng, 2010). In our study, we observed alanine uptake for all tested hepatic 
systems, including HepG2 cells. Uptake rates were in a similar range with exception of HepG2 cells, 
for which the uptake was around half of the other systems. Based on these findings, uptake of alanine 
seems to be a well-conserved function in liver cells, however, in case of HepG2 cells uptake was 
reduced probably resulting from high glycolytic and glutaminolytic fluxes and the absence of 
gluconeogenesis. Consequently, the carbon backbone of alanine is unlikely to serve as a substrate in 
gluconeogenesis, instead its use in protein synthesis and substrate in the TCA cycle are more likely. 
The urea cycle in HepG2 cells is known to be impaired due to the absence of two essential enzymes, 
ornithine transcarbamylase and arginase I (Mavri-Damelin et al., 2007). Minor production of urea, as 
also observed in our study, has been related to activity of the arginase II enzyme, which however does 
not aid in the detoxification of ammonia (Mavri-Damelin et al., 2008). It is not known how HepG2 
cells dispose of redundant ammonia. It was suggested that tumor cells directly secrete ammonia 
involving protein transporters (DeBerardinis and Cheng, 2010). Though urea formation in HepaRG 
cells is significantly higher, it remains questionable whether this is sufficient for complete removal of 
redundant ammonia. On the contrary, urea cycle was intact and highly active in PHH, being in the 
range of in vivo rates (in vitro 6 - 10 µg/(10
6
 hepatocytes × h); in vivo 5-8 µg/(10
6
 hepatocytes × h), 
(Bhatia et al., 1999)).  
Generally, secretion rates in HepaRG cells were more similar to PHH, than secretion rates in HepG2, 
as additionally confirmed in the multivariate analysis. Noteworthy, unlike HepG2 cells, carbon 
metabolism in HepaRG cells did not show notable tumor-like characteristics. 
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2.5.2 Metabolic competence in human hepatic cell lines and PHH 
Activity of the investigated CYP450 enzymes in HepG2 cells was too low and therefore no products 
could be detected using our LC/MS-based approach. In contrast, products for all isoforms were 
detected in HepaRG cells, though in most cases at lower concentrations than in PHH. Generally, lower 
CYP450 enzyme activity in HepG2 cells has been attributed to lower transcription of CYP450 genes 
based on differential expression of key transcription factors (liver enriched transcription factors, 
LETFs), such as the hepatocyte nuclear factors (HNF) (Jover et al., 2001; Rodriguez-Antona et al., 
2002).  
Despite the fact that both hepatic cell lines are tumor derived, there were striking differences in their 
CYP450 activity and we hypothesize that one explanation could lie within their origin: The HepG2 
cell line is derived from a hepatoblastoma (Dearfield et al., 1983), while HepaRG cells originate from 
a hepatocellular carcinoma (Gripon et al., 2002). The former has a higher prevalence of activation of 
β-catenin (Buendia, 2002), which is an antagonist for effects of activated peroxisome proliferator-
activated receptor α (PPARα). PPARα has also been reported to regulate CYP450 enzyme expression 
together with other transcription factors, such as HNF (Thomas et al., 2015, 2013). Aninat et al. have 
further suggested that limited chromosomal rearrangements in HepaRG cells and their ability to 
differentiate into hepatocyte and biliary epithelial-like cells (HLC, BLC), which allows more in vivo-
like cultivation, contribute to a phenotype that is closer to PHH than HepG2 cells (Aninat et al., 2006; 
Gripon et al., 2002). 
Higher CYP450 activity in PHH was most obvious for donors 2 and 3, which were both male, while 
less distinct for donor 1, which was female. Sex differences in CYP450 expression were described 
previously, but were reported to be less pronounced in humans than in other animals, e.g. rats 
(Waxman and Holloway, 2009). Parkinson et al. investigated sex differences in CYP450 activity in 
cryopreserved human hepatocytes and only found significant differences for the isoform CYP3A4 
(Parkinson et al., 2004). Inconsistent with our data, Parkinson reported a two-fold higher activity in 
female hepatocytes, compared to male, whereas in our study, activity for the female donor was around 
two-fold lower. However, variance in CYP450 activity within the population is high (Parkinson et al., 
2004) and the sample size in our study is too little to allow drawing reliable conclusions on sex 
differences in PHH. Effects of CYP450 activity in the context of drug-induced toxicity will be 
discussed in the following. 
2.5.3 Effects of acetaminophen and diclofenac treatment on viability of the different hepatic 
systems 
In our study, EC50 values upon acetaminophen exposure were lowest in PHH (9.4 mM in average), 
followed by HepaRG (18.4 mM) and HepG2 cells (23.2 mM). This is in accordance with the CYP450 
enzyme activities found in these cell systems, decreasing from PHH to HepG2 cells, underlining 
previous findings, reporting that acetaminophen-induced hepatotoxicity is mainly mediated by the 
reactive metabolite NAPQI (Dahlin et al., 1984). In both cell lines toxicity upon acetaminophen 
exposure was underestimated eminently. In addition, for HepG2 cells it also has to be noted that 
toxicity does not occur via necrosis as it is the case in vivo, PHH and HepaRG cells (Mcgill et al., 
2012; McGill et al., 2011; Xie et al., 2014), but via apoptosis (Manov et al., 2004), suggesting that the 
HepG2 cell line is a poor model cell system to study acetaminophen toxicity, at least in 2D cultures 
(Aritomi et al., 2014). The apparent discrepancy in the EC50 values in HepaRG cells and PHH can 
likely be attributed to the two different cell types in HepaRG cultures – HLC capable of metabolizing 
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acetaminophen on the one hand, and BLC incapable of acetaminophen metabolization on the other 
hand. 
Exposing the different hepatic systems to diclofenac, we found that the EC50 value of HepG2 cells was 
in line with the EC50 values obtained in PHH (0.5 mM vs 0.53 mM in average). HepaRG cells were 
least sensitive to diclofenac exposure (EC50 0.73 mM). Hence, there was no apparent correlation 
between EC50 values and the activity of the tested CYP450 isoforms. However, we did not quantify 
activity of members of the CYP2C family, being the most relevant group in case of diclofenac 
metabolization (Bort et al., 1999). Comparing expression profiles of members of the CYP2C family 
(CYP2C9 and CYP2C18) in HepG2, HepaRG and PHH from previous studies (Aninat et al., 2006; 
Gerets et al., 2012), we find a similar picture as we have shown in our study for the other CYP450 
isoforms (figure 2.3). Therefore, this would indicate that the parent compound is the major cause of 
toxicity in HepG2 cells. On the other hand, in literature EC50 values for HepG2 cells upon acute 
diclofenac exposure were around 0.8 mM (Bort et al., 1998; Choi et al., 2015), suggesting that the 
HepG2 EC50 value in our study was underestimated. Additionally, keeping in mind the two 
populations in HepaRG cultures, extent of toxicity may nevertheless correlate with CYP450 activities. 
2.5.4 Metabolic alterations in human hepatic cell lines and PHH upon drug exposure 
Next, we investigated the effects of the two drugs on the central carbon metabolism in all of the 
hepatic systems to study similarities and differences in cell lines compared to PHH. Since effects in 
PHH were partially inconsistent in themselves, we additionally reviewed other studies on 
acetaminophen- and diclofenac-induced metabolic alterations, as well as the drugs’ interactions with 
metabolism-related transcription factors.  
As demonstrated in the PCA on the metabolic alterations upon drug exposure, effects on metabolism 
were strongest in case of HepG2 cells and hence resulted in best separation from the control. At the 
same time and contrary to the other hepatic systems, the same metabolites were affected with an 
overall identical trend in HepG2 cells treated with either acetaminophen or diclofenac. Both 
observations may be related to an impaired regulation of carbon metabolism and a limited set of 
possible metabolic alterations in cells with a pronounced cancer phenotype, compared to cells with a 
healthy metabolic phenotype. One example is the assessment of mitochondrial toxicity in HepG2 cells. 
Since HepG2 cells largely depend on glycolysis for the generation of energy, they cannot be used for 
the identification of mitochondrial toxicity using standard cultivation conditions, but require special 
media compositions (Marroquin et al., 2007). Then again, recent studies have demonstrated the use of 
HepG2 cells for discriminating between different toxicological mechanisms upon drug treatment, 
including steatosis, oxidative stress and phospholipidosis (García-Cañaveras et al., 2016, 2015). 
Despite the presence of an additional cell type in HepaRG cells potentially masking metabolic 
alterations caused by HLC, separation of drug-treated conditions from controls was better than in 
PHH, except for PHH3, partially resulting from the low variance of the secretion rates within the 
replicates. 
For both drugs, upon treatment with the EC10, a trend towards decreased uptake/ increased secretion 
was observed for the vast majority of amino acids in all systems, except for PHH2 in case of 
acetaminophen and PHH1 in case of diclofenac. For the latter two conditions, behavior for most 
metabolites was contrary to all other systems as indicated in the cluster analysis, and metabolic 
alterations were statistically significant only for a small number of metabolites. For all other systems 
and conditions, the observed effects on amino acids may either originate from a lower demand in 
substrates for energy metabolism, or more likely from a lower protein synthesis and elevated 
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degradation of proteins. Based on previous findings that acetaminophen and diclofenac cause 
mitochondrial dysfunction (Bort et al., 1998; Burcham and Harman, 1990; Gómez-Lechón et al., 2003; 
McGill et al., 2014; Meyers et al., 1988), we expect treatment to trigger a metabolic switch towards 
less efficient energy formation and therefore it is unlikely that drug exposure leads to a decreased 
consumption of energy-rich substrates. Instead, the two drugs have also been associated with ER stress 
(Nagy et al., 2007; Tsutsumi et al., 2004), an indirect consequence of the mitochondrial dysfunction 
(Lim et al., 2009) and oxidative stress (Tse et al., 2016). ER stress leads to lysis of un- and misfolded 
proteins and reduced protein synthesis (Haynes et al., 2004; Ron and Walter, 2007), matching the 
observed changes in amino acid transport when cells were treated with acetaminophen and diclofenac. 
Additionally, formation of reactive metabolites has been ascribed to both, acetaminophen and 
diclofenac (Kretzrommel and Boelsterli, 1993; Mitchell et al., 1973), suggesting the induction of HIF-
1α expression upon exposure. Based on this, as well as on the impairment of mitochondrial function, 
we expected elevated glucose uptake and lactate secretion for both drugs, resulting from an 
upregulation of glycolytic genes and compensation for a less efficient energy formation. Glucose 
uptake indeed was elevated for all systems at the EC10 when treated with acetaminophen, except for 
HepG2 cells. Winnike et al. further related the increase in glucose uptake observed in acetaminophen-
exposed PHH to the glucuronidation of acetaminophen, which requires a glucose derivative as 
substrate (Winnike et al., 2012). When exposed to the EC10 of diclofenac, in none of the cases we 
observed an increased glucose uptake. Gottfried et al. recently reported a decrease in glucose 
transporter 1 (GLUT1), lactate dehydrogenase A (LDHA) and monocarboxylate transporter 1 (MCT1) 
gene expression in different diclofenac-treated tumor cell lines (Gottfried et al., 2013), an effect that 
seems to superimpose metabolic alterations originating from mitochondrial dysfunction and oxidative 
stress.  
Regarding lactate secretion upon acetaminophen exposure, we did not find a common trend for the 
different systems, and only for HepaRG cells and PHH1 we observed the expected increase at the 
EC10. For diclofenac at EC10 on the other hand, we observed a decrease in lactate secretion for all 
tested systems, which contradicts expected results based on previous studies reporting mitochondrial 
dysfunction and oxidative stress, but is in accordance with the decrease in GLUT1, LDHA and MCT1 
gene expression. 
For pyruvate, we found a trend towards (increased) uptake for both drugs at EC10 for all systems, 
except for PHH2 upon acetaminophen exposure. Pyruvate has been shown to protect against ROS-
induced cytotoxicity (Andrae et al., 1985; Kelts et al., 2015) and therefore, the observed trend in 
pyruvate uptake may serve as a general cellular response to protect cells from ROS generated upon 
drug treatment, and to compensate for pyruvate lost in the ROS quenching reaction. 
Besides glucose, alanine was one of the few significantly altered metabolites for which we found 
changes to differ between HepG2 cells and the other hepatic systems. As HepG2 cells mostly rely on 
glucose as a carbon source, and diclofenac severely impaired its uptake, alanine might have served as 
an alternative source when HepG2 cells were exposed to the EC10 of diclofenac. For the other systems, 
dependence on glycolysis was less prominent, and impairment of glucose metabolism was less severe, 
not requiring an alternative carbon source. 
Other than that, surprisingly, the changes for the majority of significantly altered metabolites were the 
same in the different cells, even though they differed tremendously in the transport rates of central 
carbon metabolites in the basal state. We expected differences to be more pronounced as the 
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abundance of metabolic regulators and drug metabolizing enzymes for many cases are strikingly 
different between PHH and HepG2 cells, and to minor extent also to HepaRG cells. 
In summary, HepaRG cells allowed to study alterations in central carbon metabolites upon drug 
exposure. Results were in accordance with changes found in PHH, as well as with literature data. 
HepG2 cells also allowed to study certain aspects of drug-induced metabolic alterations, but were not 
capable of adequately reflecting some pathways, due to intrinsic restrictions. 
 
2.6 Conclusion 
In conclusion, the basal carbon metabolism in HepaRG cells closely resembled the metabolism in 
PHH, but lacked, e.g. high urea cycle activity. On the other hand, they neither exhibited a cancer-like 
metabolic phenotype as in case of HepG2 cells, nor a metabolic phenotype dominated by a stress 
reaction as observed for certain metabolites in PHH. The metabolic response to drug exposure was 
similar in all systems including HepG2 cells, yet HepaRG cells more accurately reflected the 
metabolic alterations observed in PHH, particularly those directly or indirectly related to glucose 
metabolism. Results obtained in different donors of PHH varied greatly in some cases, likely resulting 
from interindividual differences, which cannot be mapped adequately using a single cell line. In this 
study, we illustrated that the HepaRG cell line is a promising alternative to PHH, when studying the 
metabolic phenotype of hepatocytes and its general alterations when exposed to drugs. 
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Chapter 3 Hepatotoxicity assessment in 3D and in 2D high-throughput 
systems using HepaRG cells 
3.1 Abstract 
Many new systems for three-dimensional (3D) in vitro cultivation are entering the market and are 
focus of current research in different fields. With their help, cells are supported in forming structures 
to mimic in vivo complexity and maintain tissue specific activity, allowing more reliable physiological 
and toxicological studies. In combination with cell lines, such as the human hepatic HepaRG, 3D 
cultivation systems that are amenable to high-throughput screening (HTS) potentially allow for the 
testing of the vast number of compounds currently needed in risk assessment. In this study, we 
investigate drug uptake, phase I and phase II metabolism, as well as reduced and oxidized glutathione 
levels in HepaRG cells, cultivated in different three-dimensional and two-dimensional systems, all 
suitable for HTS. The systems comprise Alvetex® polystyrene scaffold (APS), collagen sandwich, 
spheroid and monolayer cultures. Additionally, we investigate the impact of the choice of cultivation 
setup on the outcome of toxicological studies by treating cells with single and repeated doses of three 
different hepatotoxic compounds. The tested parameters differ drastically between the different 
systems, even within the 3D-type systems. Notwithstanding, EC50 values upon compound exposure 
were in the same range for the different test systems, with exception of APS cultures. In addition, in 
all systems, HepaRG cells were showing increased sensitivity upon repeated exposure to the 
compounds. Taken together, classical monolayer cultivation as well as spheroids of HepaRG cells are 
most promising candidates for application in an HTS setup, allowing for reliably testing large numbers 
of compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in preparation for submission as 
Klein S, Maggioni S, Noor F, Heinzle E. Hepatotoxicity assessment in 3D and in 2D high-throughput 
systems using HepaRG cells 
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3.2 Introduction 
Three-dimensional (3D) hepatocyte cultures are considered as one of the central tools in future in vitro 
toxicity assessment (Meng, 2010). Together with a high-throughput screening (HTS) approach, this 
allows effective and reliable assessment of potential toxicity for large numbers of compounds in an in 
vivo-like environment with corresponding functionality. Primary human hepatocytes (PHH) are the 
gold standard in in vitro toxicity assessment; however, their usefulness in an HTS setup suffers from 
their scarce availability and limited lifespan. Additionally, they often originate from heavily medicated 
patients, which may interfere with subsequent studies. Therefore, there is an urgent need for HTS 
systems that rely on the use of established cell lines (Kunz-Schughart et al., 2004). 
In the recent years, the human HepaRG cell line drew more and more attention in the field of 
toxicology as it closely resembles primary human hepatocytes (PHH) in terms of drug metabolism and 
intact liver specific pathways without sharing the disadvantages mentioned above (Aninat et al., 2006; 
Josse et al., 2008; Lübberstedt et al., 2011). Though a 3D environment is not essential for long-term 
stability of HepaRG cells (Josse et al., 2008; Klein et al., 2014), it has been shown to improve 
metabolic competence of most cytochrome P450 (CYP450) isoforms (Bhattacharya et al., 2012; 
Gunness et al., 2013; Leite et al., 2012; Malinen et al., 2014; Mueller et al., 2014; Rebelo et al., 2014).  
For our study, we chose four different cultivation systems that are amenable to an HTS setup: 2D, 
collagen sandwich (CSW), Alvetex® polystyrene scaffold (APS) and spheroid cultivation. While cells 
in 2D cultures are seeded on a single thin layer of collagen, cells in a CSW are entrapped between two 
thick collagen gels, allowing the cells to arrange in two to three layers and form an in vivo-like 
cuboidal geometry. Collagen-coated APS offer a highly porous and rigid environment, which supports 
formation of in vivo-like geometry and facilitated nutrient diffusion into deeper cell layers compared 
to other 3D setups. On the other hand, spheroid cultures are scaffold-free and thus, there are no 
interactions with an artificial surface but only to other cells. For better comparison, all experiments 
were performed in a 96-well format. 
For adequate assessment of toxicity, it is insufficient to rely only on single dose toxicity, but it is 
essential to include repeated dosing in toxicological studies. Here, we applied three hepatotoxic 
compounds which cover different mechanisms and outcomes, using single and repeated dosing 
regimens. These drugs were chlorpromazine, bosentan and valproic acid. Chlorpromazine is a 
neuroleptic medication that elicits cholestasis in vitro and in vivo (Anthérieu et al., 2012a; Padda et al., 
2011). Bosentan, an endothelin receptor antagonist, also causes cholestasis but unlike chlorpromazine 
does not depend on the formation of oxidative stress. Instead it inhibits the export of bile salts via the 
bile salt export pump (Fattinger et al., 2001). The effects of the anticonvulsant valproic acid are 
complex. It interferes with histone deacetylation as well as several enzymes of the central carbon 
metabolism and eventually causes microvesicular steatosis (Aires et al., 2011, 2010, 2008; Göttlicher 
et al., 2001; Luís et al., 2011, 2007) 
We focused our research on phase I (CYP3A4 activity and induction) and phase II metabolism as well 
as drug uptake in the different cultivation systems. Furthermore, we investigated levels of the radical 
scavenger glutathione and the effects of the drugs on cellular viability. Finally, we simulated oxygen 
supply in the tested devices to investigate for potential shortages. The results obtained within the study 
aid in selection of an adequate cultivation setup depending on the desired properties of the system. 
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3.3 Methods 
3.3.1 Cell culture  
The human hepatoma cell line HepaRG was purchased from Biopredic International (St. Grégoire, 
France). Detailed seeding instructions are described individually below. Cells were cultured in a cell 
culture incubator (Memmert GmbH, Schwabach, Germany) at 37°C with 95% relative humidity and 
5% CO2 supply. The outer wells of the culture plates were not used for cultivation, but were filled with 
sterile distilled water (Gibco Invitrogen, Darmstadt, Germany) to avoid evaporation of medium. After 
seeding, cells were cultured for 4 days in 100 µl Williams Medium E (WME; Pan Biotec, Aidenbach, 
Germany), supplemented with serum-free supplement ADD650 (Biopredic International, St. Grégoire, 
France) and 0.5% dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis, MO, USA) (Maintenance & 
treatment medium (MT medium)). On the 4
th
 day of cultivation, experiments for drug uptake, phase I 
and II metabolism, glutathione quantification as well as toxicity were initialized. In the results and 
discussion section, beginning of experiments is referred to as day 0. 
3.3.1.1 2D cultures 
Before cell seeding, 96-well plates (Greiner Bio-One, Frickenhausen, Germany) were incubated for 
1 h with 100 µl of 50 µg/ml type I rat collagen (Roche Applied Sciences, Penzberg, Germany) in 
Dulbecco’s Modified Eagle Medium (DMEM; AMIMED BioConcept, Allschwil, Switzerland). 
Afterwards, wells were rinsed once with 100 µl sterile phosphate buffered saline (PBS; Gibco 
Invitrogen, Darmstadt, Germany) and equilibrated with WME overnight. Differentiated HepaRG cells 
were seeded in the collagen-coated 96-well plates 4 days prior to treatment with a density of 72,000 
cells per well (n = 3) in 100 µl WME with supplement ADD670 (Biopredic International, St. 
Grégoire, France) and 0.5% DMSO (Thaw & seed medium (TS medium)). 
3.3.1.2 3D cultures in Alvetex® polystyrene scaffold  
Prior to cell seeding, the 96-well APS (Reinnervate, Sedgefield, United Kingdom) were incubated 
with 100 µl 70% ethanol for 2 minutes and subsequently rinsed with 100 µl PBS. Afterwards collagen 
coating and seeding was performed as described for 2D cultures. 
3.3.1.3 3D Collagen Sandwich cultures 
For 3D CSW a collagen solution of 4.5 ml type I rat collagen in 0.2% acetic acid and 0.5 ml DMEM 
was prepared, resulting in a final concentration of 1 mg collagen/ml. A neutral pH was achieved using 
sterile 1 M NaOH.  
70 µl of the freshly prepared collagen solution were added to 96-well plates to form the bottom 
collagen layer. After 1 h incubation at 37°C the collagen gel was washed once with 100 µl PBS and 
was then equilibrated with 100 µl WME for 30 minutes at 37°C. Afterwards, medium was removed 
and 72,000 cells per well in 100 µl TS medium were added. After 3 h adherence at 37°C, supernatants 
were removed and a top layer of collagen was added using a freshly prepared collagen solution as 
described above. After the collagen solidified, 100 µl of TS medium were added on top. 
3.3.1.4 3D spheroid cultures 
HepaRG cells were seeded in 96-well GravityPLUS
TM
 culture plates (InSphero, Zurich, Switzerland) 
with 2,000 cells per well, suspended in 40 µl TS medium. After 4 days in culture, spheroids were 
harvested into GravityTRAP
TM
 plates (InSphero, Zurich, Switzerland) using 80 µl TS medium. 
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3.3.2 CYP3A4 induction and activity assay 
A 10 mM rifampicin (Sigma Aldrich, St. Louis, MO, USA) stock solution was preprared in DMSO for 
the induction of CYP3A4 expression. MT medium was used to perform the dilution steps. HepaRG 
cells were incubated for 24 h with rifampicin concentrations ranging from 5 nM to 5 µM with an 
additional untreated control. For the CYP3A4 activity assay, supernatants were removed and CYP3A4 
P450-Glo Assay with Luciferin-IPA (Promega, Madison, USA) was performed according to 
manufacturer’s instructions with 45 minutes incubation at 37°C. Measured CYP3A4 activity was 
normalized to the seeded cell number. 
3.3.3 Preparation of drug solutions and treatment 
300 mM bosentan (Sequoia Research, Pangbourne, UK) and 50 mM chlorpromazine hydrochloride 
(Sigma Aldrich, St. Louis, MO, USA) stock solutions were prepared in DMSO. Sodium valproate 
stock solution (Sigma Aldrich, St. Louis, MO, USA) was prepared directly in MT medium in a 
concentration of 150 mM. First dilution of bosentan and chlorpromazine was performed in DMSO-
free MT medium, while all further dilutions were prepared in standard MT medium to keep DMSO at 
0.5% (v/v). Four days after seeding, HepaRG cells were treated with the compounds for either 24 h 
(single dose) or 72 h (three doses) with medium renewal every 24 h. Volumes were 100 µl for 2D, 
APS and CSW cultures and 70 µl for spheroid cultures. In case of CSW cultures, wells were briefly 
rinsed twice with medium containing the compound to reduce the effect of drug dilution, due to 
substantial volume of the collagen layers. 
3.3.4 Quantification of ATP 
To determine viability of the cells upon drug exposure, ATP was quantified using CellTiter Glo® 
Luminescent Cell Viability Assay (Promega, Mannheim, Germany) according to manufacturer’s 
instructions. In case of CSW cultures, the suspension was mixed vigorously upon addition of the lysis 
and substrate reagents to ensure penetration into the collagen layers and allow immediate cell lysis as 
for the other cultivation systems. 
3.3.5 Quantification of reduced and oxidized glutathione  
Reduced and oxidized glutathione (GSH, GSSG) were quantified using the GSH/GSSG-Glo
TM
 assay 
(Promega, Mannheim, Germany) according to manufacturer’s instructions. 
3.3.6 Quantification of valproic acid uptake and VPA glucuronide release 
For the determination of the drug uptake and secretion of drug metabolites, the total drug parent 
compound concentration of valproic acid and its metabolite VPA glucuronide were quantified in 
medium supernatants. The compounds were extracted from 25 µl of medium supernatants collected 
after 6 h of treatment as described in the following. As a reference, supernatants were additionally 
collected from cell-free incubations at 37°C. 
 First, the internal standard for valproic acid (Sigma Aldrich, Steinheim, Germany), valproic acid-d6 
(Toronto Research Chemicals, Toronto, Canada) was added. Then, for extraction, 75 µl acetonitrile, 
acidified with 0.1% formic acid (Sigma Aldrich, Steinheim, Germany), were added. Samples were 
vortexed for 30 s, followed by centrifugation at 12,100 g for 10 minutes. 25 µl of the supernatants 
were collected and diluted with 50 µl MilliQ water.  
Quantification was performed with a Perkin Elmer series 200 HPLC connected to an Applied 
Biosystem-SCIEX API 3000 triple quadrupole mass spectrometer. An Ascentis Express-C18 column 
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150 × 2.1 mm i.d., 2.7 μm particle size (Supelco, USA), was used for chromatographic separation. The 
mobile phases were 0.05 % formic acid in MilliQ water for negative ionization (A) and acetonitrile (B) 
with a gradient set as follow: from 30 to 100 % B in 10 minutes, 100 % B for 2 minutes, 100 to 30 % 
B in 2 minutes, 30% B for 7 minutes, at 180 μl/minute. 10 μl sample were injected into the system. 
The turbo ion spray source temperature was 350 °C, the ion spray voltage was set at -4200 V, the 
nebulizer gas was set at 7 units and the curtain gas at 8. The analysis was done in the multiple reaction 
monitoring mode (MRM). The optimized transitions and parameters were: 143.0 - 143.0 m/z for 
valproic acid, with collision energy of -15 eV, declustering potential set at -40 V and focusing 
potential at -140 V; 149.0 - 149.0 m/z for valproic acid-d6 with collision energy of -5 eV, declustering 
potential set at -20 V and focusing potential at -120 V. Settings for VPA-beta-D-glucuronide (Toronto 
Research Chemicals, Toronto, Canada) were 319.0 - 175.0 m/z with collision energy -15 eV, 
declustering potential set at -40 V and focusing potential at -180 V. 
3.3.7 Dose response curves 
Sigmoidal curves were fitted to the dose response data using Boltzmann equation (eq. 3.1),  
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with ymin and ymax being defined as the lowest and highest y-value in the data set. Missing parameters 
(EC50, slope (sl)) were estimated with least squares regression using an evolutionary algorithm within 
Excel 2010 (Microsoft, Redmond, WA, USA). Confidence intervals (CI) were drawn according to 
equation 3.2, 
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where tα;n-2 is the critical t-value for the degrees of freedom reduced by two and σest indicates the 
standard error of the estimate. The number of data points is given by n and SSxx is the sum of squared 
deviations of x-values from the mean of x. 
3.3.8 Students t-test 
Unpaired Student’s t-tests were performed using MatLab 2007b. Differences in two measurements are 
considered significant at p < 0.001, p < 0.01 and p < 0.05. 
3.3.9 Simulation of oxygen levels 
Oxygen diffusion and consumption in the different culture devices were simulated with a cylinder 
diffusion model for 2D/APS and CSW cultures, and a conical model in case of spheroid cultures. The 
dimensions for the culture devices that were introduced into the simulation are depicted in figure 3.1. 
Berkeley Madonna 8.3.9 (Berkeley, CA, USA) was used to run the simulations. The differential 
equations and parameters are depicted in the supplementary material (figure S3.1 and S3.2). In brief, 
the medium component was divided into N segments (10 for the cylinder and 30 for the cone) and for 
each of them, oxygen in- and outflow was calculated. Additionally, in the bottom segment, cellular 
oxygen uptake was implemented with a Monod-type equation. 
Chapter 3                 Hepatotoxicity assessment in 3D and in 2D high-throughput systems 
66 
 
 
Figure 3.1 Overview on 2D, Alvetex® polystyrene scaffold (APS), collagen sandwich (CSW) and spheroid 
cultures. Dimensions of the plates that were used during experiments are given and barriers imposed by medium 
(red) and collagen layers (blue) are indicated. Cells are indicated in green. 
 
3.4 Results 
3.4.1 CYP3A4 activity and induction in HepaRG cells in 2D and 3D environment  
Specific CYP3A4 activity in HepaRG cells cultured in 2D and 3D formats after 24 h and 72 h is 
shown in figure 3.2A. CYP3A4 activity in 2D HepaRG cultures after 24 h was around 3 times higher 
than in APS and CSW cultures. Spheroid cultures had the highest activity, which was 4 times higher 
than in 2D cultures. CYP3A4 activity remained stable in all tested culture conditions, with no 
significant loss at 72 h. Induction of CYP3A4 activity with rifampicin is displayed in figure 3.2B. 
Induction with 5 µM rifampicin was highest in 2D, APS and spheroid cultures with around 3-fold 
increase in activity, while CSW cultures had a significantly lower induction (1.75-fold).  
 
 
Figure 3.2 Specific CYP3A4 activity in HepaRG cells cultured in 2D and 3D formats as well as its 
induction using rifampicin. Specific CYP3A4 activity is given after 24 and 72 h (A). Induction of CYP3A4 
activity in 2D (○), APS (Δ), CSW (◊) and spheroid (□) cultures by a range of rifampicin concentrations (B). 
Error bars indicate standard deviation (n = 3). APS, Alvetex® polystyrene scaffold; CSW, collagen sandwich; 
RLU, Relative luminescence units. 
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3.4.2 Drug uptake and phase II metabolism in HepaRG cells in 2D and 3D environment  
Uptake of valproic acid and release of its metabolite VPA glucuronide by HepaRG cells in the 
different cultivation systems are summarized in table 3.1. By far highest uptake and metabolite release 
was found for spheroid cultures. Levels were 70-fold and 140-fold higher relative to the 2D cultures, 
respectively, for which we observed lowest activities among the different systems. Parent compound 
uptake and metabolite release in APS and CSW cultures were also notably lower compared to 
spheroids, but 1.3-fold and 1.9-fold higher regarding uptake and 3.7-fold and 2.2-fold higher in terms 
of VPA glucuronide release, respectively, compared to 2D cultures.  
 
Table 3.1 Mean valproic acid uptake and VPA glucuronide release rates in 2D, Alvetex® polystyrene 
scaffold (APS), collagen sandwich (CSW) and spheroid cultures of HepaRG cells within 6 h, given in 
nmol/(cell × h) ± standard deviation for n = 3. Quantification of valproic acid and its product has been performed 
by S. Maggioni at the Mario Negri Institute, Italy. 
Cultivation 
technique 
Valproic acid uptake 
[nmol/(cell*h)] 
VPA glucuronide release 
[nmol/(cell*h)] 
Absorbed valproic acid released as 
VPA glucuronide in % 
2D 0.28 ± 0.02 0.014 ± 0.002 4.8 ± 0.8 
APS 0.35 ± 0.02 0.052 ± 0.004 15.1 ± 1.5 
CSW 0.52 ± 0.02 0.031 ± 0.014 6.0 ± 2.8 
Spheroid 19.6 ± 0.87 1.903 ± 0.015 9.7 ± 0.4 
 
3.4.3 Reduced and oxidized glutathione in HepaRG cells in 2D and 3D environment  
Intracellular levels of GSH and GSSG in HepaRG cells cultivated in the different systems are given in 
figure 3.3. HepaRG cells cultivated as spheroids had the highest concentration of GSH and GSSG, 
followed by 2D cultures (43% GSH, 32% GSSG compared to spheroids), both with a roughly 10 times 
surplus of the reduced form. APS cultures had slightly lower levels of GSH than 2D cultures, while 
CSW cultures had around 2% of the concentrations found in 2D. Only in CSW cultures GSSG levels 
were higher than GSH levels. 
 
Figure 3.3 Levels of reduced (GSH) and oxidized glutathione (GSSG) in HepaRG cells cultured in 2D and 
3D formats after 24 h, normalized to the seeded cell number. Error bars indicate standard deviation (n = 3). APS, 
Alvetex® polystyrene scaffold; CSW, collagen sandwich. 
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3.4.4 Toxicity assessment in HepaRG cells in 2D and 3D environment  
EC50 values resulting from exposure of HepaRG cells to the hepatotoxic compounds bosentan, 
chlorpromazine and valproic acid for 24 and 72 h are given in figure 3.4 and dose response curves are 
depicted in figure S3.3. After 24 h of exposure (single dose), EC50 values from APS cultures differed 
notably from 2D and other 3D cultures, with cells being less sensitive to the drugs. After 72 h of 
exposure (three doses), values for all systems and drugs were in the same range, except for 
chlorpromazine-treated APS cultures. In accordance, fold changes in EC50 values from 24 h to 72 h 
were highest in APS cultures for all tested compounds. Spheroid cultures were the most sensitive 
among the cultivations, having the lowest EC50 values at both time points for bosentan and valproic 
acid. For chlorpromazine treatment, CSW (24 h) and 2D cultures (72 h) were more sensitive. 
 
 
Figure 3.4 Summary of EC50 values for HepaRG cells cultured in 2D and 3D formats after 24 h (1 dose, 
black bars) or 72 h (3 doses, white bars) exposure to bosentan (A), chlorpromazine (B) and valproic acid (C). 
90% confidence intervals are given and fold change in EC50 values from 24 h to 72 h is indicated for each drug 
and cultivation setup. Highest fold change for each drug is highlighted in grey. APS = Alvetex® polystyrene 
scaffold, CSW = Collagen sandwich. 
 
3.4.5 Simulation of oxygen concentrations in 2D and 3D environment 
Oxygen concentrations in the medium were simulated (figure 3.5) to investigate potential limitations 
in oxygen supply in the different culture devices. Steady state concentrations were reached after 
around 2 h. Surface oxygen levels were equal for all systems, yet, simulated oxygen concentrations in 
the middle and bottom region, differed greatly between the systems. For spheroids, the oxygen level 
dropped around 10% down to the middle segment, whereas it decreased by around 50% for 2D/APS 
and CSW cultures. At the bottom level, about 10% of the surface concentration was predicted to be 
left in case of spheroids, and 2.7% and 1.6% for APS/2D and CSW cultures respectively. 
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Figure 3.5 Simulated oxygen concentrations in the medium. Simulated concentrations are given for the four 
tested systems at different height: At the surface, in the middle (full lines) and at the bottom segment (dotted 
lines). 
 
3.5 Discussion 
For the prediction of human relevant toxicity, stable in vitro systems with in vivo-like behavior, 
amenable to an HTS setup, are strongly required. For this purpose, 3D cultures of human hepatocytes 
have been demonstrated to be an ideal basis. The objective of this study was to compare the human 
cell line HepaRG in different 3D cultivation systems and 2D cultivation, all suitable for HTS, in terms 
of physiological parameters and responses to drugs, to assess their potential role in toxicological 
studies.  
3.5.1 CYP3A4 activity and induction in HepaRG cells in 2D and 3D environment 
CYP3A4 is the major drug metabolizing enzyme and capable of metabolizing a wide variety of 
xenobiotic compounds. CYP3A4 activity in spheroid cultures was found to be drastically higher 
compared to 2D cultures in this study. Surprisingly, the other two tested 3D systems, namely APS and 
CSW cultures, had significantly lower activity when compared to 2D cultures. This suggests that 
certain environmental cues imposed by the culture system may drastically influence expression of 
CYP450 isoforms. For HepaRG spheroids and 2D cultures, similar findings have been described in a 
previous study, attributing the higher drug metabolizing capacity to two major factors: 1) higher 
expression of transcription factors controlling CYP450 expression, such as the pregnane X receptor 
(PXR) and 2) differential composition of HepaRG spheroid cultures regarding the two inherent cell 
types in HepaRG cultures, biliary epithelial-like cells (BLC) and hepatocyte-like cells (HLC) 
(Gunness et al., 2013; Rebelo et al., 2014). The latter phenomenon is one of the characteristics of 
HepaRG cells, which differentiate into HLC and BLC after seeding with a ratio of approximately 1:1 
in 2D cultures (Cerec et al., 2007). Similar factors may influence CYP450 activity in APS and CSW 
cultures, yet in the opposite way, i.e. differentiation would occur in favor of the BLC.  
For CSW cultures, an additional component is likely to contribute to poor metabolic competence. The 
top collagen layer acts as a second mass transfer barrier (MTB) (figure 3.1) and additionally limits 
oxygen supply as confirmed by our simulation (figure 3.5). The oxygen concentration in the bottom 
layer in CSW was about 40% lower than in 2D cultures. Available oxygen is an important factor in the 
regulation of CYP450 expression. In the in vivo liver, CYP450 activity is highest in the perivenous 
zone, a zone of low oxygen levels (Kietzmann, 2017). Camp and Capitano transferred these findings 
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into an in vitro setup with the human liver cell line HepG2 and investigated the dependence of 
CYP450 activity on medium height. In their study, highest CYP450 activity was achieved with a 
height of around 3 mm. An increase or decrease in height resulted in lower CYP450 activity (Camp 
and Capitano, 2007). To overcome this problem in CSW, more refined sandwich systems have been 
developed, using defined, synthetic layers (Du et al., 2008). Alternatively, CSW can be performed in 
wells with larger diameter, which allows reducing the thickness of the top collagen layer, therefore 
reducing the MTP, however also reducing its usefulness in a HTS setup. Schutte et al. reported lower 
gene expression for several CYP450 isoforms in primary rat hepatocytes cultured in the APS system, 
however still observed increased CYP450 enzyme activities, contrary to our observations (Schutte et 
al., 2011). This discrepancy might be related to primary hepatocytes generally greatly benefiting from 
a 3D culture environment, while the HepaRG cell line already has a stable phenotype in classical 2D 
cultivation with high expression of liver specific proteins. 
At first glance, it might be expected that CYP450 activity in spheroids should be even more affected 
by restricted oxygen supply than CSW as the MTB is almost 20% higher (figure 3.1). However, next 
to the height of the medium layer, there are other decisive parameters, and it has to be considered that 
spheroids only contain around 2,000 cells, compared to 72,000 cells in the other setups. Consequently, 
the absolute oxygen consumption is lower and the available oxygen concentration can be expected to 
be higher than in the other setups. Indeed, our simulation predicts oxygen levels in the bottom layer of 
spheroid cultures that are 3.6 and 6.2 times higher relative to 2D/APS and CSW cultures respectively. 
We found stable CYP3A4 activity in HepaRG cells under all tested culture conditions, suggesting that 
3D cultures are not required for the upkeep of metabolic competence in this cell line. In accordance, 
we previously reported high stability of CYP450 activity in HepaRG cells under 2D culture conditions 
for 30 days (Klein et al., 2014). 
Fold induction of CYP3A4 activity in HepaRG cells after rifampicin exposure was similar in all 
culture setups, except for CSW cultures. Lower fold induction in CSW cultures is probably related to 
dilution of the inducer in the collagen gel layers that constitute more than half of the volume in these 
cultures. Since the distribution of the inducer within the medium and the collagen layers, as well as 
cellular uptake are unknown, it is not possible to account for the difference in concentration. 
Nevertheless, studying CYP450 induction was possible in all systems, which is a critical part of drug 
discovery and development to ensure safe coadministration of compounds (Walsky and Boldt, 2008). 
3.5.2 Drug uptake and phase II metabolism in HepaRG cells in 2D and 3D environment  
Uptake of pharmaceuticals into the cells is in many cases essential for their beneficiary effect, but also 
for eliciting toxicity, as many targets are located within the cell. Valproic acid uptake into liver cells 
has not been fully elucidated yet and hypotheses range from diffusion based uptake (Booth et al., 
1996) to uptake by a variety of transporters including monocarboxylate transporter 1 (MCT1) (Fischer 
et al., 2008), soluble carrier 4 (SLC4) family (Terbach et al., 2011) and organic anion-transporting 
polypeptide 2B1 (OATP2B1) (Thwaites and Anderson, 2007). In our experiment, uptake of valproic 
acid in spheroid cultures was considerably higher than in all other tested cultures, while uptake in 2D 
cultures was lowest, which is likely related to an increased expression of transporters in 3D cultures, in 
particular in spheroids. Ramaiahgari et al. found an increased gene expression for two major 
transporters of a variety of drug classes (OAT2 and OAT7) in HepG2 spheroids and a 95-fold higher 
OATP1B3 mRNA level, compared to classical 2D cultures (Ramaiahgari et al., 2014), which we 
assume is regulated similarly in HepaRG 2D and 3D cultures.  
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We observed that relative VPA glucuronide production was highest in APS cultures (15%), followed 
by spheroid cultures (10%) and CSW and 2D cultures (around 5%). In vivo, phase II metabolism of 
valproic acid mainly occurs via glucuronidation by UDP-glucuronosyltransferases (UGT) (Silva et al., 
2008), whose contribution to the total valproic acid metabolization varies within a large range in 
patients and accounts for 7-89% (in average 30-50% (Silva et al., 2008)) of the total valproic acid 
metabolites (Gugler et al., 1977; Yoshida et al., 1999). Previous studies have shown that the 
expression of UGT1A6, one of the isoforms contributing to the formation of VPA glucuronide (Guo et 
al., 2012), is 10-fold higher in HepaRG cells compared to PHH (Darnell et al., 2012; Hart et al., 2010). 
Nevertheless, relative contribution of glucuronidation to valproic acid metabolization in our in vitro 
setup was at the lower end of what is known from in vivo data. Since glucuronidation of valproic acid 
does not require previous activation by a phase I reaction (Kiang et al., 2011), it can be excluded that 
prior steps are limiting the glucuronide conjugation in HepaRG cells. Instead, efflux of the conjugates 
might limit the extracellular availability of VPA glucuronide. However, there is no evidence that 
expression of multidrug resistance-associated proteins (MRP), which are responsible for transport of 
glucuronide and other conjugates (Jedlitschky et al., 1996), is impaired in the HepaRG cell line (Hart 
et al., 2010; Kanebratt and Andersson, 2008). Another possible explanation for the low concentration 
of VPA glucuronide in the supernatants is the cleavage of VPA glucuronide into its constituents by the 
VPA glucuronide hydrolase. Whereas in vivo, VPA glucuronide is readily removed from the liver via 
the blood stream, it remains in close vicinity to the liver cells in our in vitro batch setup and therefore 
remains a substrate to the VPA glucuronide hydrolase. 
3.5.3 Reduced and oxidized glutathione in HepaRG cells in 2D and 3D environment  
GSH is one of the major radical scavengers in mammalian cells and thus can have a major impact on 
the toxicity of certain compounds by preventing excessive cellular damage, e.g. as described for 
acetaminophen (McGill et al., 2011). Significantly higher GSH levels in spheroids than in other 
cultures as observed in our study might be related to upregulation of central enzymes of GSH 
metabolism in these cultures. However, data on GSH synthesis and its key enzyme glutamate cysteine 
ligase (GCL) in the context of 3D cultivation is scarce. Shimada et al. found increased gene expression 
for glutathione S-transferase (GST) in HepG2 spheroids (Shimada et al., 2007), which catalyzes the 
conjugation of GSH to a substrate. Both, GCL and GST are regulated by the nuclear erythroid factor-
2-related factor 2 (Nrf2) (Jeyapaul and Jaiswal, 2000), so it can be assumed that GCL expression in a 
3D environment is increased likewise. Low GSH and high GSSG levels, as we observed in CSW 
cultures can be caused by hypoxia, leading to production of reactive oxygen species in mitochondria 
and eventually depletion of cellular GSH (Lluis et al., 2005). For APS cultures on the other hand we 
determined similar GSH and GSSG levels as for 2D cultures, with the two systems having an almost 
identical mass transfer barrier. 
3.5.4 Toxicity assessment in HepaRG cells in 2D and 3D environment  
The uptake of a compound into the cytosol, its bioactivation or inactivation via phase I and II 
metabolism, as well as the levels of the radical scavenger GSH are decisive parameters on the outcome 
of drug exposure. Treating HepaRG cells in the different cultivation setups with drugs, we wanted to 
investigate the impact of the choice of cultivation format and of the accompanying differences in 
physiological parameters on the outcome of toxicity studies. In addition to valproic acid, we chose two 
more pharmaceutical compounds with a different mechanism of action, namely bosentan and 
chlorpromazine. Surprisingly, we barely observed differences in the EC50 values of the three tested 
pharmaceutical compounds, but for HepaRG cells cultured in the APS system. This supports the idea 
that HepaRG cells cultured in APS system are more prone to differentiate into BLC. As a result, total 
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CYP450 activity would be lower, and consequently also the susceptibility to drugs that require 
transformation for toxicity or drugs that target liver specific proteins; as in the case of bosentan, which 
inhibits the bile salt export pump. Chlorpromazine is the only drug that we tested, for which cells rely 
on protection by GSH, due to cytotoxicity mediated by reactive metabolites (Anthérieu et al., 2012a; 
MacAllister et al., 2013). While GSH depletion may occur upon valproic acid treatment, it is 
considered only concomitant (Kiang et al., 2011). Consistent with poor GSH availability that we 
observed in CSW cultures, these were more susceptible to single dose chlorpromazine treatment than 
any of the other cultures. It is not clear why EC50 values in APS cultures drop drastically and 
approximate EC50 values of the other cultures at 72 h (3 doses), though they initially are rather distinct. 
However, further detailed investigation of this phenomenon might give in-depth knowledge about the 
exact mechanisms of repeated dose toxicity for each of the compounds. 
Taken together, protective and potentially negative effects might counteract each other due to 
regulatory processes happening within the cells. E.g. high uptake of the hepatotoxic compound 
valproic acid on the one hand, and upregulated detoxification via phase I and II metabolism as well as 
subsequent secretion on the other hand, result in only minor differences in the EC50 values in the tested 
systems. In this context, determining the intracellular concentration of the drugs and their metabolites 
would be one of the most interesting parameters. However, this either requires very large cell numbers 
or very sensitive methods for quantification. 
Since for all tested cultivation systems, EC50 values decreased when treated for 72 h instead of 24 h, 
and since all systems had a stable CYP3A4 activity, we state that all the tested systems are suitable for 
assessment of repeated dose toxicity in combination with HepaRG cells. Even more, since EC50 values 
were in the same range, it might be stated that a 3D environment is not required in repeated dose 
toxicity studies using this cell line. Yet, this strongly depends on the aim of each study. 
 
3.6 Conclusion 
We conclude that HepaRG cells are a valuable tool in toxicity studies, as they have stable 
physiological parameters, even in a 2D environment. Nevertheless, the cultivation system has to be 
chosen very carefully, as some systems might greatly affect the outcome of studies, as we observed for 
the APS cultures during single dose treatment. Additionally, each of the systems comes with its own 
advantages and disadvantages, which have to be traded off against. If studies go beyond simple 
assessment of a potential hazard of a compound via dose response curves, e.g. in-depth physiological 
studies, it is even more important that the cultivation system is chosen accordingly. As for standard 
toxicity studies, there is no compelling reason for the use of the CSW or APS cultures as their 
handling is more complex and prone to errors, while offering no visible benefits. 
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Chapter 4 Long-term maintenance of HepaRG cells in serum-free 
conditions and application in a repeated dose study 
4.1 Abstract 
Chronic repeated-dose toxicity studies are still carried out on animals and often do not correlate with 
the effects in human beings mainly due to species-specific differences in biotransformation. The 
human hepatoma cell line HepaRG has been used for human relevant toxicity assessment. However, 
HepaRG cells are commonly maintained in serum containing medium which limits their use in -omics-
based toxicology. In this study, we compared the maintenance of HepaRG cells in standard serum-
supplemented and serum-free conditions. Viability and cytochrome P450 (CYP450) activity during 
long-term cultivation were assessed. Liver-specific albumin and urea production was measured. The 
extracellular metabolome (amino acids, glucose, lactate and pyruvate) was analyzed to compare 
different cultivation conditions using metabolic flux analysis. Although metabolic flux analysis reveals 
differences in certain parts of the metabolism, e.g. production of urea, the overall metabolism of 
serum-free and serum-supplemented cultured HepaRG cells is similar. We conclude that HepaRG cells 
can be maintained in optimized serum-free conditions for 30 days without viability change and with 
high CYP450 activity. We also tested the acute (24 h) and long-term repeated-dose (7 doses, every 
second day) toxicity of valproic acid. We calculated an EC50 value of 1.4 mM after repeated exposure 
which is close to the cmax value for valproic acid. Maintenance of HepaRG cells in serum-free 
conditions opens up the opportunity for the use of these cells in human long-term repeated-dose 
hepatotoxicity studies and for application in systems toxicology. 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as 
Klein S, Mueller D, Schevchenko V, Noor F (2014). Long-term maintenance of HepaRG cells in 
serum-free conditions and application in a repeated dose study. Journal of Applied Toxicology.  
J Appl Toxicol. 2014 Oct;34(10):1078-86. doi: 10.1002/jat.2929 
Chapter 4       Long-term maintenance of HepaRG cells in serum-free conditions 
74 
 
4.2 Introduction 
Long-term repeated-dose toxicity studies are still carried out on animals because of a lack of suitable 
in vitro alternatives. At the same time species-specific differences in hepatic biotransformation 
(Martignoni et al., 2006) often result in poor concordance of animal studies with human toxicity. 
Currently, primary human liver cells are used to assess human relevant metabolism-mediated acute 
toxicity. However, long-term maintenance of liver cells with high viability, liver-specific functions 
and cytochrome P450 (CYP450) activity still remains a challenge in easy-to-handle two-dimensional 
(2D) monolayer cultivation systems (Guillouzo et al., 2007). For reliable assessment of metabolism-
induced toxicity, HepaRG cells have shown immense potential as they maintain metabolic competence 
for 4 weeks in 2D cultivation (Anthérieu et al., 2012b). This cell line consists of two cell types, biliary 
epithelial-like and hepatocyte-like cells (Cerec et al., 2007). Dimethyl sulfoxide (DMSO) is essential 
for the differentiation of HepaRG cells and induction of CYP450 expression (Gripon et al., 2002; 
Hoekstra et al., 2011). Studies that involve HepaRG cells are routinely carried out in medium 
containing high DMSO concentrations (≈ 2%) and in the presence of fetal bovine serum (FBS) (Leite 
et al., 2012). As a result of undefined composition and batch-to-batch variations, the use of FBS poses 
a problem in reproducibility and standardization (Hahne and Reichl, 2011). In addition, the presence 
of FBS limits the application of -omics technologies in a systems toxicological setup. Proteins and 
peptides in the serum can serve as alternative carbon sources for the cultivated cells thereby 
challenging quantitative metabolome and flux analyses. These peptides and proteins also limit 
proteomics analyses where they usually mask the low abundant proteins/peptides which are produced 
by the cells. Furthermore, most drugs and other metabolites bind to serum albumin, thereby 
influencing the free-drug concentrations in in vitro toxicity studies (Broeders et al., 2013). However, 
other medium components, such as growth factors, also play a crucial role in the upkeep of hepatic 
functions. For example, hepatocyte growth factor (HGF) and epidermal growth factor (EGF) are 
important for the differentiation of hepatocytes and they can lead to improved liver-specific functions 
in vitro (Kim et al., 2010; Tan et al., 2012). 
We investigated the maintenance of the HepaRG cells in serum-free medium (SFM) supplemented 
with growth factors and different concentrations of DMSO, in serum-free medium without growth 
factors as well as serum-supplemented medium (SSM), which is the current standard medium for 
HepaRG long-term cultivation. A period of 30 days was chosen in accordance with the Organization 
for Economic Cooperation and Development (OECD) guideline 407, requiring a minimum of 28 days 
for long-term repeated dose toxicity studies. We evaluated the activity of CYP450 enzymes and the 
secretion of albumin, urea and glutamine as markers for liver-specific functions. Furthermore, we 
determined viability and extracellular concentrations of amino acids, glucose, pyruvate and lactate. 
Potential bottlenecks caused by a lack of nutrients were identified. Moreover, we applied metabolic 
flux analysis to analyze metabolic changes over time and to investigate differences in metabolism 
between the different cultivation conditions. Metabolic flux analysis was shown to be a valuable tool 
for understanding the effects of experimental conditions and substrates as well as toxic compounds on 
cells (Guo et al., 2010; Mueller and Heinzle, 2013; Niklas and Heinzle, 2011; Orman et al., 2011). By 
applying stoichiometric constraints, reaction rates (fluxes) within the cells can be estimated (Jin and 
Jeffries, 2004). This allows a deeper insight into the cells’ metabolism over various metabolic 
pathways. Finally, as a proof of principle, we assessed long-term (2 weeks, new dose every second 
day, 7 doses in total) toxic effects of the anticonvulsant drug valproic acid on HepaRG cells and 
compared them with acute effects (24 h) in SFM and SSM conditions. We conclude that the HepaRG 
cell line is suitable for repeated dose toxicity in serum-free conditions. This will allow an unbiased use 
of -omics technologies in systems toxicology. 
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4.3 Materials and Methods 
4.3.1 Cell culture 
The human hepatoma cell line HepaRG (differentiated cells, HPR116) was purchased from Biopredic 
International (St. Grégoire, France). The cells were maintained in Williams Medium E (Pan Biotec, 
Aidenbach, Germany) supplemented with 100 U × ml
–1
 penicillin, 100 μg × ml–1 streptomycin (c.c.pro 
GmbH, Oberdorla, Germany), 50 μM hydrocortisone 21-hemisuccinate and 5 μg × ml–1 human insulin 
(Sigma-Aldrich, St. Louis, MO, USA). Depending on the condition, 10% FBS (PAA Laboratories, 
Pasching, Austria, Germany), different concentrations of DMSO (Sigma-Aldrich) and 10 ng × ml
–1
 
human hepatocyte growth factor (HGF) (Humanzyme, Chicago, IL, USA) as well as 2 ng × ml
–1
 
mouse epidermal growth factor (EGF) (Sigma-Aldrich) were added to the medium. The different 
media compositions are summarized in figure 4.1 for seeding and adherence of the cells and in 
table 4.1 for the serum-free and serum-supplemented long-term cultivation. 
 
 
Figure 4.1. Experimental setup and media compositions used for seeding and adherence of the cells, before 
the start of the serum-free long-term cultivation. Media were changed every day, second or third day in 
respective culture plates – or + indicates the absence or presence of growth factors respectively. GF, growth 
factors (HGF and EGF). 
 
HepaRG cells from 13 vials were pooled together and seeded (480,000 cells per well) in 24-well plates 
in triplicates (Greiner Bio-One, Frickenhausen, Germany) and kept in a cell culture incubator 
(Memmert GmbH, Schwabach, Germany) at 37 °C with 95% relative humidity and 5% CO2 supply. 
Standard pre-cultivation of HepaRG cells results in a 1:1 ratio of hepatocytes and biliary epithelial-like 
cells. To reduce evaporation, the outer wells of the culture plate were filled with sterile distilled water 
(Gibco Invitrogen, Darmstadt, Germany). 
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Table 4.1 Composition of serum-free media (SFM) and serum-supplemented medium (SSM) used for the 
cultivation of HepaRG cells in the presence or absence of hepatocyte and epidermal growth factors (HGF/EGF), 
indicated by + and – respectively. FBS, fetal bovine serum. 
Medium 10% FBS 
DMSO concentration in 
% [v/v] 
HGF and 
EGF 
SFM SFM1 
 SFM2 
SFM3 
SFM4 
- 
- 
- 
- 
0 
0.5 
1.8 
1.8 
+ 
+ 
+ 
- 
SSM  + 1.8 - 
 
4.3.2 Quantification of metabolites in medium supernatants 
Glucose, pyruvate and lactate 
Glucose, pyruvate and lactate in the medium supernatants were quantified using high-performance 
liquid chromatography (HPLC) (Kontron Instruments, Neufahrn, Germany). After separation using an 
Aminex HPX 87H ion exchange column (300 × 7.8 mm, Bio- Rad, Hercules, CA, USA) at 60 °C with 
an isocratic flow rate of 0.8 ml × min
-1
 of 7 mM H2SO4 as the mobile phase, compounds were detected 
via the refractive index (glucose) or UV absorption at 210 nm (lactate and pyruvate). 
Amino acids 
Quantification of amino acids was performed with an HPLC method as described previously (Krömer 
et al., 2005). 
Urea 
Urea was quantified using an HPLC method as described previously (Clark et al., 2007; Mueller et al., 
2012). 
Albumin 
Human albumin was quantified with an indirect competitive enzyme-linked immunosorbent assay 
(ELISA) (Exocell, PA, USA). The assay was performed according to the manufacturer’s instructions. 
4.3.3 Viability Assessment 
Cell viability was determined with the CellTiter-Blue® assay (Promega, Mannheim, Germany) on 
day 0 and afterwards every 6
th
 day until day 30. The assay solution was mixed with medium in a ratio 
of 1:5. Next, 500 μl of the prewarmed mixture was added to the cells which were incubated for 2.5 h at 
37 °C. Fluorescence was detected using a Fluoroskan Ascent CF fluorescence reader (Thermo 
Labsystems, Vantaa, Finland) at 590 nm (excitation 540 nm). Medium without cells served as a 
background control. The fluorescence signals were normalized to the signal on day 0 of the 
cultivation. 
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4.3.4 CYP450 activity assay 
For the CYP450 activity assay, a cocktail of five substrates was used. The substrate cocktail mixture 
stock solution (1000×) was prepared in DMSO and consisted of 200 mM phenacetin, 100 mM 
bupropion, 100 mM dextromethorphan, 100 mM tolbutamide (Sigma-Aldrich) and 50 mM midazolam 
(Pharmacopée Européenne, Strasbourg, France). The stock was diluted in incubation medium to obtain 
final concentrations as follows: 200 μM phenacetin (CYP1A2), 100 μM bupropion (CYP2B6), 50 μM 
midazolam (CYP3A4), 100 μM dextromethorphan (CYP2D6) and 100 μM tolbutamide (CYP2C9). 
HepaRG cells were incubated in 325 μl of the medium per well in 24-well plates for 1 h, after which 
the supernatants were collected and immediately frozen. For analysis, samples were thawed at room 
temperature, diluted with a solution of stable-isotope labelled metabolites and subsequently analyzed 
by HPLC tandem mass spectrometry. The system consisted of an AB Sciex API3200 triple quadrupole 
mass spectrometer (Framingham, MA, USA) working in electrospray ionization mode, interfaced with 
an Agilent 1200SL HPLC (Santa Clara, CA, USA). Chromatography was performed at 70 °C with 
10 μl injected into a Zorbax Eclipse XDB C18 column (50 × 4.6 mm, 1.8 μm particle size), at a flow 
rate of 1.5 ml × min
-1
. The mobile phase was 0.1% formic acid in ultrapure water (A) and 0.3% formic 
acid in a mixture of methanol and acetonitrile (50% v/v) (B). The proportion of the mobile phase B 
was increased linearly from 0 to 98% in 3 min, and then the column was allowed to re-equilibrate at 
the initial conditions. The total run time was 4 min. The column eluent was split to an electrospray 
ionization interface, operating at 650 °C. Multiple reaction monitoring (MRM) mode in positive 
polarity was applied for detection. 
4.3.5 Concentration response curves 
HepaRG cells were seeded in 96-well plates with a density of 72,000 cells per well. For standard 
cultivation condition, cells were cultured according to the manufacturer’s instructions for 1 week. 
Afterwards, these cells were tested in serum-free conditions for 24 h for acute toxicity of valproic acid 
(Sigma Aldrich). For SFM2 conditions the cells were precultivated according to figure 4.1 for 4 days. 
For acute toxicity, these cells were cultivated with a range (0.1-100 mM) of concentrations of valproic 
acid for 24 h in SFM2. For long-term repeated drug exposure in SFM2, cells were exposed to fresh 
medium containing the drug, every second day for 2 weeks (7 doses in total). All toxicity assays were 
carried out in the absence of serum. Viability was assessed using the CellTiter-Blue® assay in a 
volume of 120 μl per well and an incubation time of 3 h. Medium without cells served as background 
control. The fluorescence signals were normalized to the signal of the untreated control. EC50 values 
were calculated using OriginLab 9.0 (OriginLab Corporation, Northampton, MA, USA). 
4.3.6 Metabolic flux analysis 
In this study, we adapted a previously described (Niklas et al., 2009) metabolic network model 
(table S4.1). The model consists of the glycolytic pathway, the tricarboxylic acid cycle (TCA) 
including anaplerotic reactions, the urea cycle and production of albumin, with a total of 55 reactions. 
24 of those reactions are transportation reactions which were assessed by measuring metabolite 
concentrations in the culture supernatant before and after treatment. The remaining fluxes were 
assessed by applying the principles of flux balance analysis (Varma and Palsson, 1994a, 1994b), 
assuming pseudo steady-state as previously described (Niklas et al., 2009) with equation 4.1. 
1 ( S )c c m mv S v
            [4.1] 
Sc and Sm are the matrices describing the stoichiometry of the metabolic network for which the rates 
are either calculated (c) or measured (m), and νc and νm represent the calculated and measured rates, 
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respectively. Solutions for fluxes and standard deviations were determined using Monte–Carlo 
simulation (n = 100) and afterwards calculating the mean outcome using MatLab 2007b (MathWorks, 
Nattick, MA, USA). 
4.3.7 Statistical analysis 
An unpaired Student’s t-test was performed using MatLab 2007b. Differences between two 
measurements are considered significant at p < 0.001, p < 0.01 and p < 0.05. 
 
4.4 Results 
4.4.1 Viability of HepaRG cells upon long-term cultivation  
The viability of HepaRG cells upon maintenance in different media with daily medium renewal is 
depicted in figure 4.2. HepaRG cells remained viable (all values > 83%) for the entire 30 day period 
when maintained in serum-free media supplemented with growth factors and a maximum of 
0.5% DMSO (SFM1 and SFM2). In standard culture conditions (SSM), the viability of the HepaRG 
cells decreased between day 0 and 12 to around 72% and then remained constant. For the two serum-
free conditions, SFM1 and SFM2, we observed a slight increase in the percentage of viable cells after 
day 18 of cultivation. Whereas, in case of HepaRG cells maintained in medium with 1.8% DMSO 
without FBS (SFM3 and SFM4), cell viability decreased to null after 18 days of cultivation with 
significant cell death already occurring in the first 6 days. 
 
 
Figure 4.2. Viability of HepaRG cells during 30-day cultivation upon maintenance in different media with 
daily medium renewal. SFM1, 2 and 3 (serum-free medium with growth factors and 0%, 0.5% and 1.8% DMSO 
respectively), SFM4 (serum-free medium without growth factors and 1.8% DMSO), and SSM (serum-
supplemented medium with 1.8% DMSO). Error bars indicate standard deviations (n = 3). Viability is given as 
percentage relative to HepaRG culture viability on day 0. 
 
Regarding different medium renewal intervals (figure S4.1), cells maintained in SFM1 and 2 showed 
no differences in their viability when the medium was changed daily or every second day. With 
medium being renewed every third day, for both conditions (SFM1 and 2) HepaRG cells showed a 
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decrease in the viability after day 6 of cultivation. For all other conditions (SFM3, SFM4 and SSM) 
less frequent medium renewal assured a higher viability of the cells.  
4.4.2 Assessment of CYP450 activity in HepaRG cells  
The CYP450 activity for cultures in SFM1, SFM2 and SSM (figure 4.3) was determined. For 
CYP3A4, CYP2D6, CYP2C9 and CYP2B6, the activities between day 6 and 18 were higher when 
HepaRG cells were kept in higher DMSO concentrations. Activity of CYP1A2 was only slightly 
altered by the cultivation conditions investigated. Cells maintained in SSM showed high CYP450 
activities until day 18, after which a significant loss of activities was detected. At day 30 of 
cultivation, the average remaining CYP450 activity for cells in SFM2 and SSM was in the same range 
(67% and 64% respectively), whereas for SFM1 only 38% of the remaining activity was detected. The 
activities of CYP3A4, CYP2B6, CYP3A4, CYP2C9 and CYP2D6 in HepaRG cells maintained in 
SFM were independent of the medium renewal interval (figure S4.2). However, for SSM longer 
intervals of medium change had a positive impact on the substrate conversion by the CYP450 
enzymes. 
 
 
Figure 4.3 CYP450 activity during long-term cultivation. Activities of CYP1A2, CYP2B6, CYP3A4, 
CYP2C9 and CYP2D6 enzymes in HepaRG cells during long-term cultivation with daily medium renewal. Error 
bars indicate standard deviations (n = 3). *, **, *** indicate significance at p < 0.05, p < 0.01 and p < 0.001 
respectively. Measurements have been performed by Valery Shevchenko at Biopredic International, Saint 
Grégoire. 
 
4.4.3 Uptake and secretion rates of metabolites 
Extracellular concentrations of organic acids, glucose, urea and albumin were quantified and 
uptake/secretion rates were calculated (figure S4.3). Amino acid concentrations in the supernatants 
were quantified and compared with concentrations in fresh medium (figure 4.4). In SFM, depletion of 
nutrients was observed upon renewal of medium every second day, whereas in SSM, depletion of 
nutrients only occurred when medium was renewed every third day. In terms of uptake of essential 
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amino acids, all HepaRG cultures exhibited very similar rates, except for the branched-chain amino 
acids (BCAA). Similarly, uptake and secretion rates of lactate, pyruvate and certain non-essential 
amino acids, e.g. glutamate, serine, arginine and alanine, were different. Secretion was only observed 
for serine, lactate, urea and albumin and in case of SSM cultivation additionally for alanine and 
pyruvate. Between day 18 and day 24, a significant change in metabolism was observed for all 
conditions. For lysine, histidine, phenylalanine, threonine, valine and glutamine, secretion was either 
reduced or uptake was increased. In some cases, there was a switch from secretion to uptake, e.g. for 
alanine and glycine. Concerning liver-specific functions, the production of albumin observed from 
day 18 onwards was lower when cells were cultivated in SSM conditions compared with SFM. On the 
other hand, SSM-maintained cells secreted significantly higher amounts of urea from day 6 of 
cultivation onwards, in comparison to cells maintained in SFM conditions. For all conditions, an 
increase in glucose consumption as well as lactate secretion over time was observed. 
 
 
Figure 4.4 Heat map on amino acid production and consumption. A heat map showing the ratio of amino 
acid concentrations in the supernatants upon medium renewal every day, second or third day versus amino acid 
concentrations in the fresh medium, given for each investigated time point. An orange to red color indicates 
production of amino acids, a yellow color indicates that the amino acid was neither consumed nor produced. 
Green to blue color indicates increasing consumption. 
 
4.4.4 Metabolic flux analysis 
The effects of different cultivation conditions on the intracellular fluxes were determined by metabolic 
flux analysis. Several reaction and transportation rates are depicted in a flux distribution map 
(figure 4.5). Reaction rates in the glycolytic pathway of HepaRG cells were significantly lower in 
SSM as compared to SFM. In accordance, lactate secretion was lower for cells maintained in SSM. 
Generally, glycolytic activity increased for all conditions over time. For cells cultivated in medium 
without DMSO (SFM1), approximately 40% of the glycolytic pyruvate was converted to lactate; for 
cells kept in 0.5% and 1.8% DMSO respectively (SFM2 and SSM), about 50% to 55% of glycolytic 
pyruvate was metabolized to lactate. The lactate/glucose ratios on days 6 and 30 were identical for 
SSM, SFM1 and SFM2. 
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In case of SSM at day 6, a low amount of pyruvate was converted to acetyl-CoA as compared to SFM. 
Nevertheless, reaction rates in the TCA cycle (e.g. lumped reaction rates for conversion of succinyl-
CoA to oxaloacetate) were in the same range for all conditions. Among the investigated conditions, 
HepaRG cells showed the highest TCA cycle activity when cultivated without DMSO (SFM1). 
 
 
Figure 4.5. A flux distribution map of HepaRG cells upon long-term cultivation for days 6 and 30 for SFM1 
and 2 (serum-free medium with growth factors and 0% or 0.5% DMSO, respectively) and SSM (serum-
supplemented medium with 1.8% DMSO). Fluxes are given in fmol/(cell × h). Negative values indicate fluxes 
into the direction of the arrow and positive values in reversed direction. Error bars indicate standard deviations 
(n = 3). *, **, *** (comparison of SSM to SFM1) / #, ##, ### (comparison of SSM to SFM2) indicate 
significance at p < 0.05, p < 0.01 and p < 0.001, respectively. GAP, glyceraldehyde 3-phosphate; Pyr, pyruvate; 
AcCoA, acetyl coenzyme A; OAA, oxaloacetate; AKG, α-ketoglutarate; SuccCoA, succinyl coenzyme A; Lac, 
lactate; Glu, glutamate; Gln, glutamine; Arg, arginine; Ile, isoleucine; cyt, cytosolic; mit, mitochondrial; EC, 
extracellular; TCA, tricarboxylic acid. 
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Arginine uptake and its conversion to glutamate were significantly reduced for cells maintained in 
SSM. α-Ketoglutarate, derived from the TCA cycle, was probably metabolized to glutamine which 
was subsequently secreted. The highest rates for these reactions were found for cells kept in SFM2, 
whereas the lowest rates were found for the SSM-maintained cells. 
Comparison of urea and albumin production after 30 days of cultivation shows that HepaRG cells 
exhibited high remaining activities for most conditions (table 4.2). At day 30, urea production was 
between 61% and 366% (SFM1 and SSM, respectively) and albumin production was between 45% to 
75% (SSM and SFM1) relative to respective productions on day 0. 
 
Table 4.2 Percentage remaining urea and albumin production after 30 days cultivation relative to day 0. 
SFM, serum-free medium; SSM, serum-supplemented medium. 
Medium Urea Albumin 
SFM1 61% 75% 
SFM2 103% 65% 
SSM 366% 45% 
 
4.4.5 Drug response behavior  
The 24 h EC50 values for valproic acid obtained by the concentration response curves (figure 4.6) were 
21 (± 3.4) and 24 mM (± 3.6) upon precultivation either in SSM or SFM2 according to figure 4.1. 
After 2 weeks of repeated dose application (7 doses) in SFM2, the EC50 value decreased to 1.4 mM 
(± 0.2). 
 
 
Figure 4.6 Concentration response curves upon valproic acid treatment for 24 h and 2 weeks (new dose 
every second day, 7 doses in total) under serum-free conditions. (□) shows dose response curve for HepaRG 
cells precultivated under standard cultivation conditions. (■) and (●) show dose response curves on HepaRG 
cells for 24 h and 2 weeks respectively, with precultivation of 4 days according to figure 4.1. All toxicity assays 
were carried out in the absence of serum. Error bars indicate standard deviations (n = 3). *** indicates 
significance at p < 0.001. 
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4.5 Discussion 
Serum-free long-term cultivation is essential for reliable assessment of drug-induced effects in systems 
toxicological approaches. To the best of our knowledge, long-term studies on HepaRG cells, until 
now, were exclusively performed in serum-supplemented medium and usually these studies did not 
exceed 2 weeks of cultivation after the differentiation of the HepaRG cells (Anthérieu et al., 2011; 
Josse et al., 2012). Since HepaRG cells show stable CYP450 activity, they may be reliably applied in 
long-term repeated dose toxicity studies especially in the assessment of metabolism mediated adverse 
effects. In this study, we compared cultivation of HepaRG cells in SSM and different SFM for 30 days 
and the effects on cell viability, metabolic competence and exometabolome were investigated. 
Additionally, we show the application of this test system in a long-term repeated dose study on 
valproic acid. 
We demonstrate that HepaRG cells can be maintained in growth factor supplemented medium without 
DMSO and with DMSO concentrations of 0.5% (SFM1 and 2, respectively) for 30 days. High DMSO 
concentrations (1.8%) in the absence of serum (SFM 3 and 4) led to cell death within 18 days of 
cultivation. Reports on the cytotoxic effects of DMSO on hepatic cells are ambiguous. For primary 
human hepatocytes (PHH), 2% DMSO is reported to be non-toxic upon 24 h of incubation, whereas in 
HepG2 cells 0.5% DMSO elicited cytotoxicity within 48 h (Niklas et al., 2009; Sumida et al., 2011). 
In SSM, the cytotoxic effects of DMSO were attenuated probably as a result of the membrane 
protective effects of FBS (Castro et al., 2011). Binding of DMSO to albumin might further contribute 
to its reduced toxicity in SSM. 
In SFM conditions 1 and 2, we observed a decrease in viability (≈ 20%) when the medium was 
renewed every 3 days, compared with every day and every 2 days. Upon metabolome analysis it could 
be shown that the essential amino acid tryptophan as well as aspartate and glutamate were completely 
depleted within a 3-day replenishment interval. Therefore, decreased cell viability is most probably 
due to starvation of the cells. Tryptophan contributes to the production of NAD
+
, which in turn is 
involved in signaling pathways, such as those regulating DNA repair and apoptosis (Chiarugi et al., 
2012) as well as in energy metabolism. Considering that NADH is required in the reaction of the 
viability assay, the observed drop in viability may either come from a decrease in NAD
+
 supply, or 
from an actual decrease in cell number. The slight increase in viability after 18 days of cultivation 
could be because of the regeneration of the hepatic cells, as occurring in vivo (Vodovotz et al., 2012). 
As the increase in viability is limited to serum-free conditions, it might be related to the presence of 
HGF, which is known to be a mitogen as well as for playing a role in liver regeneration (Forte et al., 
2006; Tan et al., 2012). 
For HepaRG cells cultivated in SFM2 with daily medium renewal, the average remaining CYP450 
activity after 30 days was around 70%. For CYP2C9, CYP3A4 and CYP2D6, which are responsible 
for the metabolism of the majority of current drugs (Aninat et al., 2006), the mean remaining activity 
was approximately 85%, which was the highest among all the tested conditions. 
HepaRG cultures consist of hepatocyte and biliary epithelial-like cells in a 1:1 ratio (Cerec et al., 
2007). Hence, in the following comparison of liver specific functions (e.g. urea and albumin 
production) to hepatic in vivo rates, only hepatocyte-like cells were considered. In case of urea, we 
observed a production of around 40 fmol/(h × hepatocyte) for HepaRG cells maintained in SSM. In 
SFM rates were about 6 and 10 fmol/(h × hepatocyte) (SFM1 and SFM2, respectively). Although SSM 
cultivation shows a urea production that is closer to the one in vivo [80–130 fmol/(h × hepatocyte)], 
the sum of the ammonia detoxifying reactions in all HepaRG cells catalyzed by glutamate 
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dehydrogenase (GDH), glutamine synthetase (GS) and carbamoyl phosphate synthetase 1 (CPS1) are 
identical for HepaRG cells maintained in SFM2 and SSM. For both conditions, detoxification occurs 
with rates of 60.5 fmol/(h × cell) on day 6 and 43 fmol/(h × cell) on day 30. Hoekstra et al. showed 
that DMSO increased urea production and omission of DMSO led to an increased expression of 
glutamine synthetase (Hoekstra et al., 2011), which is in accordance with our findings on urea 
formation and the decrease in glutamine secretion when DMSO was supplemented. Interestingly, in 
the case of PHH in serum-free long-term cultivation, a significant decrease in urea production over 
time is reported (Mueller et al., 2012). 
Concerning albumin production, in SFM, production rates of 0.8 to 0.9 pg/(h × hepatocyte) and in 
SSM 0.5 pg/(h × hepatocyte) after 30 days of cultivation were measured. In vivo rates, with around 2 
to 3 pg/(h × hepatocyte) (Bhatia et al., 1999) are higher than the albumin production observed in any 
condition in our study. It was reported that DMSO had no effect on albumin production (Aninat et al., 
2006). We observed this for all conditions in the first 12 days. However, after 18 days of cultivation, 
albumin production in SSM was significantly decreased. Albumin secretion by PHH after 14 days of 
cultivation (Lübberstedt et al., 2011) is roughly round 0.02 pg/(h × cell). In our system, the HepaRG 
cells, even after 30 days in SFM conditions, produced significantly higher amounts of albumin. 
Maintenance of albumin and urea production over a period of 30 days demonstrates that HepaRG cells 
under tested conditions are superior in retaining liver-specific functions as compared with PHH upon 
long-term cultivation. 
Elevated lactate secretion is reported as a signal of stress (Limonciel et al., 2011). In addition, it is a 
sign of wasteful metabolism, as further processing of glycolytic pyruvate through the TCA cycle 
instead of secretion as lactate, would yield more ATP per molecule of glucose. The ratio of glucose 
consumption and lactate secretion remained low and unchanged over time, indicating an efficient 
energy metabolism in SFM conditions. Moreover, the deprivation of FBS also did not elicit cellular 
stress, as indicated by identical lactate/glucose yields in SFM2 and SSM conditions. DMSO-free 
cultivation (SFM1) resulted in the lowest lactate/glucose yield, which further led to increased rates in 
the TCA cycle, compared with all other conditions. Therefore, we postulate that the presence of even 
low concentrations of DMSO imposes a burden on the HepaRG cells. 
Increased uptake of nutrients and consequential increased TCA cycle fluxes at later time points of 
cultivation for all conditions may be associated with increased energy demand for general 
maintenance, e.g. repair of DNA damages. After 2 weeks of cultivation HepaRG cells show first 
indications of ageing (Pernelle et al., 2011) which may explain increased energy demand. We 
observed an increased uptake of the BCAA isoleucine and leucine in SSM cultivation. These amino 
acids are mostly metabolized to acetyl-CoA. As reaction rates to acetyl-CoA coming from pyruvate 
are very low for SSM cultivation, feeding of the acetyl-CoA pool by other sources is essential to keep 
the TCA cycle running. Although we observed an increased uptake of BCAAs, we could not detect an 
increased uptake of other amino acids (such as threonine, tyrosine or lysine) which also produce 
acetyl-CoA when degraded. 
Applying the optimized serum-free conditions we tested the acute (24 h) and repeated dose toxicity 
(2 weeks, new dose every second day, 7 doses in total) of valproic acid. Although acute toxicity of 
valproic acid is often due to overdosage, valproic acid may cause severe fulminating liver impairment 
within days after therapy start and microvesicular steatosis upon clinical use (Dreifuss et al., 1987; 
Krähenbühl et al., 2000). VPA substantially binds to serum proteins (≥ 90%) (Silva et al., 2008), 
hampering its use in serum-supplemented studies. The comparison of 24 h (acute) EC50 values shows 
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that the HepaRG cells’ response to VPA was not affected by the presence of growth factors. 
Furthermore, we found a significantly lower EC50 value (17 fold) after 2 weeks of repeated drug 
application than after a single 24 h exposure, demonstrating the usefulness of this test system in long-
term repeated dose studies. The EC50 value upon long-term treatment (1.4 mM) is close to the cmax 
value which is around 714 μM (Fisher and Broderick, 2003). 
In this study, we show that the HepaRG cells can be maintained viable with constant CYP450 
activities and liver-specific functions (urea and albumin production) for at least 30 days. The long-
term viability and CYP450 activities in SFM conditions were superior to those reported for PHH. 
Metabolic flux analysis indicates that the central carbon metabolism in SFM conditions remains 
comparable to standard SSM conditions. It also indicated that there are slight adjustments in the 
central metabolism (e.g. urea production) of HepaRG cells to different cultivation conditions. This 
hints at the heterogeneity of HepaRG cells which probably allows them to adjust to the tested 
cultivation conditions with stable metabolic competence. The metabolome analysis indicated that 
depending on the medium replenishment interval, there may be nutrient limitations (e.g. some amino 
acids like tryptophan and BCAAs). Adaption of cultivation to avoid such nutrient limitations will 
allow optimal and standardized cultivation of HepaRG cells. 
Metabolic flux analysis allowed the rational design of basal medium that does not cause major 
metabolic changes in the investigated cells. The HepaRG cells in this medium showed stable 
metabolic competence, thereby increasing the reliability of the test system. Although we tested the 2D 
cultivation system, this serum-free setup could be extended to 3D cultivation techniques such as 
organoids or bioartificial livers. Serum-free long-term cultivation of HepaRG will greatly facilitate the 
application of this system for repeated dose toxicity assessments on a high content -omics platform in 
systems toxicology. 
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Chapter 5 In silico modeling for the prediction of dose and pathway related 
adverse effects in humans from in vitro repeated-dose studies 
5.1 Abstract 
Long-term repeated-dose toxicity is mainly assessed in animals despite poor concordance of animal 
data with human toxicity. Advanced human in vitro systems e.g. with metabolically competent 
HepaRG cells, are used for toxicity screening. Extrapolation of in vitro toxicity to in vivo effects 
(IVIVE) is possible by reverse dosimetry using pharmacokinetic (PK) modeling. We assessed long-
term repeated-dose toxicity of bosentan and valproic acid (VPA) in HepaRG cells under serum-free 
conditions. Upon 28-day exposure, the EC50 values for bosentan and VPA decreased by 21 and 33 fold 
respectively. Using EC10 as lowest threshold of toxicity in vitro, we estimated the oral equivalent 
doses for both test compounds using a simplified PK model for IVIVE. The model predicts that 
bosentan is safe at the considered dose under the assumed conditions upon 4-week exposure. For 
VPA, hepatotoxicity is predicted for 4 and 47% of the virtual population at the maximum 
recommended daily dose after 3 and 4 weeks of exposure respectively. We also investigated the 
changes in the central carbon metabolism of HepaRG cells exposed to orally bioavailable 
concentrations of both drugs. These concentrations are below the 28 day EC10 and induce significant 
changes especially in glucose metabolism and urea production. These metabolic changes may have a 
pronounced impact in susceptible patients such as those with compromised liver function and urea 
cycle deficiency leading to idiosyncratic toxicity. The combination of modeling based on in vitro 
repeated-dose data and metabolic changes allows the prediction of human relevant in vivo toxicity 
with mechanistic insights.  
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as 
Klein S, Maggioni S, Bucher J, Mueller D, Niklas J, Shevchenko V, Mauch K, Heinzle E, Noor F 
(2016). In silico modeling for the prediction of dose and pathway related adverse effects in humans 
from in vitro repeated-dose studies. Toxicol Sci. 2016 Jan;149(1):55-66. doi: 10.1093/toxsci/kfv218 
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5.2 Introduction 
Evaluation of long-term repeated-dose effects is still one of the most challenging areas in toxicity 
screening of compounds and risk assessment (Pfaller et al., 2001). Although for acute effects a variety 
of in vitro assays amenable to high throughput applications and multiplexing are available, long-term 
repeated-dose toxicity assessment is heavily dependent on animal studies. This is despite the fact that 
animal studies fail to predict human relevant toxicity mainly due to inter species variances (Baillie and 
Rettie, 2011; Collins, 2011; Greaves et al., 2004). 
Modern toxicology is focusing on designing in vitro assays for the identification of early perturbations 
of biological pathways in human in vitro systems and the use of these for the prediction of adverse 
effects (Sheldon and Cohen Hubal, 2009). However, extrapolation of in vitro results to human in vivo 
is sometimes limited due to the fact that nominal concentrations in the in vitro assays are used without 
consideration of the exposure magnitude, timing and duration (Coecke et al., 2013). Other factors such 
as in vivo bioavailability, metabolic clearance and in vitro specific parameters such as plastic binding 
and evaporation (Groothuis et al., 2015) are often overlooked. 
Reverse dosimetry is commonly used for the calculation of plausible exposure concentrations also 
called oral equivalent doses (OEDs). The OED represents the dose required to produce in vivo steady-
state blood concentrations equivalent to a given in vitro effective concentration (Rotroff et al., 2010; 
Wetmore et al., 2012). This approach was used to compare acute effects of chemicals and drugs in 
humans by in vitro to in vivo extrapolation (IVIVE) using simple pharmacokinetic (PK) models 
(Chang et al., 2015; Rotroff et al., 2010; Wetmore et al., 2012; Yoon et al., 2014). The PK knowledge 
is needed to relate the in vitro exposure to the in vivo target tissue concentration. Metabolic clearance 
and dose-response data, both derived from in vitro uptake, metabolism and viability, can be used for 
the estimation of the OED by IVIVE. 
Most compounds interfere with cellular carbon metabolism either directly or through effects at the 
transcriptional level. Determination of uptake and conversion rates of substrates (e.g. glucose) and 
cellular metabolites (amino acids, urea, lactate, etc.) gives insights into the pathways involved in 
central carbon metabolism and have been previously used to study drug effects (Niklas et al., 2009; 
Strigun et al., 2011b).  
The human hepatic cell line HepaRG finds increasing application in toxicity studies (Jetten et al., 
2013; Mueller et al., 2014) due to long-term functional stability and similarity to primary human 
hepatocytes in terms of drug metabolizing enzymes i.e. the cytochrome P450 (CYP450) system (Josse 
et al., 2008; Lübberstedt et al., 2011) and membrane transporters relevant for drug uptake and efflux 
(Kanebratt and Andersson, 2008).  
In the present study, using HepaRG cells, we investigated the hepatotoxic potential of two drugs 
namely bosentan and valproic acid (VPA); upon acute and repeated-dose exposure for 28 days 
(14 doses). Viability, stability of CYP450 activity, metabolites of test drugs and drug efflux 
transporter activity were measured for the assessment of the quality of the test system. Using an 
IVIVE approach, we estimated the OED from our in vitro repeated-dose toxicity data taking EC10 
values (effective concentration in 10% of cell population) as lowest threshold of in vitro toxicity for 
the prediction of in vivo human toxicity. EC10 values are considered as the lowest concentrations that 
cause statistically significant cytotoxic effects (Jover et al., 1992). For pathway relevant information, 
we investigated the alterations in the central carbon metabolism (uptake and secretion rates of selected 
metabolites) upon exposure to drug concentrations which are in the range of in vivo blood levels. The 
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study aimed at combining in vitro repeated-dose data and in silico tools for the prediction of OEDs 
and pathway relevant information for the assessment of repeated-dose toxicity in humans in vivo. Our 
approach is an important step towards replacing animal studies in long-term repeated-dose toxicity 
evaluations for which no adequate in vitro methods exist. 
 
5.3 Methods 
5.3.1 Cell culture  
The human hepatoma cell line HepaRG was obtained from Biopredic International (St. Grégoire, 
France). Before seeding, 96-well and 6-well plates (Greiner Bio-One, Frickenhausen, Germany) were 
incubated for 1 h with 50 µg/mL type I rat collagen (Roche Applied Sciences, Penzberg, Germany) in 
Dulbecco’s Modified Eagle Medium (DMEM, AMIMED BioConcept, Allschwil, Switzerland). 
Afterwards, wells were rinsed once with 0.1 or 2 mL sterile phosphate buffered saline (PBS) (Gibco 
Invitrogen, Darmstadt, Germany), respectively and equilibrated with the same volume of Williams 
Medium E (Pan Biotec, Aidenbach, Germany) overnight. Differentiated HepaRG cells were seeded in 
triplicates (n = 3) four days prior to treatment in collagen coated 96-well plates with a density of 
72,000 cells per well for viability and CYP450 activity assay, as well as for the quantification of the 
drug parent compounds and selected metabolites of central carbon metabolism. For the study of 
transporter activity (n = 1) and quantification of drug metabolites (n = 3), cells were seeded in 6-well 
plates with a density of 2.4 million cells per well. Seeding and maintenance was conducted in 
Williams Medium E supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin (c.c. pro, 
Oberdorla, Germany), 50 µM hydrocortisone 21-hemisuccinate, 5 µg/mL human insulin (Sigma 
Aldrich, St. Louis, MO, USA), 10% (v/v) fetal bovine serum (FBS, PAA Laboratories, Pasching, 
Austria) and 0.5% (v/v) dimethyl sulfoxide (DMSO, Sigma Aldrich, St. Louis, MO, USA). Medium 
was renewed one day after seeding as well as one day before treatment using serum-free seeding and 
maintenance medium, supplemented with 10 ng/mL human hepatocyte growth factor (HGF) 
(Humanzyme, Chicago, IL, USA) as well as 2 ng/mL mouse epidermal growth factor (EGF) (Sigma 
Aldrich, St. Louis, MO, USA). Cells were kept in a cell culture incubator (Memmert GmbH, 
Schwabach, Germany) at 37 °C with 95% relative humidity and 5% CO2 supply. For reduction of 
evaporation, outer wells of the 96-well culture plates were filled with sterile distilled water (Gibco 
Invitrogen, Darmstadt, Germany). Culture medium was replaced with fresh medium (with and without 
drugs) every second day in the long-term cultures. 
5.3.2 Viability assessment 
Viability was assessed using the CellTiter-Blue® assay (Promega, Mannheim, Germany). The assay 
solution was mixed with medium in a ratio of 1:5. Pre-warmed mixture (120 µL) was added to the 
cells which were incubated for 3 h at 37°C. Fluorescence was detected using a Fluoroskan Ascent CF 
fluorescence reader (Thermo Labsystems, Vantaa, Finland), measuring emission at 590 nm 
(excitation 540 nm). Medium without cells served as background control. The fluorescence signals 
were normalized to the signal of the untreated control at each investigated time point. Sigmoidal 
curves were fitted to dose-response data using OriginLab 9.0 (OriginLab Corporation, Northampton, 
MA, USA) and determined parameters were used for the calculation of the EC10 applying equation 
5.1; 
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where p represents the hill slope (p < 0). Contour graphs were plotted with OriginLab 9.0 to visualize 
time and dose dependency. From the acute and repeated-dose response curves, the viability at non-
overlapping concentrations was estimated using equation 5.2; 
 0log log1 10
x C p
TA BA
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 

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     [5.2] 
BA and TA are the bottom and top asymptote respectively. logx0 and logC represent the common 
logarithm of the EC50 and the drug concentration for which viability was to be calculated. All drug 
concentrations were corrected for the measured total concentration of the parent compound. 
5.3.3 CYP450 activity assay 
CYP1A2, CYP2B6, CYP3A4 and CYP2D6 activity was determined as described in a previous study 
(Klein et al., 2014). Additionally, the activity of CYP2E1 was assessed using chlorzoxazone (Sigma 
Aldrich, St. Louis, MO, USA) as a substrate with a final concentration of 300 µM in medium. Cells in 
a 96-well plate were incubated with 100 µL of the substrate cocktail for 1 h at 37°C, after which the 
supernatants were mixed with an equal volume of acetonitrile and frozen immediately. Details of the 
method are given in supplementary material.  
5.3.4 Assessment of efflux transporter activity using fluorescence microscopy 
For the comparison of efflux transporter activity in standard serum and serum-free cultivation, 
HepaRG cells were either cultivated for 4 days in serum as described by Kanebratt and Andersson 
(Kanebratt and Andersson, 2008) or in serum-free conditions as described before (cell culture). To 
assess activity of the multidrug resistance-associated protein 2 (MRP2), cells were incubated with 
4 µM of 5-chloromethylfluorescein diacetate (CMFDA, Thermo Fisher Scientific, MA, USA) in 
Williams Medium E. Additionally, nuclei were stained by the addition of 10 µM Hoechst 33342 
(Sigma Aldrich, Steinheim, Germany). After 15 minutes incubation at 37°C, cells were washed twice 
with 2.5 ml PBS and fluorescence was monitored using an Olympus IX70 fluorescence microscope 
(excitation at 494 nm for CMFDA and 555 nm for Hoechst 33342). 
5.3.5 Preparation of drug solutions and exposure 
For bosentan (Sequoia Research, Pangbourne, UK) a 200 mM stock solution in DMSO and for VPA 
(Sigma Aldrich, St. Louis, MO, USA) an 80 mM stock solution in serum-free seeding and 
maintenance medium were prepared. All dilutions were performed in serum-free seeding and 
maintenance medium. The end concentration of DMSO in all tested dilutions was kept at 0.5%. All 
drug concentrations and the exposure protocol are depicted in figure S5.1. A summary of the 
concentrations with the applied analyses is given in table 5.1. In case of the acute toxicity study, the 
concentrations were applied for 24 hours (1 dose). In the repeated-dose toxicity study, drug 
concentrations in fresh medium were applied every second day for 28 days (14 doses in total). 
Concentrations for the repeated-dose toxicity study were chosen from the results of the acute study. 
These concentrations ranged from 0.05% (lower limit) to 20% (upper limit) of the acute EC50 values of 
the respective drugs.  
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Table 5.1 List of concentrations used for quantification of drug clearance, central carbon metabolite 
analyses and drug metabolite quantification. The orally bioavailable concentrations (OBC) calculated from 
the recommended daily dose (Gabbay et al., 2007; Stefan and Fraunberger, 2005; Suzuki et al., 1991) and 
bioavailability (Perucca et al., 1978; Weber et al., 1999) are indicated. 
 
Bosentan [µM] VPA [mM] 
Acute Repeated-
dose 
OBC Acute Repeated-
dose 
OBC 
Drug clearance 38 32 19 to 
38 
11 0.13 0.5 to 4 
Metabolome analysis 
(High dose) 
- 65  - 1.6  
Metabolome analysis 
(Low dose) 
- 32  - 0.13  
Drug metabolite 
quantification 
1297 
(EC10) 
- - 14.8 
(EC10) 
- - 
 
5.3.6 Quantification of drug metabolites 
For the quantification of test drug metabolites in HepaRG cultures, cells were incubated with serum-
free seeding and maintenance medium (control) or 5 µM rifampicin (Sigma Aldrich, Steinheim, 
Germany) in serum-free seeding and maintenance medium (induced) for 24 h. Subsequently, control 
and induced cells were treated with bosentan and VPA with acute (24 h) EC10 (namely; 1.2 mM 
bosentan and 14.8 mM VPA) of each drug separately. Supernatants were collected after 3 h and 24 h 
incubation and stored at -80°C until quantification. The detailed method can be found in the 
supplementary material. 
5.3.7 Extraction and quantification of total drug parent compound 
For the determination of the in vitro drug removal, the total drug parent compound concentrations in 
medium supernatants were quantified at days 1, 6, 14, 20 and 28. Drugs were extracted from collected 
medium supernatants using 25 µL sample of cell medium. As reference, supernatants before and after 
incubation for 48 h at 37°C in cell-free collagen-coated 96-well plates at all sampling points were 
used.  
Internal standards were used for the quantification. These were 15 ng bosentan-
13
C2,
2
H4 sodium salt 
(Alsachim, Illkirch-Graffenstaden, France) in case of bosentan and 5 µg benzoic acid (Sigma Aldrich, 
Steinheim, Germany) for VPA. Bosentan was extracted in 75 µL acetonitrile (Sigma Aldrich, 
Steinheim, Germany). For VPA extraction, acetonitrile was acidified with 0.1% formic acid (Sigma 
Aldrich, Steinheim, Germany). Samples were vortexed for 30 s, followed by centrifugation at 12,100 g 
for 10 minutes. 25 µL of the supernatant were collected and diluted with 50 µl MilliQ water.  
Quantification was performed with a Perkin Elmer series 200 HPLC connected to an Applied 
Biosystem-SCIEX API 3000 triple quadrupole mass spectrometer. Details of the method are given in 
the supplementary material. 
5.3.8 Reverse dosimetry for the estimation of the oral equivalent dose 
Oral equivalent dose (OED) values were estimated following a published method based on the 
estimation of hepatic and renal clearance (Wetmore et al., 2012). We calculate OED values for 
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experimentally determined time-dependent EC10 values from the acute and repeated-dose experiment 
using equation 5.3. All calculations are based on the simplifying assumption of well mixed blood 
(supplementary figure S5.2). 
 10
24 1
P Hep
Oral
EC MW
OED GFR fu CL
BW BA
 
        [5.3] 
OED is the oral equivalent dose (mg/(kg BW × day) necessary to produce a steady-state in vivo blood 
concentration equivalent to the measured in vitro EC10. GFR is the glomerular filtration rate [L/h], fuP 
the fraction of unbound compound in plasma [-], and MW and BW the molecular weight [g/mol] and 
body weight [kg], respectively. BAoral is the in vivo oral bioavailability of the compound [-]. In vivo 
hepatic clearance CLHep was calculated following Poulin et al. (2012); 
int
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      [5.4] 
QL is the total blood flow in the liver (arterial and portal vein) [L/h], RBP is the blood to plasma 
concentration ratio of the test compound, CLint the intrinsic clearance rate [L/h] and fuL the fraction of 
unbound compound in the liver [-]. fuinvitro is the unbound fraction of the compound in the in vitro 
experiment [-] accounting for plastic and protein binding. Since we did not detect plastic binding for 
the two test compounds and due to the absence of serum proteins in our experiment, fuinvitro was set to 
1 (supplementary figure S5.3). 
CLint was calculated from the measured in vitro removal rate constant of the compound (Obach et al., 
1997). The calculation took into account the different cellular volumes of HepaRG and primary human 
hepatocytes (PHH). 
int
PHH
invitro invitro
HepaRG
V
CL k LW hc V
V
          [5.5]  
kinvitro is the in vitro first order rate constant calculated for a single cell [1/(cell × h)] in the case of first 
order reaction, LW the liver weight [kg], hc the hepatocellularity [cells/(kg liver)], Vinvitro is the volume 
used in the in vitro incubation [L], VPHH the average volume of a primary hepatocyte and VHepaRG the 
average volume of a HepaRG cell. In the case of Michaelis-Menten kinetics, the corresponding value 
of kinvitro, depends on the compound concentration (supplementary material). The kinetics of removal 
of the compound in the in vitro experiment were determined at different time points of the acute and 
long-term in vitro experiment using a high and low concentration at each time point, including their 
values at the beginning and after incubation with HepaRG cells. Cell volumes (VPHH and VHepaRG) were 
estimated based on measured diameters of PHH and HepaRG cells using an automated cell counter 
(supplementary material and supplementary figure S5.4). 
 fuL was calculated according to Poulin et al. (2012) as follows; 
 
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with PLR as the plasma-to-whole-liver concentration ratio, taking into account the extracellular protein 
binding in plasma relative to liver. fuP,app is the apparent unbound fraction in plasma, taking into 
account drug ionization, which is an important factor for ionizable compounds since extracellular and 
intracellular pH differs (7.4 vs. 7.0 respectively) (Poulin et al., 2012). 
 
 ,
1 10
1 10
Cytosol a
Plasma a
pH pK
P app P pH pK
fu fu





     [5.7] 
All values applied in the calculation of the OED are given in supplementary tables S5.1 and S5.2. 
5.3.9 Quantification of the metabolites of the central carbon metabolism in medium 
Glucose and lactate were quantified by high-performance liquid chromatography (HPLC) as described 
previously (Klein et al., 2014). Quantification of branched-chain amino acids (BCAA) valine, leucine 
and isoleucine was performed with an HPLC method as previously described in depth (Krömer et al., 
2005). Urea concentrations were assessed using an HPLC method formerly reported in detail (Clark et 
al., 2007; Mueller et al., 2012). 
5.3.10 Statistical analysis 
Unpaired Student’s t-tests were performed using MatLab 2007b. Differences in two measurements are 
considered significant at p < 0.001, p < 0.01 and p < 0.05. 
 
5.4 Results 
5.4.1 Characterization of the test system 
Viability of HepaRG cells upon long-term cultivation 
There was no loss of viability of untreated HepaRG cells upon long-term cultivation in serum-free 
condition (supplementary figure S5.5).  
CYP450 activity in HepaRG cells  
The CYP450 activity for untreated cultures over the course of 28 days remained stable for most 
isoforms (supplementary figure S5.6). However, at day 28, CYP3A4 (64% remaining) and CYP2B6 
(62% remaining) activities were significantly lower relative to day 6. The other isoforms (CYP2D6, 
CYP1A2 and CYP2E1) had activities in the same range as on day 6. 
Drug efflux transporter activity in serum and serum-free HepaRG cultivation 
Microscopic analysis shows that CMFDA, a substrate for MRP2, was concentrated in the bile pockets 
in both cultivations of HepaRG cells (supplementary figure S5.7).  
Quantification of drug metabolites 
Drug metabolites were quantified to assess the system’s capacity to form major metabolites upon 
incubation with the parent compounds. In the case of bosentan, all major metabolites described in 
literature were detected (supplementary figure S5.8A). As for Ro 64-1056, more than one peak was 
found, probably resulting from hydroxylation at different positions and the compound was therefore 
referred to as Ro 47-8634-OH. Pre-incubation of the HepaRG cells with rifampicin significantly 
increased the amount of bosentan metabolites found in the supernatants, except for bosentan 
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glucuronide. Between 3 and 24 h drug incubation, relative contribution of bosentan metabolites to the 
total drug molecules in the supernatant increased, while the proportion of the different bosentan 
metabolites was stable over time (supplementary table S5.3). The two primary metabolites Ro 48-5033 
and Ro 47-8634 were the most abundant metabolites, with more than 98% contribution at both time 
points.  In case of VPA, OH-VPA, ene-VPA and VPA glucuronide were detected (supplementary 
figure S5.8B). Contrary to bosentan, only the glucuronide conjugate concentration increased slightly, 
when cells were pre-incubated with rifampicin. From 3 to 24 h drug exposure, the amount of VPA 
glucuronide in the supernatant increased notably (supplementary table S5.4), whereas OH-VPA and 
ene-VPA metabolites remained below 2% of the drug metabolites. VPA-CoA, 2,4-diene-VPA and 
keto-VPA could not be detected in the supernatants. 
Quantification of the total drug parent compound concentration in vitro 
For the evaluation of the concentrations of the tested drugs to which the cells were exposed to in our in 
vitro setup, parent compound drug concentrations were measured before and after 48 h cell-free 
incubation in 96-well plates at 37°C (supplementary figure S5.3). No statistically significant 
differences in both bosentan and VPA concentrations upon incubation were observed. 
Viability of HepaRG cells upon acute and repeated-dose drug treatment 
Dynamic and dose-dependent viability of HepaRG cells upon acute and repeated-dose treatment with 
bosentan and VPA is depicted in figure 5.1. Additionally, for both drugs, EC10 and EC50 values at 
different time points are listed in table 5.2. For bosentan, EC50 values ranged from 1,603 µM in case of 
acute toxicity to 75.9 µM after 4 weeks of repeated-dose application (14 doses in total), whereas the 
EC10 dropped from 1,297 µM on day 1 to 45.3 µM after 4 weeks of treatment. EC50 values for VPA 
ranged from 26.1 mM to 0.79 mM. The EC10 after 4 weeks treatment was 0.42 mM as compared to 
14.8mM at day 1.  
 
 
Figure 5.1 Dose-response dynamics upon long-term exposure. Dose-dependent viability of HepaRG cells 
upon exposure to bosentan (A) and VPA (B) for 28 days. Viability was assessed with an alamarBlue assay. 
Hashed lines indicate EC10 and EC50 values for all depicted time points. Color indicates viability of the HepaRG 
cells according to the scale on the right side (green represents high and red represents low viability). 
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For both drugs, EC10 and EC50 values decreased constantly over time. The highest drop in the EC was 
observed within the first 6 days of treatment. Upon application of 14 doses EC50 values were reduced 
21 fold for bosentan and 33 fold for VPA, compared to values for acute toxicity. Concentrations of 
40 µM or lower in case of bosentan and 0.2 mM or lower for VPA did not elicit observable cell death 
after 4 weeks of treatment (14 doses). 
 
Table 5.2 Summary of EC10 and EC50 values for bosentan and VPA during acute and repeated-dose 
exposure. Viability was assessed with alamarBlue assay. 
time [d] Bosentan [µM] VPA [mM] 
EC10 EC50 EC10 EC50 
1 1,297 1,603 14.8 26.1 
6 115.5 316.2 2.06 7.34 
14 84.5 157.1 1.15 2.01 
20 49.5 103.4 0.58 1.08 
28 45.3 75.9 0.42 0.79 
 
5.4.2 Estimation of drug hepatotoxicity potential in humans by using reverse dosimetry 
For both drugs, the OEDs over the course of the study are depicted in figure 5.2. For bosentan (figure 
5.2A), all individuals of the virtual population remained above the recommended daily dose 
(≈ 3.8 mg/(kg BW × day)) at all time points. In the case of VPA (figure 5.2B), all estimated OEDs 
were above the maximum recommended daily dose of 60 mg/(kg BW × day) for two weeks. At the 
third week, 4% of the population had an OED below that threshold followed by 47% during week 4. 
The average calculated whole body clearances (renal and hepatic clearance, for all time points and all 
individuals of the virtual population) were 4.9 ± 2.6 and 43.6 ± 8.8 mL/(h × kg BW) for bosentan and 
VPA respectively. 
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Figure 5.2 Reverse dosimetry. OEDs for bosentan (A) and VPA (B) over 28 days of exposure. OEDs were 
calculated using equation 5.3 and conditions for which calculations were performed are indicated in table 5.1. 
Depicted statistical evaluation includes the 25 and 75 percentiles, the median and mean as well as the maximum 
and minimum values. The straight lines refer to the recommended daily dosage. Individuals of the virtual 
population (N=100) are represented by diamonds and individuals with an OED overlapping the recommended 
daily dosage are highlighted as black diamonds. 
 
5.4.3 Drug-induced metabolic alterations at orally bioavailable doses 
Bosentan 
Uptake and secretion rates for glucose, lactate, urea and BCAA in HepaRG cells upon repeated-dose 
exposure to bosentan are shown in figure 5.3. Viability and the lactate secretion to glucose uptake ratio 
are also depicted. During repeated-dose exposure to bosentan, glucose uptake was increased relative to 
the control except for the 4-week time point upon treatment with high dose (65 µM). Lactate secretion 
increased upon treatment with high dose until day 20 after which it fell to the level at low dose 
(32 µM) on day 28, both being significantly higher than the control. The ratio of lactate secretion and 
glucose uptake was affected only at the high dose (65 µM), for which it increased over time to a value 
of almost 2 on day 28. Uptake of BCAA and secretion of urea were significantly decreased when cells 
were treated with bosentan. Urea production was decreased to similar levels irrespective of doses. 
Viability was only affected upon repeated high dose exposure from day 14 onwards dropping to 66% 
of the control on day 28. 
VPA 
The rates for metabolite transport in the cells upon exposure to VPA are illustrated in figure 5.4. Until 
day 14 of repeated high dose (1.6 mM) VPA treatment, glucose uptake was lower than in the control. 
After 3 weeks of treatment (10 doses) the uptake returned to the original level and eventually 
surpassed the uptake of glucose in the control. In case of the low dose (0.13 mM) there was a 
significant increase in glucose uptake at the last sampling point on day 28. Upon repeated high dose 
exposure, lactate secretion was decreased until day 14 and remained stable afterwards until day 28. 
However, at repeated low dose exposure, the lactate secretion was increased from day 14 onwards. 
BCAA uptake rates were significantly lower in the presence of VPA at high dose. Urea secretion was 
significantly lower as compared to the control irrespective of the dose. Viability was only affected at 
application of high dose whereby it dropped to roughly 15% after 4 weeks of repeated treatment 
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(14 doses). Lactate secretion in relation to the glucose consumption was lower upon repeated treatment 
with high dose than in the control. 
 
 
Figure 5.3 Metabolite profiles of HepaRG cells upon long-term bosentan exposure. Uptake and secretion 
rates for glucose, lactate, branched-chain amino acids (BCAA) and urea in HepaRG cells upon repeated-dose 
treatment with in vivo relevant concentrations of bosentan (65µM and 32µM corresponding to high and low dose 
respectively). Viability and the lactate secretion to glucose uptake ratio are also depicted. Error bars indicate 
standard deviations (n=3). 
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Figure 5.4 Metabolite profiles of HepaRG cells upon long-term VPA exposure. Uptake and secretion rates 
for glucose, lactate, branched-chain amino acids (BCAA) and urea in HepaRG cells upon repeated-dose 
treatment with in vivo relevant concentrations of VPA (1.6mM and 0.13mM corresponding to high and low dose 
respectively). Viability and the lactate secretion to glucose uptake ratio are also depicted. Error bars indicate 
standard deviations (n=3). 
 
5.5 Discussion 
Reliable prediction of human relevant repeated-dose toxicity using in vitro systems and tools is of 
major interest not only in preclinical drug development in pharmaceutical industry but also in 
prioritization and de-risking of chemicals in other industries. Recently, biokinetic/toxicodynamic 
(BK/TD) models were used to study the time course of test compound effects in HepaRG cultures 
upon acute and long-term exposure (Teng et al., 2015) emphasizing the necessity of long-term 
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exposure in vitro data for the recapitulation of chronic hepatotoxic effects. In the present study, we 
investigated the hepatotoxic potential of bosentan and VPA on HepaRG cells upon acute and repeated-
dose exposure for 28 days and predicted their toxicity on humans in vivo by the estimation of the 
OEDs. At clinically relevant concentrations, changes in central carbon metabolism upon drug 
exposure in vitro provided mechanistic information that will help understand some of the effects 
observed in vivo.  
5.5.1 Estimation of drug hepatotoxicity potential in humans by using reverse dosimetry  
For bosentan and VPA several cases from mild to severe hepatotoxicity have been reported (Eriksson 
et al., 2011; Nanau and Neuman, 2013). However, their mechanisms of toxicity are only partially 
elucidated (Fattinger et al., 2001; Silva et al., 2008). In the case of bosentan, contradictory reports are 
available. Bosentan was reported to inhibit the bile salt export pump (BSEP) leading to hepatotoxicity 
(Fattinger et al., 2001). However, a recent study with patients showed that variants of the ABCB11 
gene coding for the BSEP transporter are not associated with bosentan hepatotoxicity (Seyfarth et al., 
2014). Another study linked the export of bosentan and its glucuronide conjugate to MRP2 rather than 
BSEP as clearance mechanism (Fahrmayr et al., 2012). CYP3A4 and CYP2C9 are involved in the 
metabolism of bosentan (Dingemanse and Van Giersbergen, 2004; Treiber et al., 2007). Recently it 
was reported that besides metabolic bioactivation, the toxicity of bosentan is dose dependent (Kenna et 
al., 2014). As for VPA, complex and multiple effects are reported. Long-term VPA treatment is 
accompanied by intracellular accumulation of lipids occasionally resulting in microvesicular steatosis, 
which is not dose-dependent, leading to liver failure (Eadie et al., 1988; Fromenty and Pessayre, 
1995). VPA causes elevation in liver transaminases in 5-10% of patients and in more than 100 fatal 
cases linked to hepatotoxicity have been reported (livertox.nih.gov/Valproate.htm, accessed on July 
24
th
, 2015). 
Bosentan causes mild hepatotoxicity in approximately 10 % of patients (Eriksson et al., 2011) 
necessitating withdrawal of therapy in about 3% of patients (Humbert et al., 2007). In susceptible 
patients there can be very severe consequences (Mulchey and Bshouty, 2009).  
In our study, all members of the virtual population had an OED above the recommended daily dose 
predicting no adverse effects in these cases within 28-day treatment with bosentan. Comparing the 
whole body clearance of bosentan estimated from our in vitro experiment (4.9 ± 2.6 mL/(h × kg BW)) 
to the clearance observed in vivo (116.6 ± 30.0 mL/(h × kg BW)) (Ubeaud et al., 1995), the predicted 
clearance of bosentan in our study is almost 24-fold underestimated which had an impact on our 
calculated OEDs. Under- and overestimation of clearances is a major problem in in vitro 
pharmacokinetic studies and there are many attempts to overcome this obstacle by introducing further 
parameters into the estimation of clearances (Berezhkovskiy, 2011; Berezhkovskiy et al., 2009; Poulin 
et al., 2012). In the case of bosentan, underestimation of the hepatic clearance can be related to the 
absence of serum in our setup. A 14 times lower clearance for bosentan is reported when the 
incubation was performed in a serum-free instead of serum-supplemented environment (Blanchard et 
al., 2006). It is hypothesized that not only the unbound fraction of a compound can be taken up into 
the cells but compound-protein complexes can be similarly involved in uptake processes (Blanchard et 
al., 2004). 
Regarding VPA, the incidence of liver failure is estimated to be below 0.02% (Nanau and Neuman, 
2013). However mild hepatotoxicity (elevation of liver enzymes) is around 11% (Powell-Jackson et 
al., 1984). The doses upon which hepatotoxicity occurs range from 0.1 to 80 mg/(kg BW × day). 
Infants and polymedicated patients are more susceptible to VPA hepatotoxicity (Nanau and Neuman, 
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2013). Moreover, inducers of CYP2E1 such as ethanol have been reported to increase hepatotoxicity 
of VPA (Neuman et al., 2001). In our study, after 4 weeks, 47% of the virtual population had an OED 
below the maximum recommended daily dose (≈ 60 mg/(kg BW ×  day) predicting hepatotoxic effects 
for these cases. VPA has a very wide therapeutic dose range. Thus, for better comparison, in vitro 
dosing should be adapted to specific recommended dosing in patients for patient-specific prediction. 
The whole body clearance for VPA in vivo was in the range of 17.0 ± 10.6 for men and 16.1 ± 17.5 
mL/(h × kg BW) in women (Perucca et al., 1984). Our estimations were above these values with 43.6 
± 8.9 mL/(h × kg BW). In the case of VPA, the absence of serum had no major effects on the 
prediction of clearance. 
Our in silico approach allows easy estimation of hepatic clearance and is amenable to high throughput 
setups. However, as a result of its simplicity there are some limitations and aspects like accumulation 
and distribution of compounds in tissues were not considered. In addition, many drugs show 
substantial serum binding and their uptake into the cells is complex. Therefore, it should be considered 
in the assessment and calculation of in vitro hepatic clearances. Moreover, incorporation of data on 
transport, permeability and metabolism is expected to improve predictions (Poulin, 2013).  
5.5.2 Drug-induced metabolic alterations at orally bioavailable drug doses 
Many drugs interfere with central carbon metabolism of cells disturbing metabolic homeostasis. These 
changes can provide important insights on the adverse outcome pathways. In this study, we 
investigated key metabolites in the central carbon metabolism of HepaRG cells upon exposure to in 
vivo relevant concentrations of bosentan and VPA. These selected concentrations were derived from 
dosing recommendations and oral bioavailability. Bosentan has not been reported to have any direct 
effects on enzymes involved in the central carbon metabolism. In our in vitro study we see an 
increased uptake of glucose with time. Collapse of glucose uptake (also lactate production) as 
observed after 4 weeks of treatment with a high dose could be the result of insulin resistance effected 
by repression of the GLUT4 gene, related to chronic PPARα activation (Finck et al., 2005; Said et al., 
2005). There was a steady increase in lactate production until day 20 of the experiment. Lactate is 
reported to be a marker for cellular stress (Limonciel et al., 2011). We observed an increase in the 
lactate to glucose ratio which may be due to increased expression of LDH which is involved in 
conversion of pyruvate to lactate. Increase in LDH is reported to be due to the activation of HIF-1α 
(Kim et al., 2006) which is a known receptor for reactive oxygen species. Accumulation of bosentan 
and its metabolites probably results in oxidative stress in hepatocytes. These hypotheses must be 
confirmed by additional experiments. Furthermore, urea formation in hepatocytes was shown to be 
impaired upon exposure to bosentan (Chatterjee et al., 2013). However, in that study, it was not 
evident whether this effect was only due to loss of cells or due to effects of bosentan on cellular 
metabolism. We show that bosentan severely reduces urea formation and BCAA uptake. 
Effects of VPA on the central carbon metabolism are manifold (Nanau and Neuman, 2013; Wang et 
al., 2012). Our observations support previous studies that show that VPA-CoA and other metabolites 
influence the carbon metabolism directly by inhibiting the dihydrolipoyl dehydrogenase, a subunit of 
the branched-chain α-ketoacid dehydrogenase complex (BCKDC) and pyruvate dehydrogenase 
complex (PDC) (Luís et al., 2007). VPA exposure resulted in a decrease in the lactate to glucose ratio 
although the formation of reactive oxygen species upon treatment is reported (Kiang et al., 2011). As 
VPA-CoA impairs the access of pyruvate to the TCA cycle by inhibiting the PDC, it is likely that 
pyruvate is converted into acetyl-CoA which then serves as a building block for fatty acid synthesis, 
contributing to the emergence of steatosis. Increasing concentrations of fatty acids are reported to up-
regulate the glycolytic genes (Kota et al., 2005). Indeed, chronic VPA treatment is linked to metabolic 
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syndromes (Nanau and Neuman, 2013). In addition, we observed significantly decreased rates in urea 
secretion during repeated dosing. This is an indirect hint to urea cycle disruption upon long-term 
repeated-dose exposure to VPA. This effect may stem from the inhibition of N-acetylglutamate 
synthase which leads to hyperammonemia in certain patients (Aires et al., 2011). Again this 
hypothesis needs further investigation for verification. Nevertheless, patients with certain metabolic 
predispositions such as ornithine transcarbamylase deficiency resulting in hyperammonemia might be 
more susceptible to drug toxicity as a result of additional stress elicited by impaired ammonia removal. 
 
5.6 Conclusion 
Long-term repeated-dose in vitro toxicity data can be used for the prediction of human relevant 
toxicity using a simple in silico method of IVIVE. Metabolic changes upon drug exposure to in vivo 
relevant concentrations identify key players in cellular stress related to idiosyncratic toxicity. This 
knowledge can help in the adjustment of individual dosing regimens in a step towards personalized 
medicine. The methods can be adapted to compound screenings for long-term repeated-dose effects 
and could significantly contribute to animal-free assessment of toxicity. 
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Chapter 6 Systems toxicological evaluation of valproic acid-induced toxicity 
in HepaRG cells 
6.1 Abstract 
Novel in vitro systems combined with state of the art –omics technologies yield unrivaled insights into 
the mechanisms underlying drug-induced toxicity. Here, we investigated VPA-induced toxicity in the 
human hepatic cell line HepaRG in a repeated dosing setup and combined functional assays with 
different –omics layers, i.e. transcriptomics, proteomics, metabolomics and fluxomics. HepaRG cells 
were exposed to VPA for 14 days, with a total of 7 doses in a serum-free setup. Measurements were 
performed for different time points throughout the exposure. Functional parameters were affected in a 
dose-dependent fashion, with an EC50 value of 0.85 ± 0.18 mM after 2-week exposure. Further, the 
composition of formed VPA metabolites was strictly dependent on the external dose. –Omics data 
revealed indications of endoplasmic reticulum stress, impaired urea cycle activity and early depletion 
of ATP. In conclusion, using this multi –omics approach it was possible to get a deeper insight into the 
underlying processes than with any of the –omics techniques alone and to reveal interesting aspects of 
VPA-induced toxicity. In the future, the wealth of the gained information gained with such an 
approach may not only help to improve current risk assessment approaches, but may eventually help in 
replacing animal studies. 
 
 
 
 
 
 
 
 
 
 
 
 
The data used in this chapter is an excerpt of the data collected by several groups within the NOTOX 
project. The complete data set is used for the preparation of a separate manuscript including the 
following coauthors (list is subject to change; order is arbitrary): 
Klein S, Tascher G, Plumel M, van Dorsselaer A, Bertile F, Mueller D, Heinzle E, Noor F, Kattler K, 
Luksic P, Tierling S, Walter J, Johannson I, Ingelman-Sundberg M, Sapony J, Tanay A, Bucher J, 
Mauch K, Shevchenko V, Guguen-Guillouzo C, Chesné C, Mitic-Potkrajac D, Apic G, Zamboni N, 
Fuhrer T, Maggioni S 
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6.2 Introduction 
Assessment of potential hazards related to the exposure to a compound is an integral part not only in 
drug development, but also within several other industrial branches. Historically, in vivo animal 
studies were the method of choice to assess toxicity and even today they play a major role therein. Yet, 
ethical concerns, questionable correlation of results with the heterogeneous human population, high 
costs and not least legislatorial incentives cause industry to rethink, and consider to expand the 
application of alternative methods, i.e. in vitro- and in silico-based tools (Blaauboer and Andersen, 
2007; Olson et al., 2000; Shukla et al., 2010; Westmoreland et al., 2010). 
As such, tools like skin, hepatic or cardiac in vitro systems of human origin may provide similar or 
even superior reliability regarding the prediction of a compound’s toxicity or pharmacokinetics in 
humans, compared to in vivo animal studies. Particularly when relevant properties differ largely from 
one species to another, human in vitro systems are beneficial (National Research Coucil, 2007; Zhang 
et al., 2012). Examples for such systems are primary human hepatocytes (PHH) and the human hepatic 
HepaRG cell line, which in several instances has been shown to be a suitable surrogate for PHH (Hart 
et al., 2010; Lübberstedt et al., 2011). Together with powerful analytical tools such as transcriptomics, 
proteomics or metabolomics, these systems allow to generate a wealth of reliable information that 
greatly contributes to a mechanistic understanding of the underlying processes and can be used to 
create predictive models or be applied within the adverse outcome pathway framework (Cui and 
Paules, 2010; Sturla et al., 2014; Vinken, 2015). Even more, the data obtained by such an approach 
may help in optimizing culture conditions for cells in general, and thereby further increase reliability 
of the output. 
In the past few years, the number of publications combining several –omics layers, i.e. multi –omics 
approaches were growing exponentially, however, in the field of toxicology, multi –omics studies 
remain scarce. Yet, they allow even deeper understanding and provide useful information required in 
setting up holistic models (Kim et al., 2016; Wilmes et al., 2013). Besides the requirement of 
additional instruments, one potential reason for the reluctance in performing multi –omics studies may 
be related to the challenging integration and interpretation of the data originating from the different –
omics layers, requiring experts from various fields. The integration of multi –omics data is a hurdle 
that is increasingly receiving attention in recent studies (Acharjee et al., 2016; Bersanelli et al., 2016; 
Schumacher et al., 2014; Shu et al., 2016). 
One of the major challenges in today’s risk assessment is the assessment of toxicity occurring upon 
repeated exposure to a compound. We have previously tackled this problem for two hepatotoxic 
compounds, bosentan and valproic acid (VPA), using the HepaRG cell line in a repeated dosing 
regimen in combination with a reverse dosimetry approach (Klein et al., 2016). VPA is a particularly 
interesting drug to study in a multi –omics setup as it interacts with a wide range of targets, broadly 
affecting cellular behavior. One example is the inhibitory effect of VPA on the histone deacetylase 
(HDAC), causing hyperacetylation of histones and thereby changing gene expression (Göttlicher et al., 
2001). On the metabolic level, VPA interferes with amino acid metabolism, fatty acid beta-oxidation, 
urea cycle and other pathways, eventually resulting in microvesicular steatosis (Aires et al., 2011, 
2010, 2008, Luís et al., 2011, 2007). 
Here, we were using VPA as a model compound and investigated its effects in a repeated dosing 
regimen on several functional parameters in HepaRG cells, including viability, cytochrome P450 
(CYP450) activity, triacylglyceride levels as well as drug uptake and metabolization. Further, we 
investigated the effects of the drug on transcript, protein, metabolite and flux levels, yielding a 
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comprehensive overall survey of the cellular state. In-depth characterization of the cell line upon drug 
exposure allows better understanding of the underlying mechanisms eliciting toxicity, and further, 
setting up extensive models for the prediction of toxicity, greatly aiding reliable hazard assessment. 
 
6.3 Methods 
6.3.1 Cell Culture 
HepaRG cells were obtained from Biopredic International (Saint-Grégoire, France). For proteomics 
and transcriptomics analyses, cells were seeded in 6-well plates, intra- and extracellular metabolomics 
samples were taken from 24-well plates and all other measurements were conducted in 96-well plates 
(figure S6.1A). Before seeding, the well surfaces were coated with type I rat collagen applying a 
50 µg/ml collagen solution in Dulbecco’s Modified Eagle medium (DMEM; AMIMED BioConcept, 
Allschwil, Switzerland), followed by 1 h incubation at 37°C. Wells were then rinsed once with 
phosphate buffered saline (PBS; Gibco Invitrogen, Darmstadt, Germany). Next, the coating was 
equilibrated with Williams Medium E (WME; Pan Biotec, Aidenbach, Germany) for 1 h at room 
temperature, after which the medium was discarded. For seeding in 6- and 24-well plates, 2.4 × 10
6
 
and 4.8 × 10
5
 cells were used respectively, with a concentration of 9.6 × 10
5
 cells/ml. For 96-well 
plates, the cell number was 7.2 × 10
4
 and the concentration was 7.2 × 10
5
 cells/ml. Seeding and 
cultivation of cells prior to start of analyses, as well as medium composition are described in figure 
S6.1B. The basal medium was WME supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin 
(c.c.pro GmbH, Oberdorla, Germany). In case growth factors (GF) were included, 10 ng/ml human 
hepatocyte growth factor (HGF) (Humanzyme, Chicago, IL, USA) and 2 ng/ml mouse epidermal 
growth factor (EGF) (Sigma-Aldrich) were added. The medium that was used throughout the 
experiment after precultivation will be referred to as cultivation medium subsequently. Cells were 
cultivated in a cell culture incubator (Memmert, Schwabach, Germany) at 37°C with 95% relative 
humidity and 5% CO2 supply. 
6.3.2 Viability assessment 
Viability was assessed using a resazurin-based assay (CellTiter-Blue® Cell Viability Assay, Promega, 
Mannheim, Germany). To conduct the assay, supernatants were replaced with 100 µl of a 1:5 mixture 
of the resazurin solution in cultivation medium, previously heated to 37°C. The cells were then 
incubated in the cell culture incubator for 3 h. Afterwards, supernatants were transferred into new 
plates and fluorescence was detected using a Fluoroskan Ascent CF fluorescence reader (Thermo 
Labsystems, Vantaa, Finland). Excitation was performed at 540 nm and emission was quantified at 
590 nm. A cell-free incubation served to assess the background signal. The fluorescence signals from 
treated samples were then normalized to the signal of the untreated control at the corresponding days. 
6.3.3 Dose response curve 
From a 100 mM VPA (Sigma Aldrich, St. Louis, MO, USA) stock solution in cultivation medium, 
drug concentrations ranging from 15 mM to 5 × 10
-3
 mM were prepared in cultivation medium. VPA 
was subsequently applied to the cells in a volume of 100 µl for 14 days, with medium renewal every 
second day (7 doses in total). Viability was assessed as described above. 
6.3.4 ATP quantification 
ATP was quantified from the same plates that were used for viability assessment by applying the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Mannheim, Germany) after supernatants 
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had been transferred to another plate. The assay was conducted according to manufacturer’s 
instructions. Relative luminescence signals from treated samples were normalized to the signal of the 
untreated control at the corresponding days. 
6.3.5 Oil Red staining 
For quantification of neutral lipids, an Oil Red O staining was applied by first aspirating the culture 
medium. Afterwards, cells were washed twice with 110 µl PBS. Cells were then fixed with 100 µl of a 
3.7% formaldehyde solution for 10 minutes. The formaldehyde solution was removed and cells were 
covered with 50 µl fresh Oil Red O (Sigma Aldrich, St. Louis, MO, USA) working solution. The 
working solution was prepared by first dissolving Oil Red O in isopropanol (0.35% w/v), which was 
then mixed with H2Odest in a ratio of 3:2. After 15 minutes incubation, cells were washed 3 times with 
130 µl tap water to remove unbound dye. Water was removed and wells were left until remaining 
water evaporated completely. For extraction of the bound dye, 100 µl isopropanol were added into 
each well, and plates were kept on a microplate mixer for 20 minutes. The solution was diluted 1:5 
with isopropanol and 100 µl of the dilution were transferred into new 96-well plates, followed by 
measuring the absorbance at 500 nm. Oil Red signals were normalized to the cell number calculated 
from the viability data. 
6.3.6 Quantification of CYP450 activity 
The activity of four CYP450 isoforms, namely CYP1A2, CYP2B6, CYP2D6 and CYP3A4 was 
quantified via a liquid chromatography-mass spectrometer (LC-MS) method at Biopredic 
International, France. The same method has been applied in previous studies and is described in detail 
in chapter 4. 
6.3.7 Drug metabolite quantification 
Drug metabolites were quantified at Mario Negri Institute, Italy. For the determination of VPA and 
VPA metabolite concentrations in the medium supernatants, compounds were extracted from collected 
medium using a volume of 25 µl, to which an internal standard (valproic acid-d6, Toronto Research 
Chemicals, Canada) was added. Then, 75 µl acetonitrile, acidified with 0.1% formic acid (Sigma 
Aldrich, Steinheim, Germany) were added and samples were vortexed for 30 s, followed by 
centrifugation at 12,100 g for 10 minutes. 25 µl of the supernatant were collected and diluted with 
50 µl MilliQ water.  
The instrumental system is a Perkin Elmer series 200 HPLC connected to an Applied Biosystem-
SCIEX API 3000 triple quadrupole mass spectrometer. An Ascentis Express-C18 column 150×2.1 mm 
i.d., 2.7 μm particle size (Supelco, Bellefonte, PA, USA), was used for chromatographic separation. 
The mobile phases were 0.05% formic acid in MilliQ water for negative ionization (A) and acetonitrile 
(B) with a gradient set as follow: from 30 to 100% B in 10 min, 100% B for 2 min, 100 to 30% B in 
2 min, 30% B for 7 min, at 180 μl/min. 10 μl sample was injected into the system. The turbo ion spray 
source temperature was 350°C, the ion spray voltage was set at -4200 V, the nebulizer gas was set at 7 
units and the curtain gas at 8. The optimized LC-MS/MS parameters for the selected compounds are 
summarized in the table S6.1. 
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6.3.8 Quantification of intracellular metabolites 
Sample preparation 
After collection of supernatants, cells were washed twice with 600 µl of freshly prepared washing 
solution. Washing solution was 75 mM ammonium acetate in water, with a pH of 7.4, which was 
adjusted by addition of acetic acid. For extraction of metabolites, 150 µl of a cold (-20°C) 
acetonitrile:methanol:water (40:40:20) mixture were added to the cells, which were then incubated for 
10 minutes at -20°C. After incubation, supernatants were transferred into tubes and the extraction 
procedure was repeated once. Before transferring the supernatants into the tubes the second time, cells 
were scraped off using rubber-policemen (Sarstedt, Nuembrecht, Germany). Then, the suspension was 
transferred into its corresponding tube and tubes were centrifuged at 12,100 g for 2 minutes in a 
centrifuge cooled down to 4°C. 200 µl of the supernatants were transferred into fresh vials and stored 
at -20°C until analysis. 
Metabolite quantification 
For quantification, samples were shipped to Nicola Zamboni at the Institute of Molecular Systems 
Biology at the ETH Zurich. Metabolites were quantified with flow injection Time-of-flight mass 
spectrometry as described in detail by Fuhrer et al. (Fuhrer et al., 2011). 
Data processing 
The first steps of data processing, i.e. ion annotation and matching, were performed by Nicola 
Zamboni as described in the publication highlighted above.  
Next, all annotations were curated manually, i.e. metabolites were checked for potential occurrence in 
in vitro cultures of human liver cells. Metabolites not possible to occur in these cultures, e.g. those 
related to food or drug intake, or similar conditions, were considered unknown and labeled 
accordingly. Medium components including VPA and its metabolites were considered an exception 
and original names were kept. Afterwards, in case of duplicates, the metabolite with the higher score 
was kept and the other metabolite was considered unknown. In some instances, signal intensity was 
“1”, i.e. the metabolite could not be detected in that sample. Metabolites were removed from further 
analysis when more than 20% of the samples had a signal intensity of “1” for that metabolite. This led 
to removal of two metabolites. Remaining “1” were imputed a random number between 0 and the 
measured minimum signal intensity for the corresponding metabolite (excluding “1”) to prevent a 
negative impact on statistical evaluation. As a last step, cell numbers calculated from the viability 
determined with the CellTiter-Blue® Cell Viability Assay were included to receive signal intensities 
per 10
3
 cells. 
6.3.9 Quantification of intracellular proteins 
Sample preparation 
Samples were collected and analyzed by Georg Tascher from CNRS, Strasbourg. At each time point, 
cells were washed twice with warm (37°C) and twice with cold (4°C) PBS before lysis in the culture 
plates using lysis buffer containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% (w/v) N-lauryl 
sarcosine and protease inhibitors (Sigma Aldrich, St. Louis, MO, USA). After 30 minutes at 4°C, cells 
were scraped off the plates using a rubber-policeman and cell debris was pelleted by centrifugation at 
5,000 × g for 10 minutes at 4°C. Supernatants were snap-frozen in liquid nitrogen and stored at -80°C 
before further analysis. Protein concentration in the cell extracts was estimated by a Bradford assay 
using BSA as standard (Bio-Rad, Hercules, CA, USA). 50 µg of protein of each sample were 
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precipitated with 10% trichloroacetic acid overnight at 4°C. After centrifugation (10 minutes at 
13,000 × g), protein pellets were washed with tetrahydrofuran (3 × 400 µL) to remove remaining salts 
and co-precipitated lauroyl sarcosinate. Proteins were solubilized in 200 µl of denaturation buffer 
(Urea 8 M, NH4HCO3 0,1 M), disulfide bonds were reduced with 12 mM dithiotreitol (30 minutes at 
37°C) and free sulfhydryl groups were alkylated using 40 mM iodoacetamide during one hour at room 
temperature in the dark. Afterwards, samples were diluted with digestion buffer (NH4HCO3 0.1 mM) 
to reduce concentration of urea below 1 M, and proteins were digested with trypsin (Promega, 
Mannheim, Germany) at a trypsin-to-protein-ratio of 1:100 overnight at 37°C. Trypsin activity was 
quenched by the addition of formic acid to a final concentration of about 0.5% and peptides were 
cleaned-up using SPE cartridges (SEP-PAK tC18, 50 ccm; Waters, Milford, MA, USA). Sample 
volume and organic solvent concentration were reduced using a vacuum centrifuge (SpeedVac Savant, 
Thermo, St. Herblain, France) and samples were adjusted to 100 µl with 0.1% formic acid in water 
before MS-analysis. 
Mass spectrometry analysis  
Peptide mixtures were analyzed on a NanoACQUITY UPLC system (Waters, Milford, MA, USA) 
coupled to an Impact-HD Q-TOF mass spectrometer equipped with Captive Spray source and 
nanobooster (Bruker Daltonics, Bremen, Germany). Both instruments were controlled by Hystar V3.2 
and OtofControl Rev. 3.4 (Bruker Daltonics, Bremen, Germany). The solvent system consisted of 
0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). 1 µg of sample 
was injected and first trapped on a precolumn (BEH C18, 180 μm × 20 mm, 5 µm; Waters, Milford, 
MA, USA) at 1% B at a flow rate of 5 µl/minute for 3 minutes and then eluted to a separation column 
(BEH C18, 250 mm × 75 µm, 1.7 µm; Waters, Milford, MA, USA) using a 180-minute gradient from 
2 to 35% B at 450 nl/min. The Impact HD was operating in positive mode using the following 
settings: Source temperature was set to 150°C while dry gas flow was 3 l/minute and spray voltage 
was optimized to −1300 V. Acetonitrile was used as dopant in the nanobooster and nebulizer pressure 
was set to 0.2 bar. Spectra were acquired by automatic switching between MS and MS/MS modes in 
the mass range of 100-2200 m/z with a fixed cycle time of 3 seconds. MS acquisition rate was set to 
2.5 Hz and MS/MS acquisition rate ranged from 3 to 25 Hz depending on the precursor intensity. 
Preferably, ions with a charge of 2 to 5 were selected for CID fragmentation using nitrogen as 
collision gas. Ions were excluded from fragmentation after the acquisition of 1 MS/MS spectrum and 
exclusion was released after 1 minute, but only if precursor intensity did not exceed the value during 
the first selection by a factor of at least 3. If this was the case, the precursor was again fragmented to 
increase MS/MS spectra quality and excluded for 1 minute starting from this second fragmentation 
event. Online correction of TOF calibration was performed using hexakis(2,2,3,3,-
tetrafluoropropoxy)phosphazine ([M+H]
+
 922.0098 m/z) as lock-mass which was spiked into the 
dopant solvent and thus continuously delivered together with the nebulizer gas. 
Protein identification 
Peak lists in mascot generic format were generated using Data Analysis (version 4.0; Bruker 
Daltonics, Bremen, Germany) and searched against a SwissProt-derived combined target-decoy 
database (created 2014-02-10, containing 20372 target sequences plus the same number of reversed 
decoy sequences) using Mascot (v2.3.02; Matrix Science, London, UK). The database contained 
sequences of human proteins including common contaminants and was created using an in-house 
database generation toolbox (Carapito et al., 2014). During database search, up to one missed cleavage 
by trypsin and two variable modifications (oxidation of methionine (+16 Da) and 
carbamidomethylation of cysteine (+57 Da)) were considered. The search window was set to 15 ppm 
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for precursor ions and 0.02 Da for fragment ions. Peptide and protein identifications were validated in 
Scaffold (v3.6.5; Proteome Software, Portland, OR, USA). Only peptides with a minimum ion score of 
25 were considered and both protein and peptide false discovery rate was adjusted below 1% by 
adjusting the discriminant score (i.e. ion score minus identity score). 
Protein quantification 
Before quantification, peptides shared between proteins as well as peptides containing methionine(s) 
were removed from the dataset. Ion chromatograms were extracted using Skyline v2.1 (Schilling et al., 
2012) using a window of 3 minutes around retention times of MS/MS identifications and a resolving 
power of 40,000. All extracted ion chromatograms were validated by visual inspection and area under 
curve of P, P+1 and P+2 ions were summed per peptide. After quantile normalization using 
Normalyzer v1.0 (Chawade et al., 2014), intraprotein-correlation of peptide abundance profiles across 
all experimental conditions was checked by comparing individual peptide intensities to a “model 
profile” (generated by averaging peptide signals for each protein and within each condition) using 
Pearson’s correlation. For proteins with only one peptide quantified, no correlation analysis could be 
performed. For proteins with two peptides, proteins were removed if both peptides exhibited a 
Pearson’s correlation coefficient below 0.8. For proteins with three peptides, if less than 3 peptides 
had a Pearson’s correlation coefficient above 0.8, the peptide with the lowest correlation coefficient 
was excluded from the dataset. For proteins with 4 peptides or more, the 25% of peptides with the 
lowest correlation coefficients were removed if their correlation coefficient was below 0.8. In total, 
less than 10% of all identified peptides were excluded due to low correlation. 
6.3.10 Gene expression analysis 
Total RNA extraction 
The RNA for transcriptomic studies was extracted using the AllPrep DNA/RNA/Protein kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s recommendation. The HepaRG cells were lysed 
directly in the culture dishes. RNA preparations from all samples maintained high quality and showed 
a mean RNA integrity number of 9.22 ± 0.14. 
Gene expression analysis 
RNA samples were received by Inger Johannsson and submitted to the Bioinformatic and Expression 
Analysis (BEA) core facility (Karolinska Institutet, Huddinge, Sweden) for subsequent processing and 
gene expression analysis. Whole genome gene expression was determined using the Affymetrix® 
GeneChip Human Transcriptome Arrays 2.0 (Affymetrix, SantaClara, CA, USA) following the 
manufacturer’s instructions. The raw data (.cel files) was analyzed using the Signal Space 
Transformation-Robust Multichip Analysis (SST-RMA) sketch in Affymetrix® Expression Console™ 
software. 
6.3.11 Quantification of extracellular metabolites and flux analysis 
Metabolite quantification in supernatants 
Glucose, pyruvate and lactate in the supernatant were quantified using a Kontron HPLC (Kontron 
Instruments, Neufahrn, Germany) as described previously in detail (Hans et al., 2003). Amino acids 
and urea were quantified in an Agilent 1100 HPLC system (Agilent, Waldbronn, Germany). 
Technicalities on the methods have been elaborated before (Clark et al., 2007; Klein et al., 2014; 
Krömer et al., 2005). Albumin was quantified using a reverse ELISA Kit (Albuwell II, Exocell, 
Philadelphia, PA, USA) as described by the manufacturer. 
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Secretion rates and metabolic flux analysis 
From measured extracellular metabolite concentrations, secretion rates νi were calculated using 
equation 6.1. 
1 0, ,
1 0( )
i t i t
i
c c
v V
t t X

 
 
       [6.1] 
Ci is the concentration of a metabolite i at a given time point (t1, t0). X represents the mean cell 
number during the cultivation and V is the culture volume. 
For the calculation of intracellular fluxes, a stoichiometric model, consisting of several metabolic 
pathways was generated. The model includes the glycolytic pathway, the tricarboxylic acid (TCA) 
cycle including anaplerotic reactions, the urea cycle and production of albumin, with a total of 
53 reactions (figure S6.2 and table S6.2). The rates of 23 of those reactions were assessed directly 
from the extracellular concentrations as described above. The remaining 30 fluxes (intracellular 
reaction rates) were assessed by applying the principles of metabolite balancing (Varma and Palsson, 
1994a, 1994b), assuming pseudo steady-state as previously described (Niklas et al., 2009) with 
equation 6.2. 
        [6.2] 
Sc and Sm are the matrices describing the stoichiometry of the metabolic network for calculated (c), or 
measured (m) conditions, with νc and νm representing the calculated and measured rates, respectively. 
Solutions for fluxes and standard deviations were determined using a Monte–Carlo simulation 
(n = 100) with standard deviations of the measured rates as input error using MatLab 2007b 
(MathWorks, Nattick, MA, USA). The resulting mean values are reported. 
6.3.12 Statistics 
Student’s t-test 
Unpaired Student’s t-tests were performed using Excel 2010 (Microsoft, Redmond, WA, USA). T-
tests with subsequent multiple testing correction via the Benjamini-Hochberg procedure were 
performed within the MetaboAnalyst 3.0 Software (Xia et al., 2015). 
Principal component analysis 
The signal intensity for each metabolite i, SIi was normalized to the cell number calculated from the 
resazurin-based viability data. Subsequently, data was log2-transformed and Pareto-scaled and then 
subjected to a principal component analysis (PCA) to reduce the complexity of the data set. Loading 
coefficients were determined to identify the relevance of the individual metabolites to separation of the 
data points as well as potential outliers. The PCA was performed using MatLab 2007b (MathWorks, 
Nattick, MA, USA). 
Fold changes 
Log2 fold changes were calculated by simple division as described in equation 6.3, 
1
2 2
0
log log
SI
fc
SI
 
  
 
       [6.3] 
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where SI1 and SI0 represent the signal intensities of two different conditions or time points, normalized 
to the cell number using the data obtained with the resazurin-based viability assay. 
 
6.4 Results 
6.4.1 Viability and ATP content upon repeated exposure to VPA 
First, a dose response curve of HepaRG cells exposed to VPA for 14 days (in total 7 doses) was 
prepared (figure 6.1) to identify concentrations for further in-depth investigation. The EC50 value was 
0.85 mM ± 0.18 mM. 
 
 
Figure 6.1 Dose response curve of HepaRG cells upon 14-day repeated valproic acid (VPA) exposure. 
Viability was assessed after 14 days of VPA treatment (7 doses) using a resazurin-based viability assay and 
normalizing results to the untreated control. Error bars indicate standard deviation (n = 3). 
 
The following three concentrations of VPA below the 2-week EC50 value were selected for more 
comprehensive analyses: 0.05, 0.15 and 0.5 mM VPA. Viability and the cellular ATP content were 
assessed during a 14-day period (figure 6.2). Viability was significantly reduced to 87.8% on day 14, 
after exposure to 7 doses of 0.5 mM VPA. ATP levels on the other hand were decreased stepwise, 
with both time and concentration within 14-day treatment. Reduction in ATP content was significant 
from day 8 onwards for HepaRG cells exposed to 0.5 mM VPA. Levels were 77.9% and 58.4% 
relative to the control at day 8 and 14 respectively. 
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Figure 6.2 Viability (A) and ATP content (B) in HepaRG cells upon repeated valproic acid (VPA) 
exposure. HepaRG cells were exposed to VPA for 14 days with 7 doses in total. Parameters were assessed at 
indicated time points using a resazurin-based viability assay and a luminescence-based assay for ATP 
quantification. Results were normalized to the untreated control (white bars) at the corresponding time points. 
Results for the different concentrations of VPA, 0.05, 0.15 and 0.5 mM are represented by light, medium and 
dark grey bars. Error bars indicate standard deviation (n = 3). * and ** indicate p-values of < 0.05 and < 0.01 
upon unpaired Student‘s t-test in comparison to the control respectively. 
 
6.4.2 Morphological observations upon repeated VPA exposure 
Effects of VPA treatment on cellular morphology were investigated using light microscopy (figure 
6.3). On day 2, the morphology of HepaRG cells was indistinguishable between treated cells and the 
untreated control. On day 14, cell detachment was visible in case of the 0.5 mM condition. This was 
concluded from uncovered spots on the plate surface and spherically shaped cells floating in the 
medium. The latter effect could also be observed for the cells treated with lower concentrations, 
however to a notably less pronounced extent. There was no sign of major lipid accumulation, e.g. in 
the form of large lipid vacuoles or alterations in cellular shape, under any of the tested conditions. 
 
 
 
Figure 6.3 Light microscopic pictures of HepaRG cells during repeated valproic acid (VPA) exposure. 
Pictures were taken using a light microscope with phase contrast. Flattened cells represent biliary epithelial-like 
cells, and elevated and brighter cells represent hepatocyte-like cells. White bars represent 100 µm.  
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6.4.3 Triacylglyceride quantification upon repeated VPA exposure 
The cellular content of triacylglycerides was assessed using an Oil Red staining (figure 6.4). On day 2, 
a dose-dependent effect was observed with the triacylglyceride content being significantly elevated in 
case of treatment with 0.15 and 0.5 mM VPA (128% and 139% relative to the control respectively). In 
the following days, triacylglycerides returned to normal levels, except for the 0.5 mM condition, for 
which levels remained significantly elevated on day 8 and 14 with 131% and 127% respectively. 
 
 
Figure 6.4 Quantification of cellular triglyceride content based on Oil Red staining. Signals were 
normalized to the cell number and to the untreated control (white bars) at each day. The different concentrations 
of valproic acid (VPA), 0.05, 0.15 and 0.5 mM are represented by light, medium and dark grey bars respectively. 
Error bars indicate standard deviation (n = 3). Significance of differences was tested for VPA treatment 
compared to the untreated control using an unpaired Student’s t-test at each time point, with p-value thresholds 
of < 0.05 (*) and < 0.01 (**). 
 
6.4.4 CYP450 activity in HepaRG cells repeatedly exposed to VPA 
The activity of different CYP450 isoforms and effects of VPA on their activities were assessed during 
the 14-day period (figure 6.5, absolute values in table S6.3). For CYP1A2, significantly reduced 
activity was observed only on day 14, independent of the dose. CYP2B6 activity was generally 
independent of VPA treatment. For both, CYP2D6 and CYP3A4 on the other hand, activity was 
significantly reduced in a dose-dependent manner, starting on day 2 and 8 respectively. In both cases, 
the decrease was strongest on day 14 with exposure to the highest concentration of VPA, with a 
reduction to 32% for CYP2D6 and 35% in case of CYP3A4, relative to the initial activity. 
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Figure 6.5 Dynamic CYP450 activities in HepaRG cultures upon repeated exposure to valproic acid (VPA) 
normalized to the untreated control at each day. CYP1A2 (A), CYP2B6 (B), CYP2D6 (C) and CYP3A4 (D) 
activities are given. The different concentrations of VPA are represented by light, medium and dark grey colors 
(0.05, 0.15 and 0.5 mM VPA respectively). The horizontal line at 100% indicates activity of the control and error 
bars indicate standard deviation (n = 3). To test for differences between VPA-treated cells and the untreated 
control, an unpaired Student’s t-test was performed at each time point, with p-value thresholds of < 0.05, < 0.01 
and < 0.001 (*, ** and *** respectively). Measurements have been performed by Valery Shevchenko at 
Biopredic International, Saint Grégoire. 
 
6.4.5 Time profile of VPA removal and metabolization 
Specific removal of VPA and secretion of VPA metabolites were quantified using an LC-MS approach 
(figure 6.6). Removal of VPA increased significantly from day 2 to day 8 from 3.1 to 
7.7 fmol/(cell × day) in case of 0.05 mM VPA treatment, while no increase was observed from day 8 
to day 14. In case of treatment with 0.15 mM VPA, removal was constant over all investigated time 
points, with an average removal of 14.5 fmol/(cell × day). When HepaRG cells were treated with 
0.5 mM VPA, removal on day 2 was 87.5 fmol/(cell × day), which then declined significantly to 70.4 
and 56.7 fmol/(cell × day) on day 8 and 14 respectively. 
The secretion of VPA metabolites was monitored over time: VPA-beta-D-glucuronide (VPA-
glucuronide), 3-keto-VPA, 3-OH- and 4-OH-VPA (figure 6.6.B). In case of HepaRG cells treated with 
0.05 mM VPA, the major metabolite was 3-keto-VPA with 82% on day 2, decreasing to 75% of the 
measured released metabolites on day 8 and 14. The metabolite with the second highest prevalence 
was VPA-glucuronide with 15% on day 2, increasing stepwise to 23% on day 14. Both metabolites of 
VPA also play the major role when HepaRG cells were treated with 0.15 and 0.5 mM VPA, but VPA-
glucuronide became the metabolite with the highest abundance in the extracellular compartment. For 
0.15 mM VPA treatment, levels ranged from 60 to 66%, and in case of 0.5 mM VPA treatment, 
percentages were 77 to 87%. Also for the minor metabolites, i.e. 3-OH- and 4-OH-VPA a trend upon 
exposure to different concentrations of VPA could be observed. The percentage of 3-OH-VPA 
decreased with exposure to higher concentrations of VPA, with a trend towards increase over time in 
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all conditions. In case of 4-OH-VPA, the trend was less clear, but levels seemed to decrease with 
increasing VPA concentrations. Overall, the effect of different VPA concentrations was more 
pronounced than effects of treatment duration. 
 
 
Figure 6.6 Specific valproic acid (VPA) removal and metabolite formation in HepaRG cells during 
repeated dose long-term exposure. VPA removal at different time points is indicated by light, medium and 
dark colors for day 2, 8 and 14 respectively (A). Error bars indicate standard deviation (n = 3). Significance of 
differences to the preceding time point within one condition was tested using an unpaired Student‘s t-test. * and 
** indicate p-values of < 0.05 and < 0.01 respectively. Dynamic relative composition of the secreted VPA 
metabolites upon treatment with different concentrations is represented by ring plots (B). Percentage is given 
relative to the sum of the four metabolites quantified within the study. Associated pathways for the 
metabolization of VPA (C). The Graph was adapted from Kiang et al. 2011. Measurements have been performed 
by Silvia Maggioni at the Mario Negri Institute, Milan. 
 
6.4.6 Metabolic alterations upon repeated VPA exposure 
A PCA was performed on the signal intensities of the intracellular metabolites, normalized to the cell 
number (figure 6.7). Along PC1, there is a clear formation of two clusters - on the one hand, all 
conditions on day 0 and day 2, and on the other hand all conditions on day 8 and day 14. Along PC2, 
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there is a trend, separating the control and treatment with low concentrations from treatment with 
0.5 mM VPA. With progression of time, the cluster of HepaRG cells treated with 0.5 mM VPA more 
clearly separates from the other conditions. As for the loadings plot (figure S6.3), metabolites were 
homogenously distributed and there was no sign of outlying metabolites. 
 
 
 
Figure 6.7 Principal component (PC) analysis on the intracellular metabolome data. The PCA was 
performed on the normalized intracellular metabolome data obtained at all time points and drug concentrations 
including the control (n = 3). The first two PC are depicted and ellipses correspond to the 95% confidence 
intervals. The loadings plot is depicted in figure S6.3. Measurement of the underlying data has been performed 
by Nicola Zamboni at ETH Zurich. 
 
Volcano plots comparing treatment with different concentrations (figure 6.8, list of highlighted 
metabolites in table S6.3) and comparing changes within one condition over time (figure S6.4) were 
prepared to identify critical time points and concentrations, as well as pathways most affected by VPA 
exposure. Similar to the PCA, it is seen in the volcano plots that alterations in metabolite levels 
induced by cultivation alone are more pronounced than effects induced by drug exposure. The number 
of metabolites exceeding the thresholds set for fold change and p-value increase with both, time and 
concentration (figure 6.8). When treated with 0.05 and 0.15 mM VPA, elevated metabolite levels are 
predominant among the significant metabolites, while for treatment with 0.5 mM, decreased levels 
prevail for the metabolites of interest. Even more, on day 8 and 14, the number of metabolites with 
significantly decreased levels (|log2 fold change| > 1) is higher in the controls, than in treated HepaRG 
cells. On the other hand, metabolites with significantly increased levels are notably higher in treated 
cells, compared to the control at the corresponding time points. While for HepaRG cells treated with 
0.5 mM VPA 72 metabolites are significantly altered already on day 2 (|log2 fold change| > 1), major 
changes do not occur until day 8 for HepaRG cells exposed to 0.05 and 0.15 mM VPA. However, as 
the same findings apply to the control, it is not clear whether effects originate from cultivation or drug 
exposure. 
Using the volcano plots, pathways of highest relevance upon VPA exposure were identified. Most hits 
were related to nucleotide metabolism, amino acid metabolism including dipeptides and fatty acid 
metabolism including acylglycines. To a lesser extent, changes in glycolytic intermediates as well as 
TCA cycle metabolites and metabolites involved in drug metabolism were observed. 
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Figure 6.8 Volcano plot comparing the intracellular metabolome in HepaRG cells upon exposure to 
different concentrations of valproic acid (VPA). A p-value of 0.05 and an absolute log2 fold change of 1 were 
selected as thresholds which are indicated by dotted lines. Metabolites exceeding both thresholds are highlighted 
as yellow circles, while all other metabolites are depicted as blue circles. For the former, metabolites are further 
distinguished according to whether levels are decreasing or increasing, with corresponding numbers indicated. 
The p-values are based on a t-test with subsequent Benjamini-Hochberg correction for multiple testing. 
Measurement of the underlying data has been performed by Nicola Zamboni at ETH Zurich. 
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6.4.7 Effects of repeated VPA treatment on different cellular levels 
An overview on intracellular metabolites (M) and enzymes (P) in the previously identified pathways 
has been plotted with indication of changes upon VPA exposure (figure 6.9). Detailed time courses 
and data on transcripts and fluxes (F) are given in the supplementary (figures S6.5 to S6.9) 
Fatty acid metabolism 
Metabolites related to fatty acid metabolism were significantly increased in HepaRG cells upon 
treatment with VPA (figure 6.9, figure S6.5). These metabolites include octanoyl-CoA, an 
intermediate of fatty acid β-oxidation, derivatives of β-oxidation intermediates, such as (R)-3-
hydroxyoctadecanoic acid and octanoic acid, as well as acylglycines. Likewise, enzymes involved in 
β-oxidation were found to be upregulated in HepaRG cells upon VPA treatment (figure 6.9, 
figure S6.5 P1 to P8). On the other hand, levels of enzymes related to fatty acid synthesis (FASN, P9), 
triacylglycerol synthesis (glycerol-3-phosphate dehydrogenase, P10) and activation of fatty acids 
(acyl-coenzyme A synthetases, P11, 12) were decreased, with exception of the long-chain fatty acid 
CoA ligase 1 (P13) (figure S6.5, figure 6.9). The trend observed for the enzymes likewise was found 
for the corresponding transcripts. 
Nucleotide metabolism 
Regarding nucleotide metabolism, with increasing VPA concentration, levels of metabolites either 
decreased from the beginning of the study (5-phosphoribosyl-N-formylglycineamide, 
aminoimidazoleribotide, adenosine, guanosine, thymine, (R)-5,6-dihydrothymine, 5,6-dihydrouracil, 
3-ureidopropionate, CDP, CTP, ADP, UTP) or remained unaltered initially but then decreased at a 
later time point (1-(5’-phosphoribosyl)-5-formamido-4-imidazolecarboxamide, orotidylate, inosine, 
urate, β-alanine), independent of the anabolic or catabolic nature of the pathways (figure 6.9 and figure 
S6.6). There were few notable exceptions to this observation. Only in case of dADP (M41), a 
significant increase in concentration was observed. Interestingly, levels of nucleoside monophosphates 
increased initially (not significantly), but eventually declined as shown for uridine, inosine and 
guanosine monophosphate (UMP, IMP, GMP; M35, M15, M38), as well as xanthine (M20). In respect 
to the enzymes involved in pyrimidine catabolism, dihydropyrimidine dehydrogenase levels (P15) 
decreased upon VPA exposure, while there was no trend on transcript level. Contrary, a subunit of the 
ribonucleotide reductase (RRM2, P16) was found to be upregulated with treatment. The enzyme is 
responsible for the formation of deoxyribonucleotides from ribonucleotides. 
Amino acid metabolism 
Intracellular levels of L-glutamate, L-glutamine and glycine were generally lower when HepaRG cells 
were exposed to VPA (figure 6.9 and figure S6.7). Alterations in metabolic fluxes were observed for 
the conversion of 2-oxoglutarate into L-glutamate (F4), being reduced when cells were treated with 
VPA. The uptake of L-glutamine and its subsequent conversion into L-glutamate on the other hand 
were increased in case of treatment (F2, F5). Uptake of glycine and L-glutamate were generally low 
and effects of VPA on cellular intake were minor (F1, F3). 
Intracellular levels of the branched-chain amino acid (BCAA) L-isoleucine were significantly elevated 
with treatment, and concentrations of propanoate (figure 6.9, figure S6.7 M54), a late metabolite of L-
valine degradation, were lower upon treatment. The uptake of the three BCAA was reduced in a dose-
dependent manner when HepaRG cells were exposed to VPA (figure S6.7 F6 to F8). Expression of the 
enzyme catalyzing the first step in the catabolism of BCAA, the BCAA aminotransferase (figure 6.9, 
figure S6.7 P17), was not affected by VPA treatment, neither on the level of transcripts nor on protein 
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level. Protein concentrations and to a lesser extent transcript levels of the methylcrotonyl-CoA 
carboxylase (P18), which is involved in L-leucine catabolism, were elevated with VPA treatment. 
Further, there was a slight trend towards upregulation of the short/branched-chain specific acyl-CoA 
dehydrogenase (P19). The enzyme catalyzes a step in the catabolism of L-isoleucine, but may also use 
valproyl-CoA as a substrate. 
Levels of metabolites closely related to L-serine and L-cysteine, i.e. L-homocysteine and L-
cystathionine (figure 6.9, figure S6.7 M57, M58) were elevated with treatment.  
With exposure to VPA, intracellular concentrations of metabolites of the urea cycle, i.e. L-arginine 
and L-ornithine significantly increased and decreased, respectively. Levels of guanidinoacetate (M65), 
which marks the first step in the formation of creatine, were slightly elevated, whereas concentrations 
of the two subsequent metabolites creatine and phosphocreatine (figure 6.9 M66, M67) were lower 
with VPA treatment. The carbamoyl-phosphate synthase (P20), which catalyzes the first committed 
step in the urea cycle, and the arginase 1 (P21), decreased in a dose-dependent fashion on protein and 
transcript level upon VPA treatment. For the glycine amidinotransferase (P22), the trend was towards 
increasing protein concentrations when exposed to VPA. 
Several dipeptides were quantified and in many cases concentrations significantly declined with 
exposure as shown exemplarily for asparaginyl-proline (figure S6.7 M75). For two dipeptidyl 
peptidases, DPP3 and CTSC (figure S6.7 P23, P24), we found interesting but opposing trends, i.e. 
decreasing and increasing levels respectively 
Carbohydrate metabolism 
Trends for the intermediates of the glycolytic pathway were mixed, e.g. with levels of 3-phospho-D-
glyceroyl phosphate decreasing and phosphoenolpyruvate increasing upon exposure to VPA 
(figure 6.9 M78, M80). Other quantified intermediates did not change significantly (M77, M79 and 
M81). Uptake of D-glucose, secretion of lactate as well glycolytic fluxes (figure S6.8 F10 to F13) 
declined with treatment. The ratio of secretion of lactate relative to glucose intake initially dropped 
from 1.26 on day 0, to 0.84 on day 4, and eventually rose to 1.45 on day 14. Similar to effects on 
glycolytic fluxes, VPA caused downregulation of several of the corresponding enzymes and 
transcripts (ALDOB (P25), PKLR (P26), LDHA (P28), PFKL (P30); figure 6.9, figure S6.8). 
Concentrations of all quantified TCA cycle intermediates (cis-aconitate, citrate, fumarate, (S)-malate) 
decreased with treatment, with exception of 2-oxoglutarate (figure 6.9, figure S6.8). Likewise, the 
fluxes of the corresponding reactions decreased with VPA exposure (figure S6.8 F14, F15). In case of 
the pentose phosphate pathway, transcripts and protein levels of glucose-6-phosphate 1-dehydrogenase 
(P31) increased upon VPA exposure. 
Miscellaneous pathways 
Generally, identified proteins in the context of oxidative phosphorylation were observed to be 
upregulated on protein level upon exposure to VPA (figure S6.9 P33 to P39). 
Concentrations of 3-hydroxybutyryl-carnitine were significantly increased when cells were exposed to 
VPA (figure S6.9 M104). Levels of (R)-mevalonate on the other hand were lower in treated cells 
compared to the control (figure 6.9, figure S6.9 M105). Two enzymes, hydroxymethylglutaryl-CoA 
synthase 2 (mitochondrial) and 1 (cytosolic) are responsible for the formation of ketone bodies and the 
first step of the cholesterol synthesis via the mevalonate pathway respectively. While the  
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Figure 6.9 (Continued on the following page) 
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Figure 6.9 Metabolic pathway map for HepaRG cells treated with valproic acid (VPA). The map shows 
pathways that were identified to be particularly affected by 2-week treatment with VPA. Metabolites are 
represented by circles, while the enzymes catalyzing the adjacent reactions are shown as triangles. Key 
metabolites are labeled with their full name and highlighted by circles with bold lines. Names are in accordance 
with the Kyoto Encyclopedia of Genes and Genomes. Different major pathways are indicated by colored lines – 
blue, carbohydrate metabolism; orange, amino acid metabolism; red, nucleotide metabolism; green, lipid 
metabolism; grey, miscellaneous pathways. For metabolites that were quantified, circles are filled with either 
yellow, blue or red, depending on whether there was no significant alteration, a significant decrease or a 
significant increase upon drug exposure after Benjamini-Hochberg correction, respectively. Triangles were 
colored in the same way, when there was a trend upon exposure to VPA. Time courses for selected metabolites, 
reaction rates, proteins and transcripts are depicted in figures S6.5 to S6.9. Abbreviations for metabolites (M) 
and proteins (P): M1, N-heptanoylglycine; M2, capryloylglycine; M3, nonanoylglycine; M5, octanoic acid; M6, 
ictanoyl-CoA; M7, glutaryl-CoA; M8, 2-oxoadipate; M9, 5-phosphoribosylamine; M10, 5’-phosphoribosyl-N-
formylglycineamide; M11, 2-(formamido)-N1-(5’-phosphoribosyl)acetamidine; M12, aminoimidazoleribotide; 
M13, 1-(5-phospho-D-ribosyl)-5-amino-4-imidazolecarboxylate; M14, 1-(5’-phosphoribosyl)-3-formamido-4-
imidazolecarboxamide; M16, xanthosine 5’-phosphate; M18, adenosine; M19, guanosine; M20, xanthine; M21, 
inosine; M23, hypoxanthine; M25, (R)-5,6-dihydrothymine; M27, 5,6-dihydrouracil; M28, 3-ureidopropionate; 
M30, CMP; M31, CDP; M33, AMP; M34, ADP; M36, GDP; M38, UMP; M39, UDP; M41, dADP; M42, 
dCDP; M43, dUTP; M47, L-glutamyl 5-phosphate; M48, (S)-1-pyrroline-5-carboxylate; M50, N-acetyl-L-
glutamate-5-semialdehyde; M51, N-acetylornithine; M53, urocanate; M54, propanoate; M56, 3-methyl-2-
oxobutanoic acid; M57, L-homocysteine; M58, L-cystathionine; M60, O-phosphoserine; M61, 
mercaptopyruvate; M62, taurine; M65, guanidinoacetate; M66, creatine; M67, phosphocreatine; M70, L-
kynurenine; M71, 5-hydroxyindoleacetate; M73, L-2-aminoadipate; M77, beta-D-fructose 6-phosphate; M78, 3-
phospho-D-glyceroylphosphate; M79, 2-phospho-D-glycerate; M80; phosphoenolpyruvate; M81, pyruvate; 
M82, (S)-lactate; M85, cis-aconitate; M87, fumarate; M88, (S)-malate; M90, D-ribulose-5-phosphate; M93, 
(R)-5-diphosphomevalonate; M100, UDP-glucose; M102, D-glucuronate; P3, medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial (ACADM); P4, very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
(ACADVL); P5, enoyl-CoA hydratase, short chain 1 (ECHS1); P6, long-chain 3-hydroxyacyl-CoA 
dehydrogenase (HADHA); P7, 3-ketoacyl-CoA thiolase (HADHB); P8, 3-ketoacyl-CoA thiolase, mitochondrial 
(ACAA2); P9, fatty acid synthase (FASN); P13, long-chain fatty acid CoA ligase 1 (ACSL1); P14; 
amidophosphoribosyltransferase (PPAT); P15, dihydropyrimidine dehydrogenase [NADP+] (DPYP); P16, 
ribonucleotide-diphosphate reductase subunit M2 (RRM2); P17, branched-chain amino acid amino-transferase, 
mitochondrial (BCAT2); P18, methylcrotonyl-CoA carboxylase beta chain, mitochondrial (MCCC2); P19, 
short/branched-chain specific acyl-CoA dehydrogenase (ACADSB); P20, carbamoyl-phosphate synthase 
ammonia, mitochondrial (CPS1); P21, arginase 1 (ARG1); P22, glycine amidinotransferase, mitochondrial 
(GATM); P25, fructose-bisphosphate aldolase B (ADOLB); P26, pyruvate kinase (PKLR); P27, 
phosphoglycerate kinase 1 (PGK1); P28, L-lactate dehydrogenase A Chain (LDHA); P29, putative hexokinase 
(HKDC1); P30, 6-phosphofructokinase, liver type (PFKL); P31, glucose-6-phosphate dehydrogenase (G6PD); 
P32, 6-phosphogluconolactonase (PGLS); P42, farnesyl pyrophosphate synthase (FDPS) (FDPS); P43, cytosolic 
10-formyltetrahydrofolate dehydrogenase (ALDH1L1); P44, UDP-glucuronosyl-transferase 1A6 (UGT1A6); 
P45, UDP-glucose 6-dehydrogenase (UGDH). The measurement of the metabolome data was performed by 
Nicola Zamboni, ETH Zurich. Proteome data originates from Georg Tascher, CNRS Strasbourg. 
 
mitochondrial form was upregulated on transcript and protein level, the opposite was observed for the 
cytosolic form with VPA treatment (figure S6.9 P40, P41). Another enzyme within the synthesis of 
cholesterol, namely the farnesyl pyrophosphate synthase, was likewise downregulated (P42). 
The formyl-group donor 10-formyltetrahydrofolate was significantly increased by treatment, while 
particularly the protein levels of the corresponding enzyme 10-formyltetrahydrofolate dehydrogenase 
were found to be decreased (figure 6.9, figure S6.9 M94, P43). Concentrations of a set of metabolites 
Chapter 6         Systems toxicological evaluation of valproic acid-induced toxicity 
124 
 
directly or indirectly involved in drug detoxification were significantly decreased compared to the 
control, including ophthalmate, norophthalmate and UDP-glucuronate, whereas there was no 
significant change for the oxidized form of glutathione (GSSG). On the level of transcripts, a slight 
increase was observed for the UDP-glucuronosyl-transferase 1A6 (UGT1A6, P44), catalyzing the 
conjugation of VPA to glucuronate. CYP2C9 levels on the other hand decreased with treatment. 
Protein levels of the enzyme that is responsible for the conjugation of reduced glutathione to 
xenobiotics, i.e. the microsomal glutathione S-transferase were notably elevated upon VPA exposure 
(figure S6.9). 
6.4.8 Transcriptional alterations in stress-related and lipid pathways 
ER stress, Nrf2 oxidative stress response, the p53 pathway, protein degradation as well as lipid 
regulators upon VPA exposure were investigated on transcriptional level (figure 6.10). ER stress 
elicits a so called unfolded protein response (UPR), resulting in the activation of the three branches, 
PERK/ATF4, IRE1/XBP1 and ATF6. On day 2 and day 8, there was a strong downregulation of 
several transcripts related to the PERK/ATF4 branch of the UPR, which includes transcripts associated 
with amino acid uptake and translation, i.e. members of the solute carrier family and tRNA 
synthetases. Only on day 14, there was a switch towards upregulation for several transcripts, including 
ASNS, ATF3 and certain isoforms of solute carriers, particularly SLC7A11. In case of the IRE1/XBP1 
branch, MYC was particularly interesting, with dose-dependent downregulation upon treatment, with 
exception of the 14-day time point and treatment with the two highest concentrations. 
Like MYC, FOS and JUN, part of the Nrf2 oxidative stress response, were initially downregulated, but 
upregulated after 14-day treatment with 0.15 and 0.5 mM VPA. While most transcripts related to 
glutathione were independent of VPA exposure, glutathione peroxidase 2 (GPX2), also part of the 
Nrf2 response, decreased notably with treatment. 
Two isoforms of growth arrest and DNA-damage-inducible (GADD45A and GADD45B) and 
PMAIP1 which are all associated with the p53 pathway were upregulated when HepaRG cells were 
exposed to 0.15 and 0.5 mM VPA for 14 days. Upon treatment, moderate upregulation of transcripts 
related to protein degradation was observed throughout the duration of the treatment, including several 
proteasomes, heat shock and ubiquitin-related proteins. 
For transcripts of lipid regulators, there was a clear downregulation for NFKB1, MLXIPL (ChREBP) 
and the associated MLX. For transcripts regulated by the ChREBP/MLX heterodimer, namely 
SLC2A2 (GLUT2), PKLR and FASN, a dose-dependent downregulation was observed. 
Transcripts related to the peroxisome proliferator-activated receptor α (PPARα)/RXR heterodimer, 
were found to be upregulated in case of CYP450 isoforms, but mildly downregulated in case of the 
acyl-coenzyme A thioesterase 1 (ACOT1). However, transcripts of the hepatocyte nuclear factor 4α 
(HNF4α), which is also involved in the regulation of ACOT1 expression, were not altered by VPA 
treatment. 
Liver X receptor α (LXRα (NR1H3)) was slightly downregulated with treatment, while LXRβ 
(NR1H2) mRNA levels were independent of VPA treatment. Downstream elements such as ATP-
binding cassettes, CYP7A1 and the sterol regulatory element-binding protein-1 (SREBP1) were 
moderately downregulated. 
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Figure 6.10 Heatmap on the effects of repeated VPA treatment on transcriptional levels of stress-related 
and regulatory molecules in HepaRG cells. Transcriptional levels are normalized to the control at the 
corresponding day with alterations color coded as indicated at the bottom. Selected relevant transcripts were 
taken from Wilmes et al. 2013, with exception of the lipid regulators which were taken from Jump et al. 2013. In 
case of lipid regulators, selected related transcripts are highlighted by an additional line next to the heat map. 
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Transcript levels of elements regulated by SREBP1 and SREBP2, e.g. fatty acid elongation and 
desaturation, as well as cholesterol synthesis (HMGCR) respectively, were found in lower levels when 
HepaRG cells were exposed to VPA. 
 
6.5 Discussion 
Multi –omics studies are an essential approach in promoting in vitro and in silico tools in the field of 
toxicology. They not only allow access to a tremendous amount of information that is pivotal in the 
generation of holistic models, but also allow to challenge in vitro cultures and, when needed aid in 
their optimization. In a previous study, Wilmes and coworkers demonstrated the relevance of an 
integrated –omics approach in a repeated dose toxicity environment using renal epithelial cell culture 
(Wilmes et al., 2013). Here, we investigated the effects of a repeated VPA dosing regimen in the 
human hepatic cell line HepaRG on the different layers of cellular hierarchy, as well as on its 
functionality with the aim of better understanding VPA-induced toxicity. 
6.5.1 Functional and morphological analyses in HepaRG cells exposed to VPA in a repeated 
dosing setup 
In previous studies, we identified that drug-mediated toxicity in HepaRG cells occurs at lower drug 
concentrations when the drug was applied over a prolonged period with repeated dosing (Klein et al., 
2016, 2014; Mueller et al., 2014). To assess the extent of toxicity after a 14-day repeated VPA 
treatment, we assessed viability of HepaRG cells in an initial run, for selection of ideal treatment 
concentrations in a second in-depth investigation. After 2-week exposure, corresponding to a total of 
7 doses, the EC50 value was 0.85 mM +/- 0.18 mM (figure 6.1), compared to a 24 h EC50 value of 
24 to 26 mM (Klein et al., 2016, 2014). Based on this result, three concentrations were selected: 
0.05 mM VPA as a concentration in the subtoxic range, 0.15 mM being on the verge of overt adverse 
reactions, and 0.5 mM eliciting mild toxic effects. 
Consequently, in the subsequent in-depth study, viability was only affected upon 14-day treatment 
with 0.5 mM VPA. ATP levels on the other hand decreased significantly already after 8 days of 
treatment and the trend could already be denoted on day 2 (figure 6.2). This strongly indicates that 
VPA interferes with energy metabolism and that a decline in ATP precedes overt toxicity. This is even 
likely to contribute to the adverse drug reaction as the upkeep of processes strongly depending on 
energy may no longer be assured. Studies from the group of Silva, stated a VPA-induced inhibition of 
mitochondrial pyruvate uptake and inhibition of the dihydrolipoyldehydrogenase (DLDH), part of the 
pyruvate dehydrogenase complex (Aires et al., 2008; Luís et al., 2007). In another study, the authors 
reported the inhibition of the carnitine palmitoyltransferase I (CPT1) by VPA (Aires et al., 2010), 
which normally aids in the transfer of fatty acids into the mitochondria for subsequent β-oxidation. 
Severe impairment of mitochondrial fatty acid β-oxidation often goes along with accumulation of 
lipids inside the liver (Wajner and Amaral, 2016), causing a microvesicular steatotic phenotype in case 
of VPA treatment (Tang et al., 1995). However, investigation of the cellular phenotype using light 
microscopy did not allow us to reveal the presence microvesicular steatosis. Instead, in addition to the 
quantitative description of viability above, it can be stated that control cells maintain a healthy 
phenotype throughout the period of treatment, while the occurrence of cell death can be observed 
when HepaRG cells were exposed to VPA, particularly in case of treatment with 0.5 mM VPA 
(figure 6.3). Yet it is also worth mentioning, that light microscopy without additional staining is not 
particularly suitable for assessing microvesicular steatosis, as appendant lipid vesicles are less than 
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1 µm in diameter. Neither can other characteristics of microvesicular steatosis, such as distended 
hepatocytes (Tandra et al., 2011), clearly be stated in our experiment. Therefore, Oil Red O staining 
with subsequent quantification was chosen as another approach to investigate the accumulation of 
lipids inside the HepaRG cells (figure 6.4). Using the Oil Red O staining, slight but significant 
accumulation of neutral lipids was observed in HepaRG cells upon VPA exposure. Surprisingly 
however, accumulation was largest on day 2, and accumulation partially regressed within the 
following days. Unlike in vivo, in our setup, fatty acids are not supplied externally, but originate solely 
from internal sources such as de novo synthesis or membrane decomposition. Hence, accumulation of 
fatty acids might be limited compared to a setup with external supply of fatty acids. Further supporting 
this hypothesis, the finding that accumulation was highest on day 2 of treatment could be related to 
remnant fatty acids from initial cultivation in serum-supplemented medium. On the other hand, at least 
under physiological conditions, around 90% of fatty acids in mammalian cells come from the de novo 
synthesis (Kopf et al., 2012). Consequently, the absence of external fatty acid supply should not 
drastically impair triacylglyceride accumulation upon VPA treatment. 
VPA metabolization involves several potential pathways (partly depicted in figure 6.6), including 
hydroxylation and desaturation, which are both mediated by CYP450 enzymes. The main CYP450 
isoform contributing to metabolization is CYP2C9, yet CYP2B6 and CYP2A6 are also capable of 
metabolizing VPA (Kiang et al., 2011, 2006). In our study, CYP450 activity was reduced significantly 
and in a dose-dependent fashion in case of CYP1A2, CYP2D6 and CYP3A4, while CYP2B6 activity 
remained stable (figure 6.5). The observed decrease in activity for CYP1A2, CYP2D6 and CYP3A4 
may originate from VPA entering and blocking the active site of the enzyme without being 
metabolized or only at a very low rate. Indeed, it was shown in a previous study that VPA in vitro 
competitively inhibits activity of certain CYP450 isoforms including CYP2C9 (Ki = 600 µM) and to a 
lesser extent CYP3A4 (Ki = 8 mM) (Wen et al., 2001). Yet, based on the Ki values and the magnitude 
of the observed decrease in CYP450 activities in our study, the effect is more likely to be based on the 
transcriptional level. This is strongly supported by the observation that both transcript and protein 
levels of CYP2C9 were downregulated dose-dependently with VPA treatment (figure S6.9). Previous 
results on the effect of VPA on CYP450 activity are contradictory. In a study from 2007, it was 
reported that VPA results in upregulation of CYP3A4 activity via the main regulators of CYP450 
expression, i.e. pregnane X receptor (PXR) and constitutive androgen receptor (CAR) (Cerveny et al., 
2007). Since that study has been performed in the poorly metabolizing cell line HepG2, secondary 
effects originating from metabolites of VPA as well as other indirect effects, may have been missed. 
Consequently, another study performed in epilepsy patients supports our findings on the 
downregulation of CYP2C9 (Gunes et al., 2007). Nevertheless, further in-depth studies are required to 
clarify effects of VPA on drug metabolizing enzymes. 
Interestingly, VPA uptake was enhanced with duration of the treatment in case of exposure to 
0.05 mM VPA, but declined when cells were exposed to 0.5 mM VPA (figure 6.6A). Uptake of VPA 
into the liver has been studied in few instances and as a result, several transporters have been 
suggested to be involved in its uptake into cells (Booth et al., 1996; Fischer et al., 2008; Terbach et al., 
2011; Thwaites and Anderson, 2007). Up to now, however, there is no unambiguous study on the 
uptake of VPA into liver cells. Hence we may only speculate that VPA is taken up by an ATP-
dependent transporter, which is induced when exposed to low levels of VPA. In case of treatment with 
higher concentrations of VPA, ATP might therefore strictly limit its uptake. 
There were two major VPA metabolites in the supernatant, namely VPA-glucuronide and 3-keto-VPA 
(figure 6.6B). While 3-keto-VPA was predominant upon exposure to 0.05 mM VPA, there was major 
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trend towards VPA-glucuronide with exposure to higher VPA concentrations. Even though the 
absolute amount of 3-keto-VPA in the supernatant increased when HepaRG cells were exposed to 
higher concentrations of VPA, the increase in case of VPA-glucuronide was drastically more 
pronounced. This phenomenon may be explained by the decrease in the protein levels of CYP2C9, the 
main CYP450 isoform contributing to the formation of 3-keto-VPA, with exposure to higher VPA 
concentrations. The decrease in CYP2C9 level goes along with a decrease in the capacity of the 
pathway and may therefore result in a saturation of the hydroxylation and dehydrogenation step. 
Levels of UGT1A6, one of the UDP-glucuronosyltransferases responsible for the glucuronidation of 
VPA (Guo et al., 2012), on the other hand remained stable throughout the treatment (figure S6.9). The 
differences in metabolite formation are particularly interesting as the VPA metabolites may differ in 
target molecules as well as in their potential to deplete radical scavengers and eventually in eliciting 
toxicity (Kiang et al., 2011; Luís et al., 2007). Hence, different dosing may drastically change effects 
elicited in patients. 
6.5.2 –Omics analyses on HepaRG cells treated with VPA in a repeated dosing setup 
Levels of metabolites, proteins and transcripts changed notably when HepaRG cells were exposed to 
VPA, but also as a result of mere cultivation. In both instances, affected metabolites were similar, 
broadly related to the major central pathways, i.e. lipid, nucleotide, amino acid and carbohydrate 
metabolism, but also metabolites associated with drug and one carbon metabolism. Despite having the 
medium adapted to the final composition two days prior to the start of treatment to reduce the effects 
resulting from changes in medium composition on cellular behavior, effects in several cases were 
greater than those induced by VPA. To a certain extent, changes might be related to aging of the cells, 
though in previous studies, putative aging effects were only mild, despite a 30-day study period (Klein 
et al., 2014). Yet this overlap between drug and cultivation effects does not impair subsequent 
analyses, and effects originating from cultivation alone were not considered in the following. 
One of the most interesting pathways in our study in terms of the number of affected metabolites by 
VPA treatment was the metabolism of lipids, with a focus on fatty acid metabolism (figure 6.9, 
figure S6.5). Levels of metabolites related to fatty acid metabolism were generally elevated and 
included intermediates as well as derivatives of β-oxidation. Several of these metabolites belong to the 
group of acylglycines, which have previously been associated with disturbances in mitochondrial β-
oxidation and oxidative damage (Derks et al., 2014; Wajner and Amaral, 2016). The enzyme glycine 
N-acyltransferase, responsible for the formation of acylglycines, normally serves the detoxification of 
xenobiotics like salicylic acid (Matsuo et al., 2012) but in this case might help to prevent accumulation 
of free fatty acids. To further investigate the observed increase in fatty acids and metabolites, we 
examined levels of enzymes involved in fatty acid metabolism and major regulators thereof. Enzymes 
in the context of fatty acid degradation (P1 to P8) were found to be upregulated, while enzymes related 
to fatty acid and triacylglycerol synthesis (P9, P10) were partially downregulated (figure 6.9, 
figure S6.5). Upregulation of fatty acid degradation and downregulation of their synthesis may help to 
counteract increasing levels of fatty acids, yet, downregulation of triacylglycerol synthesis is 
contradictory. The upregulated ACSL1 (P13) might help in degradation of fatty acids via their 
activation. There are several major regulators of lipid metabolism, including the nuclear receptors 
PPARα, SREBP1, LXR and ChREBP. While PPARα regulates genes associated with β-oxidation, the 
latter three were shown to be involved in the regulation of lipogenic genes such as FASN (Joseph et 
al., 2002; Rakhshandehroo et al., 2010; Sae-Lee et al., 2016). Using the gene expression data 
(figure 6.10) we could show activation for PPARα and repression of the other nuclear receptors, in 
accordance with our protein and other transcript data on downstream targets. In case of PPARα, 
Chapter 6         Systems toxicological evaluation of valproic acid-induced toxicity 
129 
 
saturated and unsaturated fatty acids serve as ligands, explaining the increase in activation of PPARα 
when HepaRG cells were exposed to VPA. In previous studies, the question on the mechanistic 
background for the impairment of β-oxidation was addressed. Though mechanisms are not yet fully 
understood, impairment is thought to be caused by sequestration of CoA and carnitine, as well as 
direct inhibition of enzymes involved in fatty acid oxidation (Aires et al., 2010; Silva et al., 2008), 
while these regulators only received minor attention. In case of CoA, we indeed observed decreased 
intracellular levels (figure 6.9, figure S6.9), which may contribute to impairment of β-oxidation in our 
setup. 
Another central pathway greatly affected by VPA treatment in HepaRG cells, was the metabolism of 
nucleotides (figure 6.9, figure S6.6). There was a general trend towards lower concentrations in 
nucleotides as well as their catabolic end products. It is not possible to conclude from these 
observations that the observed decrease results from either an increased demand and consequently 
consumption of nucleotides, or a decrease in the demand and a subsequently lower production. 
However, there are few hints, suggesting a generally lower production of nucleotides. 1) Transcripts of 
MYC, a critical transcription factor in the regulation of nucleotide synthesis were downregulated 
throughout the period of exposure, with exception of day 14 and exposure to 0.15 and 0.5 mM VPA 
(figure 6.10), 2) elevated concentrations found for 10-formyltetrahydrofolate (figure 6.9, figure S6.9), 
which is an essential cofactor required in two steps in the synthesis of purines, might come from a 
lower demand due to reduced nucleotide synthesis, 3) catabolic products like thymine, β-alanine and 
urate decreased together with nucleotides (figure 6.9, figure S6.6), yet we would expect an increase in 
case of a higher metabolic turnover of nucleotides, 4) levels of the catabolizing enzyme 
dihydropyrimidine dehydrogenase (P15, figure 6.9, figure S6.6) were found to be decreased with 
treatment. 
What might be the reason behind the potential downregulation of nucleotide synthesis? With exposure 
to VPA, HepaRG cells show strong signs of ER stress, such as transcriptional upregulation of 
proteasomes and downregulation of tRNAs and amino acid transporters (figure 6.10). ER stress is a 
condition triggered by mitochondrial dysfunction and oxidative stress, during which protein folding is 
impaired and mis- or unfolded proteins accumulate. To restore normal conditions, cellular protein 
synthesis is reduced and chaperone levels are increased in the context of the UPR (Begriche et al., 
2011; Sano and Reed, 2013). Since in non-proliferating cells, the majority of nucleotides is required 
for the synthesis of RNA (mRNA, rRNA and tRNA) (Lane and Fan, 2015), downregulation of 
nucleotide synthesis via MYC, which is also regulated within the UPR, might be a mechanism to adapt 
nucleotide synthesis to reduced requirements in ER stress conditions. 
Interestingly, activation of MYC on day 14, goes along with a renunciation from the UPR, i.e. 
elevated transcript levels for tRNA synthetases as well as amino acid transporters, but also with 
notably upregulated levels of GADD45A, GADD45B, PMAIP1, FOS and JUN (figure 6.10). The 
latter molecules are involved in regulation of apoptosis (Oda et al., 2000; Shaulian and Karin, 2002; 
Takekawa and Saito, 1998) and coincide with the observed decrease in viability (figure 6.2). The 
initiation of apoptotic pathways is a common fate of cells that fail to recover from ER stress (Sano and 
Reed, 2013) and suggests that ER stress could be a major contributor to cell death in HepaRG cells 
exposed to VPA. 
The initial increase in nucleoside monophosphates (UMP, IMP and GMP; M38, M15 and M35) as 
well as xanthine (M20) upon treatment (figure 6.9, figure S6.6) is particularly interesting, as the trend 
for other purine and pyrimidine intermediates was clearly towards the opposite direction. Nucleoside 
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monophosphates result either from de novo synthesis, or by cleaving of a pyrophosphate from a 
nucleoside triphosphate. Further conversion of nucleoside monophosphates into di- and triphosphates 
might be hampered in case of critical ATP levels, as the phosphate groups required in these reactions 
commonly originate from ATP. The slight decrease in ATP levels already observed on day 2 might 
have slowed down the conversion of nucleoside mono- into diphosphates and hence led to an 
accumulation of UMP, IMP and GMP. At later time points, the impairment of nucleotide synthesis 
suggested above would lead to a drop in nucleoside monophosphate levels, which in turn would result 
in the fading of the initial dose-dependent increase as observed in our experiment. 
The effects of VPA on amino acid metabolism in HepaRG cells were very diverse. E.g., intracellular 
L-glutamate levels decreased in a dose-dependent manner, despite being increasingly fed from the L-
glutamine pool as well as extracellular L-glutamate in the first 8 days (figure S6.7 F5, F2). Yet, on the 
other hand, feeding from 2-oxoglutarate was reduced with increasing VPA concentration (figure S6.7 
F4). Since protein synthesis is expected to be reduced based on the ER stress stated above, it is more 
likely that the reduction of L-glutamate levels is a result of increased formation of the radical 
scavenger glutathione than due to an increase in synthesis of proteins or nucleotides. Supporting this 
hypothesis, glycine, which is also part of the tripeptide glutathione was found to be reduced in a 
similar fashion when HepaRG cells were exposed to VPA, despite a minor increase in its uptake 
(figure S6.7 M46, F3). Though levels of several enzymes involved in glutathione metabolism were not 
affected by exposure to VPA, protein concentration of the microsomal glutathione S-transferase 1 
increased up to around 2.5-fold with VPA (figure S6.9 P47). The enzyme catalyzes the conjugation of 
reduced glutathione to a wide range of exogenous and endogenous electrophiles. However, GPX2, 
which detoxifies organic hydroperoxides and hydrogen peroxide was the most prominently 
downregulated enzyme within the Nrf2 response, when cells were exposed to VPA (figure 6.10). This 
suggests that transcription of the molecule was either directly or indirectly impaired by VPA. VPA and 
particularly its dehydrogenated metabolites are well known to be capable of depleting cellular 
glutathione (Kiang et al., 2011). In another study on mouse liver treated with acetaminophen, similar 
findings were observed with reduced levels for L-glutamine, L-glutamate and glycine, relative to 
untreated cells (Soga et al., 2006). 
In case of BCAA, the effect of VPA on their metabolism was consistent. Uptake of all three BCAA 
was reduced with treatment (F6 to F8), while intracellular L-isoleucine (M55) accumulated and levels 
of propanoate (M54) as a product of L-valine catabolism declined (figure 6.9, figure S6.7). Thus, it 
can be concluded that catabolism of BCAA is impaired by VPA, with subsequent intracellular 
accumulation of the amino acids. Though transcriptional regulation of the associated enzymes is 
poorly studied, it is likely that accumulation of the amino acids triggers an upregulation of the 
associated enzymes as we observed for the methylcrotonyl-CoA carboxylase (P18) and 
short/branched-chain specific acyl-CoA dehydrogenase (P19). Consistently, Luis et al., who 
previously studied the effects of VPA and its metabolites on BCAA metabolism, found inhibitory 
effects on the activity of the branched-chain alpha-keto acid dehydrogenase complex as well as the 
short/branched-chain specific acyl-CoA dehydrogenase (Luís et al., 2011, 2007). Since VPA did not 
cause an effect on the protein and transcript level of the BCAA aminotransferase (P17), any 
impairment would have to be based on the level of direct or indirect inhibition of its activity 
(figure S6.7). 
The results obtained for downstream products of L-serine and L-methionine catabolism are partly in 
contrast to the hypothesis on elevated glutathione synthesis upon VPA exposure. L-homocysteine and 
L-cystathionine were found in significantly higher concentrations (figure 6.9, figure S6.7 M57, M58), 
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despite being a potential source for L-cysteine, which commonly is the bottleneck in the synthesis of 
glutathione. Yet, in our in vitro setup, supply of L-cysteine might not be limiting. Supporting this idea, 
we even observed a decrease in the concentrations of ophthalmate and norophthalmate (figure 6.9, 
figure S6.9 M97, M98), which are increasingly produced as a substitute of glutathione in case L-
cysteine supply is running low (Soga et al., 2006). 
Further, detoxification of ammonia via the urea cycle was impaired by VPA in a dose-dependent 
manner (figure S6.7 F9). At the branching point towards urea and guanidinoacetate formation, there 
seems to be a trend towards the latter, with the corresponding enzyme being upregulated, while 
arginase 1 levels decreased with VPA (figure 6.9, figure S6.7 P21, P22). As the carbamoyl-phosphate 
synthetase I (P20), the key enzyme of the urea cycle, was also downregulated at protein and transcript 
level, the urea cycle is likely to be downregulated in general. Impairment of the urea cycle may have 
severe consequences such as hyperammonemia. We and others have previously described effects of 
VPA on the urea cycle (Aires et al., 2011; Klein et al., 2016), but up to now the impairment was 
thought to reside in a decrease in the formation of the activator of the carbamoyl-phosphate synthetase 
I, N-acetylglutamate. These results suggest a more complex mechanism underlying the inhibition of 
the urea cycle activity. 
Eventually, we found a significant decrease for several dipeptides in HepaRG cells exposed to VPA 
(figure S6.7). Being formed by the action of dipeptidyl peptidases, which cleave dipeptides from 
polypeptides, they are an intermediate product in protein catabolism. As such, alterations found in 
dipeptides may well be associated with ER stress mentioned above. 
Besides lipid, nucleotide and amino acid metabolism, VPA likewise affected carbohydrate 
metabolism, including the glycolytic pathway, the TCA cycle and the pentose phosphate pathway 
(figure 6.9, figure S6.8). Though there was no clear trend for metabolite levels in case of glycolysis, 
metabolic fluxes were markedly reduced in HepaRG cells exposed to VPA (figure S6.8 F10 to F13). 
As already stated in the context of fatty acid metabolism, we found a strong indication for 
downregulation of ChREBP. ChREBP not only regulates lipid metabolism, but is also the key 
responsible for activation of several enzymes of the glycolytic pathway, like pyruvate kinase, liver 
type (Iizuka, 2013) and thus, might play a pivotal role in the decrease in glycolytic reaction rates 
observed in our study. The activation process of ChREBP is not fully understood, but suggested to 
involve xylulose-5-phosphate, glucose-6-phosphate and/or fructose-1,6-bisphosphate as ligands 
(Filhoulaud et al., 2013). The secretion of lactate (Limonciel et al., 2011), or the ratio of secreted 
lactate to ingested D-glucose may be used as an indicator of cellular stress, and in our study, indicates 
an initially stressed phenotype, which might be related remnant stress in the context of seeding and 
alterations in the medium composition. After an interim recovery, said ratio steadily increased from 
day 8 onwards, suggesting an increase in cellular stress in HepaRG cells. 
As a result of the decline in substrate supply via the glycolytic pathway, reaction rates in the TCA 
cycle dropped in a similar fashion as observed for glycolytic fluxes (figure S6.8 F14, F15). 
Additionally, other reactions such as degradation of BCAA, which might normally help supplying 
carbon sources and thus, maintaining normal TCA cycle activity, were also decreased by treatment 
with VPA. These observations are in accordance with the early drop in ATP levels described above 
(figure 6.2). 
The key enzyme of the pentose phosphate pathway (glucose-6-phosphate 1-dehydrogenase, P31) was 
upregulated with VPA treatment (figure 6.9, figure S6.8), which probably results from an increased 
demand in NADPH for the recovery of reduced glutathione. Though NADPH may also be used for de 
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novo lipogenesis and the pentose phosphate pathway may as well serve for the production of ribose 5-
phosphate, these scenarios are unlikely in the light of already elevated fatty acid levels and low 
nucleotide formation as speculated before. 
Upregulation of proteins involved in oxidative phosphorylation was consistent throughout the different 
molecules (figure S6.9 P33 to P39), suggesting a common regulation. Regulation of these genes is not 
fully elucidated, but might involve PPARα and the PPARγ coactivator-1α (Misu et al., 2007; 
Rakhshandehroo et al., 2010), indicating regulation at least partially via fatty acids. Despite 
upregulation of enzymes of the oxidative phosphorylation, cells were not able to maintain ATP levels 
when exposed to 0.5 mM VPA for two weeks (figure 6.2), likely as a result of diminished supply of 
reducing equivalents from upstream pathways. 
Besides these major pathways, VPA also interfered with minor pathways, such as the formation of 
ketone bodies (figure S6.9). 3-hydroxybutyryl-carnitine for example was found to be notably elevated 
with treatment. The metabolite is a carnitine conjugate of 3-hydroxybutyrate, which is formed from 
acetoacetate. In agreement with increased levels of 3-hydroxybutyryl-carnitine, the mitochondrial 
hydroxymethylglutaryl-CoA synthase was found upregulated, while its cytosolic isoform and (R)-
mevalonate were downregulated. Whereas the former enzyme is responsible for the formation of 
ketone bodies, the latter is involved in the synthesis of cholesterol, suggesting a prioritization of 
ketone bodies under VPA exposure. Additional downregulation of the farnesyl pyrophosphate 
synthase strengthens the subordination of cholesterol formation. The potential increase in ketone body 
formation however is surprising, as they are formed in mitochondria, whose function is assumed to be 
impaired by VPA. Further, their physiological meaning is mainly related to extrahepatic tissue. Yet, 
the increase might simply be a consequence of PPARα activation, which also controls the expression 
of the mitochondrial hydroxymethylglutaryl-CoA synthase (Rakhshandehroo et al., 2010). 
Interestingly, in addition to the inhibition of HDAC via VPA, 3-hydroxybutyrate is capable of 
inhibiting HDAC2 and HDAC3 (Sleiman et al., 2016). 
 
6.6 Conclusion 
Taken together, VPA affected a multitude of pathways in HepaRG cells. ER stress, depletion of ATP 
and the impairment of the urea cycle are probably the most critical steps in VPA-induced toxicity. 
Despite expecting to see major accumulation of lipids, we only found a minor increase 
triacylglycerides. This may either indicate that microvesicular steatosis only plays a minor role in the 
course of toxicity of VPA, or that the cultivation setup needs to be further optimized, e.g. by supplying 
fatty acids with the cultivation medium. In a next step, the –omics data may be used in setting up a 
model for the prediction of adverse events induced by VPA. For that purpose, targeted and absolute 
quantification of metabolites of the pathways of interest would provide more reliable parameters and 
confirm annotation within the untargeted analysis. 
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Chapter 7 Summary, conclusion and outlook 
In the context of this thesis, the suitability of the human hepatic HepaRG cell line for its application in 
toxicological studies and eventually in risk assessment was elaborated. The aim of this study was to 
provide tools and knowledge that help to ultimately replace in vivo animal studies in pharmaceutical 
and cosmetics industry. The initial studies were limited to short-term acute toxicity, but in later 
studies, the focus shifted towards long-term repeated dose toxicity. The approach that was taken can 
be divided into three major parts. In the first part, the performance of the HepaRG cell line was 
compared to well-established systems in the context of toxicological studies (chapter 2), while in the 
second part, the cells were optimized in respect to their culture environment (chapter 3 & 4). In the 
third and last part, the knowledge gained from previous studies was used to apply the HepaRG cells in 
in-depth characterization with relevance for risk assessment (chapter 5 & 6). The individual chapters 
will be summarized in more detail in the following. 
Part I Metabolic characterization of HepaRG cells 
In chapter 2, HepaRG cells were compared to the well-established human hepatic cell line HepG2 and 
to the gold standard in in vitro toxicological studies, primary human hepatocytes (PHH). The central 
carbon metabolism of each of these hepatic systems was in the focus of this study. For that purpose, 
we investigated the basal carbon metabolism, but also alterations in metabolism when cells were 
exposed to two hepatotoxic compounds, acetaminophen and diclofenac. The comparison was rounded 
off by including functional analyses, such as cytochrome P450 (CYP450) activity as well as viability 
assessment. We could show that basal carbon metabolism in HepaRG cells closely resembled 
metabolism in PHH, whereas metabolism in HepG2 cells was dictated by its hepatoblastoma origin. 
Further, we found that CYP450 activity in HepaRG cells was clearly superior to HepG2 cells, and in a 
similar range to one of the tested PHH batches, yet slightly lower than in PHH from the other two 
donors. Surprisingly, even though HepaRG cells performed slightly better than HepG2 cells, we found 
effects of the hepatotoxic compounds acetaminophen and diclofenac on viability and metabolism to be 
similar in all tested systems. With these results, we were able to demonstrate from a metabolic point of 
view that HepaRG cells may well serve as a surrogate for PHH in toxicological studies. 
To predict adverse events that are relevant for humans, it is essential that the model system used to 
assess required parameters correctly depicts the in vivo situation in humans. By performing a 
comparison of HepaRG cells to PHH on metabolic level, we revealed major overlaps between the two 
hepatic in vitro models. This is of particular importance for two reasons. First, among the different 
cellular levels, the metabolome best reflects the cellular phenotype as well as changes therein. Second, 
PHH are currently the closest system available to the in vivo situation and therefore, are considered as 
the gold standard in in vitro toxicology. 
Unlike for PHH, availability of HepaRG cells is unlimited. Also, they are easier to handle than their 
primary counterpart and cells are more suitable for long-term studies. However, it is not possible to 
adequately represent the heterogeneity of the human population using only the HepaRG cell line. 
Though in some instances, the variance caused by inter-donor differences is unwanted, it is necessary 
to consider for prediction of toxicity in a population. At least to some extent, variance may be included 
in in silico approaches as we did for the estimation of the oral equivalent dose in chapter 5. 
Based on our results, as well as results obtained in previous studies, HepaRG cells are well suitable as 
a surrogate for PHH. With current research focusing on the improvement of stem cells and genetically 
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modified primary hepatocytes, these systems might eventually replace HepaRG cells and PHH in 
toxicological studies. Particularly in the context of personalized medicine, stem cells and modified 
PHH would be beneficial, but they both currently still struggle with teething problems and their 
success depends on researchers managing to overcome these problems. 
Part II Optimization of HepaRG cell culture conditions for short and long-term studies 
Next, in chapter 3, we investigated the effects of the culture environment on functional parameters 
and on the outcome of toxicity studies in HepaRG cells. Four different setups suitable for application 
in high-throughput screening were used for the cultivation of HepaRG cells: 1) Traditional 2D 
cultivation, 2) collagen sandwich cultivation, 3) cultivation in an Alvetex® polystyrene scaffold and 4) 
spheroid cultivation. Investigated parameters included drug uptake, drug metabolization via phase I 
and II enzymes and levels of the radical scavenger glutathione. Subsequently, short-term toxicity upon 
single and repeated dosing was assessed using bosentan, chlorpromazine and valproic acid as test 
compounds. We found that the individual functional parameters differed to a great extent between the 
different cultivation systems, with spheroid cultures being the most active among the systems. In 
collagen sandwich cultures on the other hand, we observed lowest CYP450 activity and induction, as 
well as a critical ratio of reduced to oxidized glutathione. Interestingly, despite in some instances 
major differences in decisive functional parameters, EC50 values obtained in the context of the 
toxicological studies were in the same range with exception of those in the Alvetex® polystyrene 
scaffold after single dosing. In total, we demonstrated that collagen sandwich HepaRG cultures require 
further optimization for application in toxicity-related studies, and we could show that Alvetex® 
polystyrene scaffold cultures did not provide superior results compared to the cheaper and easier to 
handle 2D cultures. Spheroid and 2D cultures on the other hand were shown to be overall most 
promising for future application in high-throughput screening approaches. 
In chapter 4, we went about long-term cultivation of HepaRG cells for later application of the cells in 
a long-term repeated dose setup. Different compositions and renewal intervals for the cultivation 
medium were tested for providing best functionality and longevity to the HepaRG cell line. To avoid 
interference of medium components with subsequent analyses like proteomics and metabolomics, 
medium was kept serum-free, and serum-supplemented medium served as a reference. In accordance 
with the Organization for Economic Cooperation and Development (OECD) guideline 407, a duration 
of 30 days was chosen to investigate the performance of the different media. Over that period, stability 
of functional parameters, i.e. viability and CYP450 activity was assessed. Additionally, we quantified 
extracellular metabolites to identify potential bottlenecks in nutrients, as well as to perform metabolic 
flux analysis to better understand differences in cultivation with the different media. In order to 
maintain cells viable for 30 days, we found that in serum-free medium a maximum concentration of 
0.5% dimethyl sulfoxide (DMSO) could be used, while HepaRG cells were able to cope with 1.8% 
DMSO in classical serum-supplemented medium. As DMSO induces the expression of several 
CYP450 isoforms, high DMSO concentrations offer an advantage in respect to the metabolization of 
xenobiotics. Yet, we observed a more stable CYP450 activity over the 30-day period in HepaRG cells 
cultivated in serum-free medium with 0.5% DMSO. Further, we identified the essential amino acid 
tryptophan and other non-essential amino acids as potential bottlenecks in nutrient supply, even when 
fresh medium was added every day. Therefore, the addition of tryptophan might further improve 
results obtained in the long-term cultivation of HepaRG. As a prove of principle, we could further 
show that HepaRG cells were susceptible to repeated dosing of valproic acid, with a 17-fold decrease 
in the EC50 value after 2-week treatment, compared to a 24-h exposure. 
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In these two studies, we have shown the potential in optimizing media and the culture system 
environment to improve functionality of the HepaRG cell line as well as its potential application in 
long-term repeated dose toxicity studies. The latter is essential for reliable predictions of adverse 
events, as in many cases, toxicity does not occur before several weeks of exposure. Generally, there 
are three major points to improve current and future in vitro systems, which are described in the 
following. Particularly the first two points are intensively studied within the field of toxicology. 
First, including additional cell types, i.e. co-cultivation of cells, often improves functionality of the 
hepatic system, but in some cases may also be indispensable to correctly predict adverse events. E.g. 
when the adverse reaction involves inflammatory responses, cells of the immune system will be 
necessary to fully depict the toxic processes. Combing different cell types is also part of the body-on-
a-chip concept, which connects organotypic cultures or other types of cultures with a constant medium 
flow. This additionally allows studying processes like cardiotoxicity mediated by drug metabolites 
originating from drug metabolization in liver cells. Also, this approach eventually enables in vitro 
models to catch up with in vivo animal studies in terms of their systemic nature, which currently is 
likely to be the most striking reason for the use of animals in toxicology. 
Second, improvement of in vitro cultures may be accomplished by cultivating cells in a 3D 
environment. As we have shown in our study on cultivation of HepaRG cells in a 3D environment, 
effects on cellular parameters may be tremendous and may help in adapting cellular activity to levels 
as observed in vivo. The 3D environment enables the cells to spread with in vivo-like cell-cell 
interaction and geometry, thereby triggering cellular responses that improve cells’ functionality. 
Probably the most promising system among the plethora of available 3D cultivation tools is spheroid 
cultivation. Next to improved functionality, they offer other advantages, such as compatibility with 
microfluidic devices and high-throughput setups, as well as minimal cell number requirements. The 
latter however may become a problem in case analyses require large amounts of cell material, as it is 
the case for proteome analyses, but the problem can be overcome by pooling the necessary amount of 
spheroids. It is also worth mentioning that HepaRG spheroids have already been successfully applied 
to the body-on-a-chip concept (Maschmeyer et al., 2015). 
Third, systems may be improved by optimizing the composition of the cultivation medium, as shown 
in chapter 4 of this thesis. Here, the goal is to provide nutrients and external stimuli required for 
optimal functionality of the cultures. For co-cultures as described before, the optimization process may 
become difficult, as the medium needs to be adapted for all involved cell types simultaneously and 
some essential supplements might be incompatible between different cell types. At the same time, the 
medium should be kept as close as possible to the in vivo situation. 
In face of these challenges, it becomes clear that alternative systems for the study of toxicity will 
further require several years of intensive research to yield truly reliable data for the prediction of 
toxicity in humans. 
Part III Application of HepaRG cells in repeated dose toxicity studies 
Following the metabolic characterization and optimization of culture conditions for the HepaRG cell 
line, its applicability in risk assessment was investigated in a 4-week study in chapter 5. For that 
purpose, HepaRG cells were exposed to the two compounds bosentan and valproic acid, and viability 
was monitored throughout the treatment. Additionally, drug clearance was quantified and results were 
combined with viability data to estimate the oral equivalent dose using a reverse dosimetry approach. 
The oral equivalent dose is the amount of a compound that is needed to be taken up by an individual to 
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reach a steady state blood concentration of interest, such as the EC10 for a given compound. In addition 
to the oral equivalent dose, we assessed alterations in metabolism in HepaRG cells upon repeated 
exposure to clinically relevant concentrations of the two compounds to better understand the 
underlying mechanisms inducing adverse events. Using the reverse dosimetry approach, we were able 
to estimate the risk that the compounds exert on a virtual human population, but also highlighted 
possible improvements to the technique. Based on alterations in concentrations of key metabolites, we 
could further demonstrate the influence of the compounds on metabolism and relate the effects to 
direct modulation of enzymatic activity or indirect effects via nuclear receptors. Verification of these 
hypotheses on the origin of metabolic alterations will be required in upcoming studies. 
In a second application study, described in chapter 6, effects of valproic acid on HepaRG cells were 
assessed in a multi –omics approach to gain in-depth knowledge on the key mechanisms preceding an 
overt toxic response. In the context of this study, HepaRG cells were treated with valproic acid for 
2 weeks in a repeated dosing regimen, and samples for functional assays, transcriptomics, proteomics, 
metabolomics and fluxomics analyses were collected on 4 different time points. We observed mild 
depletion of ATP already after 2 days of treatment, while viability was not affected until 14 days of 
exposure. Despite previous studies stating microvesicular steatosis as an adverse outcome upon 
valproic acid treatment, accumulation of triacylglycerides was only minor in our study. Instead, using 
transcriptomics, proteomics and metabolomics data, we found strong indications for endoplasmic 
reticulum stress on day 2 and day 8, turning into an apoptotic response by day 14. Further, fluxomics 
data provided information on an impaired ammonia detoxification via the urea cycle. Together, these 
three mechanisms are likely to be major contributors to the adverse response induced by valproic acid. 
In summary, we could demonstrate that the integration of several layers of –omics yields notably more 
comprehensive and more reliable information than any of the individual –omics tools could provide. 
In these two chapters, we have applied two approaches, on the one hand reverse dosimetry to estimate 
the oral equivalent dose, supported by metabolic data, and on the other hand a multi –omics approach. 
Noteworthy, both approaches are independent of the cell system and may likewise be applied to 
genetically modified PHH or other cells. 
Simple in vitro to in vivo extrapolation as we used in the reverse dosimetry approach gives first 
information on the risk associated with the compound of interest. The method is generally applicable 
and also compatible with high-throughput setups. Eventually, more sophisticated models will be 
required to predict adverse events. For example, the accumulation of a compound is not considered in 
with reverse dosimetry and requires more comprehensive pharmacokinetic models. 
Multi –omics approaches as used in the second of these studies, are primarily applied to gain a better 
understanding of the mechanisms underlying adverse reactions. This may then be used to create in 
silico models, or to fill in gaps in already existing ones, thereby improving prediction of toxicity. The 
new insight in the corresponding processes may however also be used for improvements of the test 
system in the initial phase, in case needed. Even more, better understanding of the mechanisms of 
toxicity but also disease mechanisms may assist in relabeling of chemicals, i.e. the reallocation of 
known drugs to other indications, which further helps in reducing tests on animals. 
Generally, in silico tools become more and more powerful and together with advances in in vitro 
approaches, they are a major driving force in replacing animals in the context of risk assessment. 
Moreover, not only may these approaches help in reducing animal experiments, but also in saving 
drug candidates from unnecessarily being sorted out during preclinical animal tests, despite being 
harmless to the human being. Using cell systems of human origin, false positive indications for 
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adverse events can be avoided. Therefore, it may be concluded, that upcoming methods are not meant 
to only replace animal studies, but to serve as an even better tool in the assessment of toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Supplementary material 
139 
 
Supplementary material 
Table of content 
 
 Supplementary material of chapter 2 140 
 Supplementary material of chapter 3 144 
 Supplementary material of chapter 4 145 
 Supplementary material of chapter 5 148 
 Supplementary material of chapter 6 161 
 
  
         Supplementary material 
140 
 
Supplementary material of chapter 2 
Supplementary figures 
 
 
Figure S2.1 Scheme of the connection of the carbon atoms of [1,2-
13
C] glucose, [U-
13
C] glutamine and 
other compounds to lactate via different pathways. The connection of labeled and unlabeled sources for the 
formation of lactate applied in our study is highlighted. Carbon atoms of relevant compounds are represented as 
grey circles, with light grey circles representing unlabeled carbon atoms, and dark grey circles representing 
labeled, i.e. 
13
C carbon atoms. The resulting mass isotopomers of lactate and their dependence on the source is 
highlighted. 
 
 
Figure S2.2 Loading coefficients of the secretion rates in untreated hepatic cells used for the first two 
principal components (PC) of the PCA shown in figure 2.1. A distance of greater 0.2 from the origin was used as 
a threshold (red circle) for metabolites particularly contributing to the differences in the hepatic cells. 
Metabolites with major contribution to the separation, as well as alanine, are labeled. 
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Figure S2.3 Mass isotopomer fractional enrichment in extracellular lactate over the course of 24 h in 
untreated HepG2 (A) and HepaRG cells (B), as well as for primary human hepatocytes from three different 
donors (PHH1 (C), PHH2 (D), PHH3 (E)). Mass isotopomers M0, M1, M2 and M3 are indicated by ■, ●, ▲ and 
▼ respectively. Curve fits to the time course for the individual mass isotopomers are represented by lines in the 
respective color. Error bars indicate standard deviation (n = 3). 
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Figure S2.4 Principal component analyses representing all calculated secretion rates in treated 
(acetaminophen, diclofenac) and untreated hepatic cells (n = 3), for each system individually (HepG2 (A); 
HepaRG (B); PHH1 (C); PHH2 (D); PHH3 (E)). Circles and diamonds represent secretion rates from cells 
treated with acetaminophen and diclofenac, respectively. The different conditions are color-coded with light 
grey, dark grey and black representing cmax, subtoxic concentration and EC10, respectively. White squares 
represent control cells. Dotted, dashed and full lines indicate 95% confidence ellipses for acetaminophen-treated, 
diclofenac-treated and control cells, respectively. Filled ellipses represent confidence regions for all tested 
concentrations combined (cmax, subtoxic concentration and EC10).  
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Supplementary tables 
 
Table S2.1 Donor characteristics of primary human hepatocytes (PHH1, PHH2, PHH3). 
Donor Sex Age Liver pathology Diabetes Smoking Alcoholism Batch number 
PHH1 f 64 Hepatic 
synovialosarcom 
No No No HEP187225 
PHH2 m 76 Cirrhosis No No Not available HEP187156 
PHH3 m 25 Liver metastasis from 
colorectal cancer 
No No No HEP187103 
 
Table S2.2 Summary of significantly altered secretion rates in the different hepatic cell systems upon 
exposure to the EC10 for each drug relative to the control. *, ** and *** indicate a p-value lower than 0.05, 0.01 
and 0.001 respectively. 
 Acetaminophen Diclofenac 
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Alanine ** **   * *** * ** *** *** 
Asparagine **    * **   * *** 
Aspartic Acid        *  ** 
Glucose *** **    *** ***    
Glutamic Acid *      ** ** * * 
Glutamine ** *    *** *** * ** ** 
Glycine *      * **  *** 
Histidine **    * **   *  
Isoleucine ** *   * ** **  * ** 
Lactate *  ** ***  * ** ** *** ** 
Leucine ** *   ** ** **  ***  
Lysine    *     *  
Methionine *** *   ** *** *  ** *** 
Phenylalanine ***     ***  * * *** 
Pyruvate * * *** * *** ** ** *** *** *** 
Serine **    ** ** **  ** *** 
Threonine *     *   ** * 
Tryptophan * *** **  ** * * * *** ** 
Tyrosine     **      
Urea * * ** *   *   ** 
Valine *     ** *   ** 
 
Significantly altered 
metabolites 
18 9 4 4 10 15 14 9 15 16 
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Supplementary material of chapter 3 
Supplementary figures 
 
Figure S3.1 Differential equations for the calculation of oxygen diffusion in 2D/APS and CSW cultures. 
 
Figure S3.2 Differential equations for the calculation of oxygen diffusion in spheroid cultures. 
{DIFFMTP}
{Program for calculating the dynamic diffusion profiles in a microtiter plate.  The active, respiring cell layer is 
located at the bottom of the plate} {The number of finite difference elements can be changed with N.}
{Values with no further indication were taken from Dunn et al., 2005, Biological Reaction Engineering, doi: 10.1002/3527603050}
DT=10
STOPTIME=21600 ;[s]
method stiff
dtmax=10
{Constants}
R =0.00315 ;Radius of single well in 96-well plate [m]
L =0.0032    ;height of MTP filling [m] /(in case of CSW cultures, value was 0.0054)  
DO =3.1E-9   ;Diffusion coeff. for Oxygen in biofilm [m^2/s] (compost.css.cornell.edu/oxygen/oxygen.diff.water.html)
C_OS =0.3 ;Saturation conc. for oxygen at 35°C mM=[mol/m^3]    
C_OG =C_OS
vmax =1.65E-15 ;[mol/(s x cell)] (estimated from doi: 10.1016/j.biomaterials.2015.11.026)
nCells =72E3 ;Number of cells  in the bottom layer
KO =0.1      ;Saturation constant for Oxygen, mM=[mol/m^3]
N =10   ;Number of finite differences
Z =L/N  ;Thickness of a biofilm segment [m]
V_N =3.14*Z*R^2 ;Volume of one segment [m^3]
{Initial concentration, mol/m3}
init C_O[0..N] =C_OG
{For graphing purposes}
Nmid =round(N/2)
Osurface =C_O[0]
Omid =C_O[Nmid]
Obot =C_O[N]
{BALANCES FOR BIOFILM IN N SEGMENTS}
d/dt(C_O[0]) =0
d/dt(C_O[1..N-1]) =DO*(C_O[i-1]-2*C_O[i]+C_O[i+1])/(Z*Z)
d/dt(C_O[N]) =DO*(C_O[i-1]-C_O[i])/(Z*Z)+r_O/V_N
{Reaction rates in the biofilm segments, [mol/(m^3 x s)]}
r_O =-vmax*nCells*C_O[N]/(KO+C_O[N])
METHOD stiff
STOPTIME=21600 ;[s]
DT=10
DTMAX=10
DTOUT=10
{geometry}
d0 =  0.001 ; [m]
d1 = 0.0045 ; [m]
d2 = 0.0055 ; [m]
h1 = 0.004 ; [m]
h2 = 0.0024 ; [m]
hfill=h1+h2
r0 =d0/2
r1 =d1/2
r2 =d2/2
h1tot =h1*r1/(r1-r0)
h2tot =h2*r2/(r2-r1)
Nelements =30 ;Number of difference elements
Nupper=ROUND(Nelements*h2/hfill) ;Element at the transition upper_lower
delta2=h2/Nupper
delta1=h1/(Nelements-Nupper)
h[0..Nupper]=hfill-i*delta2
r[0..Nupper]=(h[i]-h1)*r2/h2tot+r1
h[Nupper+1..Nelements]=h1-(i-Nupper)*delta1
r[Nupper+1..Nelements]=h[i]/h1tot*r1+r0
A[0..Nelements]=r[i]^2*PI
V[0]=0
V[1..Nelements]=PI/3*(r[i-1]^2*h[i-1]-r[i]^2*h[i])
Vtot=ARRAYSUM(V[*]) ;Total volume [m^3]
VtotmL=Vtot*1e6 ;Total volume [µL]
{Constants} 
DO =3.1E-09         
C_OS =0.3
vmax =1.65E-15
nCells =2E3          
KO =0.1        
{Initial Conditions}
INIT C_O[0..Nelements] =C_OS
{SUBSTRATE OXYGEN BALANCES FOR EACH DELTA R ELEMENT}
dcdt[0]=0
{upper cone}
dcdt[1..(Nelements-1)]=DO*(A[i-1]*(C_O[i-1]-C_O[i])/(h[i-1]-h[i]) - A[i]*(C_O[i]-C_O[i+1])/(h[i]-h[i+1]))/V[i]
{Bottom layer}
dcdt[Nelements]=DO*A[i-1]*(C_O[i-1]-C_O[i])/(h[i-1]-h[i])/V[i] +r_O/V[Nelements]
d/dt(C_O[0..Nelements])=dcdt[i]
limit C_O>=0
Osurface =C_OS
Omid =C_O[Nupper]
Obot =C_O[Nelements]
{RATE EQUATION}
r_O=-vmax*nCells*C_O[Nelements]/(KO+C_O[Nelements])    
timeh=Time/3600
         Supplementary material 
145 
 
 
 
 
Figure S3.3 Dose response curves of HepaRG cells in different cultivation systems exposed to bosentan (A), 
chlorpromazine (B) and valproic acid (C) for either 24 h (single dose, closed symbols, full lines) or 72 h (three 
doses, open symbols, dashed lines). Symbols indicate 2D (■), Alvetex® polystyrene scaffold (♦), collagen 
sandwich (▲) and spheroid (●) cultures. Viability was assessed by quantification of ATP. 
 
Supplementary material of chapter 4 
Supplementary figures 
 
 
 
Figure S4.1 Effect of different medium renewal intervals on the viability of HepaRG cells when kept in 
different media. Medium renewal was performed daily (X), every second day (♦) or every third day (+) in 
SFM1 / 2 / 3 [serum-free medium with growth factors and 0% / 0.5% and 1.8% dimethylsulfoxide (DMSO), 
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respectively] and SSM (serum-supplemented medium with 1.8% DMSO). Error bars indicate standard deviation 
(n = 3). Viability is given in percentage relative to HepaRG culture viability on day 0. 
 
 
 
Figure S4.2 Effect of different medium renewal intervals on the activity of CYP3A4 for HepaRG  
maintained in SFM2 [serum-free medium with growth factors and 0.5% dimethylsulfoxide (DMSO)] and SSM 
(serum-supplemented medium with 1.8% DMSO). Dark grey histograms represent every day, light grey 
histograms show every second day and black histograms every third day renewal interval. Error bars indicate 
standard deviation (n = 3). *, **, *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively. 
 
Figure S4.3 Secretion and uptake rates of organic acids, glucose, urea and albumin for HepaRG cells 
during 30-day cultivation. SFM1 / 2 [serum-free medium with growth factors and 0% or 0.5% 
dimethylsulfoxide (DMSO), respectively] and SSM (serum-supplemented medium with 1.8% DMSO). Negative 
values mean uptake, positive values correspond to secretion. Splines were fitted to the extracellular rates using 
MatLab 2007b and SLM spline toolbox. 
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Supplementary tables 
Table S4.1 Stoichiometric matrix used for metabolic flux analysis. The first 24 reactions represent transport 
of the metabolites from the extracellular environment across the membrane into the cell, while reactions 25 to 55 
correspond to chemical conversions of metabolites as indicated. AA, amino acids. 
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Supplementary material of chapter 5 
Supplementary figures 
 
 
Figure S5.1 Experimental design. Protocol for acute and repeated-dose exposure to bosentan and VPA. Time 
schedule and performed analyses are given (A). Vertical lines indicate medium renewal (blue) or medium 
renewal plus analyses (green). Sampling points are highlighted by green arrows. Exposure concentrations for 
both bosentan and VPA including experimental setup for drug clearance (parent compound quantification) is 
depicted (B). Conditions investigated in detail are highlighted in dark blue (metabolites analyses) and grey (in 
vitro drug removal). 
 
         Supplementary material 
149 
 
 
Figure S5.2 Graphical representation of in vitro and in vivo balances for drug clearance. Schemes of 
experimental in vitro system (A) and of the human body (B) PK model used for the calculation of OED. The in 
vitro system uses 2D cultures of HepaRG cells attached to the bottom of a microtiter plate well. Since there are 
no free cells and no plasma in the system, only binding of the compound to the walls of the microwell has to be 
considered. The removal by the HepaRG cells is quantified by the reaction velocity v (A). The human body 
model consists of the blood containing plasma, plasma proteins and blood cells. The test compound is introduced 
with a rate characterized by the oral equivalent dose (OED). It may bind to blood cells and serum proteins as 
characterized by fuP, the fraction of unbound compound in plasma. The compound is removed by the liver, 
characterized by hepatic clearance, CLHep and by the kidney, characterized by GFR, the glomerular filtration rate 
[L/h] (B). 
 
 
Figure S5.3 Parent compound concentration in the in vitro setup. Mean drug parent compound 
concentrations in medium before (white bars) and after (grey bars) 48 h cell-free incubation at 37°C. Error bars 
indicate standard deviations from measurements taken at different sampling time points during repeated-dose 
study (N=4, total n=12 for samples after incubation, N=4 for samples before incubation). Unpaired Student’s t-
test was performed for comparison of parent drug concentrations in medium with and without cell-free 
incubation. Bosentan concentration changed from 34.6 µM to 32.3 µM after incubation. VPA was found in 
concentrations of 111 µM before and 119 µM after incubation. The differences were not statistically significant. 
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Figure S5.4 Cell size. Cell diameters of HepaRG cells and primary human hepatocytes in suspension. Cell size 
was determined using a Countess™ Automated Cell Counter giving the average cell diameter of living cells. 
Pictures and histograms are given for HepaRG (n=3) and primary human hepatocytes (n=2). 
 
 
Figure S5.5 Long-term viability. Viability of HepaRG cultures assessed with CellTiter-Blue® assay over a 
period of 28 days. Viability was calculated by normalizing fluorescence signals to the initial signal assessed on 
day 0. Error bars indicate standard deviations (n=3). 
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Figure S5.6 Metabolic competence. CYP450 activities for CYP2D6, CYP1A2, CYP2B6, CYP3A4 and 
CYP2E1 in untreated HepaRG cells over time. Error bars indicate standard deviations (n=3). Unpaired Student’s 
t-test was performed for comparison of each CYP450 activity to its activity on day 6. Significance is indicated 
by *, **, *** corresponding to p < 0.05, p < 0.01 and p < 0.001 respectively. 
 
 
Figure S5.7 Drug efflux transporter activity. Light and fluorescence microscopy for the localization of 
CMFDA in the assessment of MRP2 activity. HepaRG cells were either incubated with serum-free or serum-
supplemented medium for 4 days prior to microscopy. Nuclei were stained using Hoechst dye. White bars 
represent 200 µm. 
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Figure S5.8 Drug metabolism. Drug metabolite formation in HepaRG cells. Relative peak area of bosentan (A) 
and VPA (B) drug metabolites found in the supernatants after 24 h incubation with the parent compound. Peak 
areas upon induction of HepaRG cells with rifampicin (light grey) are normalized to the peak areas found in the 
un-induced control (dark grey). Error bars indicate standard deviations (n = 3). Significance is indicated by *, 
**, *** corresponding to p < 0.05, p < 0.01 and p < 0.001 respectively. 
 
Supplementary tables 
Table S5.1 Physiological parameter ranges used for the virtual population. Values were taken from (ICRP, 
2002). 
 Mean Lower limit Upper limit 
GFR [L/h] 7.5 3.75 11.25 
QL [L/h] 97.8 78 114 
LW [kg] 1.6 1.1 2.1 
BW [kg] 66.5 50 90 
QL = Liver blood flow, LW = Liver weight, BW = Body weight 
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Table S5.2 Summary of parameters used during the calculation of the OED and their sources. 
 Value Source 
RBP (bosentan) 0.55 (Poulin, 2013) 
RBP (VPA) 0.2 (Shirkey et al., 1985) 
pH (cytosol) 7.0 (Poulin et al., 2012) 
pH (plasma) 7.4 (Poulin et al., 2012) 
pKa (bosentan) 5.2 (Poulin, 2013) 
pKa (VPA) 4.8 http://www.drugbank.ca/drugs/DB00313 
accessed on July 10, 2015 
PLR 13.3 (Poulin et al., 2012) 
fup (bosentan) 0.0053 (Poulin, 2013) 
fup (VPA) 0.1425 Average value calculated from data available on 
http://www.drugbank.ca/drugs/DB00313 
accessed on July 10, 2015 
BAOral (bosentan) 0.5 (Weber et al., 1996) 
BAOral (VPA) 1 (Perucca et al., 1978) 
Hepatocellularity (hc) 1.39*10
11
 cells per kg 
liver 
(Sohlenius-Sternbeck, 2006) 
Vinvitro 100*10
-6 
L Experimental parameter 
VHepaRG 0.86*10
-12 
L Experimentally determined  
VPHH 1.29*10
-12 
L Experimentally determined 
kinvitro (bosentan) day 1 2.73*10
-12
 h
-1
 Calculated   
kinvitro (bosentan) day 6 2.57*10
-11
 h
-1
 Calculated 
kinvitro (bosentan) day 14 3.30*10
-11
 h
-1
 Calculated 
kinvitro (bosentan) day 20 4.84*10
-11
 h
-1
 Calculated 
kinvitro (bosentan) day 28 5.13*10
-11
 h
-1
 Calculated 
kinvitro (VPA) 1.44*10
-11
 h
-1
 Calculated 
 
Table S5.3 Relative distribution of bosentan and its metabolites in the supernatant after 3 and 24 h 
incubation with HepaRG cells. Relative distributions are given for the drug and its metabolites (total), and 
separately only for the metabolites (metabolites). 
Incubation 
period (h) 
Percentage 
of Bosentan Ro 48-5033 Ro 47-8634 
Ro 47-8634-
OH 
Bosentan 
glucuronide 
3 
Total 96.6 1.5 1.9 0.04 0.01 
Metabolites - 42.5 56.2 1.2 0.2 
24 
Total 95.0 2.6 2.3 0.07 0.01 
Metabolites - 51.3 47.0 1.4 0.3 
 
Table S5.4 Relative distribution of VPA and its metabolites in the supernatant after 3 and 24 h incubation 
with HepaRG cells. Relative distributions are given for the drug and its metabolites (total), and separately only 
for the metabolites (metabolites). 
Incubation 
period (h) 
Percentage 
of VPA 
OH-
VPA 
ene-
VPA 
VPA 
glucuronide 
VPA-
CoA 
2,4-
diene-
VPA 
Keto-
VPA 
3 
Total 96.8 0.01 0.04 3.1 
n.d. n.d. n.d. 
Metabolites - 0.4 1.2 98.4 
24 
Total 88.5 0.03 0.03 11.5 
Metabolites - 0.2 0.3 99.5 
n.d. = not detected. 
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Supplementary methods 
CYP450 activity assay 
Frozen samples were thawed at room temperature and diluted with 0.1% formic acid in ultrapure 
water. OH-chlorzoxazone was quantified by HPLC tandem mass spectrometry.  The system consisted 
of an AB Sciex API3200 triple quadrupole mass spectrometer (Framingham, USA) interfaced with an 
Agilent 1200SL HPLC (Santa Clara, USA). Chromatography was performed at 70°C with 20 µL 
injected into a Zorbax Eclipse XDB C18 column (50 mm × 4.6 mm, 1.8 µm particle size) at a flow 
rate of 1.5 mL/min. The column eluent was split to an electrospray ionization interface, operating at 
650°C in multiple reaction monitoring mode (183.9 to 119.9) in negative polarity. The mobile phase 
was 0.01% formic acid in ultrapure water (A) and acetonitrile (B). The proportion of the mobile phase 
B was increased linearly from 10 to 50% in 1.2 min and then the column was flushed with 95% of the 
mobile phase B and then allowed to re-equilibrate at initial conditions. 
Quantification of drug metabolites 
Samples for drug metabolite quantification were precipitated by the addition of acetonitrile. After 
centrifugation, the supernatants (containing 90% acetonitrile) were analyzed by LC/MS. A high 
performance LC system consisting of an Accela U-HPLC pump and an Accela auto sampler (Thermo 
Fisher Scientific, USA) was used. The LC was performed in the gradient mode using acetonitrile with 
0.2% acetic acid as organic phase (A), and aqueous 0.2 % acetic acid (B); the pump flow rate was set 
to 420 µl/min (% A (t (min), 0(0-0.1)-97(1.2-2.5)-0(2.6–5.0). LC was performed using a Kinetex 
Phenyl-Hexyl, 2.6 µm, 50 × 2.1 mm (Phenomenex, Germany) analytical column with a pre-column 
(UHPLC Phenyl for 2.1 mm ID columns, Phenomenex, Germany). Mass spectrometry was performed 
on a Q-Exactive or an Exactive mass spectrometer (Orbitrap® technology with accurate mass) for 
valproic acid and bosentan respectively, equipped with a heated electrospray interface (Thermo Fisher 
Scientific, USA) connected to a PC running the standard software Xcalibur 2.1. 
As MS tune file, a generic tune file was used, applying the negative or positive ion mode for valproic 
acid or bosentan respectively. As lock mass for internal mass calibration the [M+H]
+
 ion of the 
Diisooctyl phthalate (m/z 391.28429), which is ubiquitously present in the solvent system, was used. 
The analytes were acquired by scanning +/- 1 Thomson around the expected mass of the monoisotopic 
[M+H]
+
. High-resolution mass measurement was performed in Orbitrap® mode with a resolution of 
50,000. The accurate mass of each metabolite was used for peak integration. Further instrument 
settings were as follows: high-energy collisional dissociation 20 eV, automatic gain control high 
dynamic range, max. trap injection time 100 ms, sheath gas 30, aux gas 8, sweep gas 2, spray voltage 
4 kV, capillary temperature 250°C, electrospray ionization 2 heater temperature 250°C. The data 
acquisition was performed on a Thermo Fisher Scientific mass spectrometer, consisting of a 
standalone Orbitrap® mass analyser (Exactive). 
For the analysis of VPA metabolites, the accurate masses of VPA and the following metabolites were 
used ([M+H]
+
, theoretical exact mass): VPA (143.1078), monohydrolated valproic acid (159.1027, 
OH-VPA), dehydrogenated valproic acid (141.0921, ene-VPA) and valproic acid glucuronide 
conjugate (319.1398, VPA glucuronide). 
For the analysis of bosentan metabolites, the accurate masses of bosentan and the following 
metabolites were used ([M-H]-, theoretical exact mass): bosentan (552.1911), monohydrolated 
bosentan (568.1861, Ro 48-5033), demethylated bosentan (538.1754, Ro 47-8634), monohydrolated 
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and demethylated bosentan (554.1704, Ro 47-8634-OH) and bosentan glucuronide conjugate 
(727.7382, bosentan glucuronide). 
Extraction and quantification of total drug parent compound 
Quantification was performed with a Perkin Elmer series 200 HPLC connected to an Applied 
Biosystem-SCIEX API 3000 triple quadrupole mass spectrometer. A Kinetex XB-C18 column 
50 × 2 mm i.d., 5 μm particle size (Phenomenex, USA), was used for chromatographic separation. The 
mobile phases were 0.1 % formic acid in MilliQ water for positive ionization and 0.05 % acetic acid in 
MilliQ water for negative ionization (A) and acetonitrile (B) with a gradient set as follow: from 30 to 
100 % B in 6 min, 100 % B for 2 min, 100 to 30 % B in 2 min, 30 % B for 7 min, at 200 μL/min. The 
injection volume was 10 μL of the sample. The turbo ion spray source temperature was 350 °C. Ion 
spray voltage was set to 5000 V for bosentan and -4200 V for VPA. The nebulizer and the curtain gas 
were set at 7 and 8 units respectively. The analysis was done in the multiple reaction monitoring mode 
(MRM). The optimized transitions and parameters were: 552.2-202.2 and 552.2-280.2 m/z for 
bosentan, with collision energy of 47 and 57 eV respectively, declustering potential set at 60 V and 
focusing potential at 220 V; 558.3-202.3 and 558.3-280.1 m/z for Bosentan-
13
C2,
2
H4, with collision 
energy of 45 and 55 eV respectively, declustering potential set at 55 V and focusing potential at 200 
V; 143.0-143.0 m/z for VPA, with collision energy of -5 eV, declustering potential set at -40 V and 
focusing potential at -140 V; 121.0-77.0 m/z for benzoic acid with collision energy of -17 eV, 
declustering potential set at -10 V and focusing potential at -70 V. 
Reverse dosimetry for the estimation of the oral equivalent dose 
Reverse dosimetry was used for the estimation of the oral equivalent dose (OED). These calculations 
are based on simplified balances of the in vitro in in vivo model systems as depicted in supplementary 
figure S5.2. 
Kinetics estimation 
Most common kinetics used for the description of drug metabolism are first order and to a lesser 
extent Michaelis-Menten-type kinetics (MM kinetics). A common procedure to identify first order 
kinetics it to check for constant half-life time of the reaction. In our experiment, we obtained data for 
one high concentration and one low concentration at each time point of the repeated-dose experiments, 
i.e. at days 1, 6, 14, 20, 28. We measured the conversion over a period of 24 h or 48 h. Apparent first-
order rate constants were determined by 
        [S5.1] 
C is the drug concentration (mol/L). If the estimated k values [1/h] were identical at high and low 
initial concentrations, first order kinetics were assumed. This was the case for valproic acid (VPA) but 
not for bosentan. Dividing by the viable cell number yields the rate constant per cell that is used in 
equation 5.5 of the main text. 
        [S5.2] 
We found that kinvitro remained nearly constant throughout the 28 days of experiment. This was the case 
for valproic acid (VPA) but not for bosentan. Therefore, we decided to estimate one constant (k) value 
0 1
0 1
ln lnC C
k
t t

 
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invitro
invitro
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
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for the whole dataset in the case of VPA. In the case of bosentan MM kinetics were applied and one 
single set of constants (kMM and KM) was determined for the whole set of bosentan experimental data 
using a numerical procedure. MM kinetics were defined as 
       [S5.3] 
kMM is the rate constant [mol/(L × h × cell)] and KM the Michaelis-Menten constant (mol/L). The 
resulting differential equation  
         [S5.4] 
was solved numerically using the function ode15s of MATLAB. Simultaneously, all experimentally 
determined concentrations were compared with concentrations calculated by the model. A suitable 
objective function, i.e. weighted least squares, was used to find optimal parameter values. Weighting 
was done by division of model deviation by the model value at that time point. Parameter estimation 
was accomplished by using the function fmincon of MATLAB. In the case of VPA, kMM and KM were 
highly correlated and only the ratio could be determined 
         [S5.5] 
In the case of MM kinetics, kinvitro used in equation 5.5 of the main text depends on the test compound 
concentration C as can be derived from the following equation; 
        [S5.6] 
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Bosentan in vitro kinetics 
The parameter estimation progress is depicted in figure SM1 showing the objective function, kMM and 
KM.  
 
 
Figure SM1 Parameter estimation progress using MM kinetics. qmax is kMM of equation S5.3. 
 
Table SM1 lists the resulting experimental and model data of the kinetic experiment. A graphical 
comparison is shown in figure SM2 
 
Table SM1. Experimental and model data of Bosentan removal by HepaRG cells in 96-well plates. 
Day C0 Cexp Cmodel Cmodel- Cexp 
 µmol/L µmol/L µmol/L µmol/L 
1 37.56 26.68 22.94 -3.74 
6 30.73 3.77 7.27 3.50 
6 7.65 0.43 0.71 0.28 
14 32.09 7.15 8.02 0.87 
14 4.94 0.46 0.43 -0.03 
20 31.21 8.22 6.83 -1.39 
20 4.56 0.59 0.35 -0.24 
28 5.25 0.63 0.46 -0.17 
 
The determined kinetic parameters are: 
kMM = 3.62×10
-5
 mol/(L × h × cell) 
KM = 25.2 mol/L 
 
         Supplementary material 
158 
 
 
Figure SM2 Bosentan removal by HepaRG cells following MM kinetics. The right-hand part shows data with 
a magnified concentration scale. 
 
VPA in vitro kinetics 
The parameter estimation progress is depicted in figure SM3 showing the objective function, 
kMM and KM.  
 
 
Figure SM3 Parameter estimation progress using MM kinetics. qmax is kMM of equation 3. 
 
Table SM2 lists the resulting experimental and model data of the kinetic experiment. A 
graphical comparison is shown in figure SM4. 
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Table SM2 Experimental and model data of VPA removal by HepaRG cells in 96-well plates. 
Day C0 Cexp Cmodel Cmodel- Cexp 
 mmol/L mmol/L mmol/L mmol/L 
1 53.105 47.154 49.594 2.440 
1 10.991 10.448 9.686 -0.762 
6 1.655 1.288 1.313 0.026 
6 0.115 0.087 0.090 0.002 
14 1.558 1.373 1.319 -0.054 
14 0.117 0.096 0.091 -0.005 
20 1.553 1.318 1.415 0.097 
20 0.117 0.089 0.090 0.001 
28 1.692 1.641 1.636 -0.005 
28 0.127 0.096 0.099 0.003 
 
The determined kinetic parameters are: 
kMM =9.66×10
-3
 mmol/(L h cell) 
KM = 66920 mmol/L 
The very high estimated KM value indicates first order kinetics that are described by 
kMM/KM  = 1.4429×10
-7
 (1/h) 
 
 
 
Figure SM4 VPA removal by HepaRG cells. The lower parts show data at a magnified concentration scale. 
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Cell size determination for upscaling HepaRG to PHH 
For the determination of the cell volumes of HepaRG cells and primary human hepatocytes, both cell 
types were brought in suspension using cryopreserved HepaRG cells and primary human hepatocytes.  
20 µL of each suspension were mixed with an equal volume of trypan blue (Invitrogen Life 
Technologies, Darmstadt, Germany) and pipetted onto a Countess™ cell counting chamber slide 
(Invitrogen Life Technologies, Darmstadt, Germany). A Countess™ Automated Cell Counter 
(Invitrogen Life Technologies, Darmstadt, Germany) was used to determine the average size of living 
cells including the distribution of the cell size (figure S5.4). Cells with a diameter below 5 µm and 
above 23 µm were excluded from the calculation of the average cell size to avoid including cell debris 
and cell clusters into the calculation. Average cell sizes were used to calculate the volume of HepaRG 
cells and primary human hepatocytes under the assumption of a spherical cell shape. 
Average cell size in HepaRG cells was 11.8 µm and 13.5 µm for primary human hepatocytes. 
Volumes calculated from the diameters were 0.86 and 1.29 pL, respectively, resulting in a volume 
ratio RV of 1.5. 
Supplementary discussion 
Characterization of the test system 
There was no significant change in the viability of the culture upon 28-day cultivation. The CYP450 
activities (CYP2D6, CYP1A2, CYP2B6, CYP3A4 and CYP2E1) in the present study remained stable 
over the 28-day cultivation period. Additionally, we previously reported high CYP2C9 activity in 
serum-free HepaRG culture (Klein et al., 2014).  
HepaRG cultures have been reported to show mRNA levels and activity of various transporters; 
namely uptake transporters such as Na
+
-taurocholate cotransporting polypeptide (NTCP) and organic 
anion transporting polypeptide (OATP); efflux transporters such as bile salt export pump (BSEP), 
multidrug resistance associated proteins (MRP), multidrug resistance proteins (MDR) and breast 
cancer resistance protein (BCRP) (Anthérieu et al., 2012a; Bachour-El Azzi et al., 2015; Kanebratt and 
Andersson, 2008; Kotani et al., 2012; Le Vee et al., 2013; Pernelle et al., 2011; Sharanek et al., 2014; 
Ulvestad et al., 2012). In the present study, HepaRG cells with and without serum show comparable 
MRP2 activity (drug efflux). Investigation of all transporters was beyond the scope of this study. 
However, the presence of metabolites in culture supernatants especially the glucuronide conjugates 
proves functional uptake of parent compounds and efflux of drug metabolites in our system. Bosentan 
is taken up by OATP transporters (Treiber et al., 2007), whereas uptake mechanisms of VPA are 
discussed controversially. Various hypotheses include passive diffusion and transporter-mediated 
uptake by OATP, monocarboxylate transporters and solute carrier 4A11 (Booth et al., 1996; Fischer et 
al., 2008; Terbach et al., 2011; Thwaites and Anderson, 2007). The glucuronide conjugates of both 
compounds are secreted via the MRP2 transporters (Fahrmayr et al., 2013; Jedlitschky et al., 1996). 
We detected glucuronide conjugates of both bosentan and VPA in our experiments. In addition, all 
major metabolites of bosentan described in literature (Ro 48-5033, Ro 47-8634, Ro 47-8634-OH) and 
primary metabolites of VPA (OH-VPA and ene-VPA) were detected. Keto-VPA, 2,4-diene-VPA and 
VPA-CoA could not be detected probably due to the instability of these metabolites and/or generally 
low abundance. Additionally, we found that the metabolism of bosentan was significantly changed 
upon induction with rifampicin and resulted in more oxidation products in the supernatant. Bosentan is 
a substrate for CYP3A4 (Treiber et al., 2007) and therefore induction of these enzymes led to an 
increase in the  oxidative metabolism of bosentan in HepaRG cultures. In case of VPA, changes in 
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drug metabolism upon induction were minor. VPA is not a substrate of CYP3A4, hence effects of 
CYP3A4 induction on metabolism of VPA were lower as compared to bosentan (figure S5.8). 
Summarizing, we found that HepaRG cells in our setup, not only exhibit stable metabolism similar to 
in vivo but also respond to induction of CYP450 leading to changes in drug metabolism. 
Investigating the binding of the tested drugs in our in vitro system, we show that phenomena inherent 
to in vitro systems such as compound degradation or plastic binding are negligible for the investigated 
drugs in our experimental setup. 
 
Supplementary material of chapter 6 
Supplementary figures 
 
 
Figure S6.1 Experimental design. Summary of the plate setups (6-, 24- or 96-well) used for the different 
analyses (A) and the cultivation scheme highlighting the time points for medium renewal and sampling (B). In 
case of fluxomics data, sampling was additionally performed on day 4 and 12. Standard medium refers to 
Williams Medium E (WME) with 0.5% dimethyl sulfoxide (DMSO), additive 650 (ADD650) obtained from 
Biopredic International and epidermal and hepatocyte growth factor (GF). VPA, valproic acid; FBS, fetal bovine 
serum. 
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Figure S6.2 Metabolic network for flux analysis. In the metabolic network, all 53 reactions that were applied 
in the metabolic flux analysis are depicted. The glycolytic pathway, tricarboxylic acid and urea cycle, and the 
amino acid metabolism are highlighted in green, yellow, red and grey respectively. AA, amino acids. 
 
 
Figure S6.3 Loading coefficients of intracellular metabolome data for the first two principal components 
(PC), shown in figure 6.7. 
         Supplementary material 
163 
 
Figure S6.4 Volcano plot comparing the intracellular metabolome in HepaRG cells upon exposure to 
valproic acid (VPA) at different time points. A p-value of 0.05 and an absolute log2 fold change of 1 were 
selected as thresholds which are indicated by dotted lines. Metabolites exceeding both thresholds are highlighted 
as yellow circles, while all other metabolites are depicted as blue circles. For the former, metabolites are further 
distinguished according to whether levels are decreasing or increasing, with corresponding numbers indicated. 
The p-values are based on a t-test with subsequent Benjamini-Hochberg correction for multiple testing. 
Measurement of the underlying data has been performed by Nicola Zamboni at ETH Zurich, Switzerland. 
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Figure S6.5 Time courses of metabolites, proteins and transcripts in fatty acid metabolism for HepaRG 
cells treated with valproic acid (VPA) for two weeks. Profiles of selected molecules within fatty acid 
metabolism that were shown to be particularly affected by 2-week treatment with VPA are depicted. Further, 
selected enzymes within the top 250 significantly altered proteins based on ANOVA were added. Furthermore, 
the subset was completed by the key enzymes of the corresponding pathways. The graph complements figure 6.9 
in the main body of the chapter and metabolite (M) and protein (P) numbers match. Proteome and transcriptome 
data were normalized to day 0 and plotted in the same graph. The gene name is given in brackets. Proteome data 
is represented by triangles and full lines, whereas transcriptome data is represented as squares with dashed lines. 
VPA concentrations are color coded. Blue, green, yellow and red represent the control and 0.05 mM, 0.15 mM 
and 0.5 mM VPA respectively. For the metabolome data, the time points day 2, 8 and 14 are represented by 
increasingly dark colors, while the common control on day 0 is presented in grey. Error bars indicate standard 
deviation with n = 3. 
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Figure S6.6 Time courses of metabolites, proteins and transcripts in nucleotide metabolism for HepaRG 
cells treated with valproic acid (VPA) for two weeks. Profiles of selected molecules within nucleotide 
metabolism that were shown to be particularly affected by 2-week treatment with VPA are depicted. Further, 
selected enzymes within the top 250 significantly altered proteins based on ANOVA were added. Furthermore, 
the subset was completed by the key enzymes of the corresponding pathways. The graph complements figure 6.9 
in the main body of the chapter and metabolite (M) and protein (P) numbers match. Proteome and transcriptome 
data were normalized to day 0 and plotted in the same graph. The gene name is given in brackets. Proteome data 
is represented by triangles and full lines, whereas transcriptome data is represented as squares with dashed lines. 
VPA concentrations are color coded. Blue, green, yellow and red represent the control and 0.05 mM, 0.15 mM 
and 0.5 mM VPA respectively. For the metabolome data, the time points day 2, 8 and 14 are represented by 
increasingly dark colors, while the common control on day 0 is presented in grey. Error bars indicate standard 
deviation with n = 3. 
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Figure S6.7 Time courses of metabolites, proteins, transcripts and fluxes in amino acid metabolism for 
HepaRG cells treated with valproic acid (VPA) for two weeks. Profiles of selected molecules within amino 
acid metabolism that were shown to be particularly affected by 2-week treatment with VPA are depicted. 
Further, selected enzymes within the top 250 significantly altered proteins based on ANOVA were added. 
Furthermore, the subset was completed by the key enzymes of the corresponding pathways. The graph 
complements figure 6.9 in the main body of the chapter and metabolite (M) and protein (P) numbers match. 
Proteome and transcriptome data were normalized to day 0 and plotted in the same graph. The gene name is 
given in brackets. Proteome data is represented by triangles and full lines, whereas transcriptome data is 
represented as squares with dashed lines. VPA concentrations are color coded. Blue, green, yellow and red 
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represent the control and 0.05 mM, 0.15 mM and 0.5 mM VPA respectively. For the metabolome data, the time 
points day 2, 8 and 14 are represented by increasingly dark colors, while the common control on day 0 is 
presented in grey. Error bars indicate standard deviation with n = 3. 
 
 
Figure S6.8 Time courses of metabolites, proteins and transcripts in carbon metabolism for HepaRG cells 
treated with valproic acid (VPA) for two weeks. Profiles of selected molecules within carbon metabolism that 
were shown to be particularly affected by 2-week treatment with VPA are depicted. Further, selected enzymes 
within the top 250 significantly altered proteins based on ANOVA were added. Furthermore, the subset was 
completed by the key enzymes of the corresponding pathways. The graph complements figure 6.9 in the main 
body of the chapter and metabolite (M) and protein (P) numbers match. Proteome and transcriptome data were 
normalized to day 0 and plotted in the same graph. The gene name is given in brackets. Proteome data is 
represented by triangles and full lines, whereas transcriptome data is represented as squares with dashed lines. 
VPA concentrations are color coded. Blue, green, yellow and red represent the control and 0.05 mM, 0.15 mM 
and 0.5 mM VPA respectively. For the metabolome data, the time points day 2, 8 and 14 are represented by 
increasingly dark colors, while the common control on day 0 is presented in grey. Error bars indicate standard 
deviation with n = 3. 
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Figure S6.9 Time courses of metabolites, proteins and transcripts in miscellaneous pathways for HepaRG 
cells treated with valproic acid (VPA) for two weeks. Profiles of selected molecules within miscellaneous 
pathways that were shown to be particularly affected by 2-week treatment with VPA are depicted. Further, 
selected enzymes within the top 250 significantly altered proteins based on ANOVA were added. Furthermore, 
the subset was completed by the key enzymes of the corresponding pathways. The graph complements figure 6.9 
in the main body of the chapter and metabolite (M) and protein (P) numbers match. Proteome and transcriptome 
data were normalized to day 0 and plotted in the same graph. The gene name is given in brackets. Proteome data 
is represented by triangles and full lines, whereas transcriptome data is represented as squares with dashed lines. 
VPA concentrations are color coded. Blue, green, yellow and red represent the control and 0.05 mM, 0.15 mM 
and 0.5 mM VPA respectively. For the metabolome data, the time points day 2, 8 and 14 are represented by 
increasingly dark colors, while the common control on day 0 is presented in grey. Error bars indicate standard 
deviation with n = 3. 
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Supplementary tables 
Table S6.1 LC-MS/MS parameters used for valproic acid and its metabolites. Transitions used for 
quantification are highlighted in bold. 
Compound Molecular ion 
(m/z) 
Transition ion 
(m/z) 
Declustering 
potential (V) 
Focusing 
potential (V) 
Collision 
energy (eV) 
VPA 143 143 -40 -140 -15 
VPA-d6 149 149 -20 -120 -5 
VPA-beta-D-
glucuronide 
319 
319 
175 
113 
-40 
-40 
-180 
-180 
-15 
-20 
3-OH-VPA 159 
159 
101 
97 
-40 
-40 
-120 
-120 
-15 
-7 
4-OH-VPA 159 
159 
159 
141 
113 
99 
-60 
-60 
-60 
-90 
-90 
-90 
-18 
-20 
-25 
3-keto-VPA 157 
157 
113 
95 
-30 
-30 
-60 
-60 
-5 
-15 
 
Table S6.2 Reactions used for metabolite balancing. EC, extracellular; IC, intracellular. 
 
 
Reaction 
Number Substrate Product
Reaction 
Number Substrate Product
v1 GlucoseEC GlucoseIC v2 LactateEC LactateIC
v3 PyruvateEC PyruvateIC v4 AlanineEC AlanineIC
v5 ArginineEC ArginineIC v6 AsparagineEC AsparagineIC
v7 AspartateEC AspartateIC v8 GlutamateEC GlutamateIC
v9 GlutamineEC GlutamineIC v10 GlycineEC GlyineIC
v11 HistidineEC HistidineIC v12 IsoleucineEC IsoleucineIC
v13 LeucineEC LeucineIC v14 LysineEC LysineIC
v15 MethionineEC MethionineIC v16 PhenylalanineEC Phenylalanine IC
v17 SerineEC SerineIC v18 ThreonineEC ThreonineIC
v19 TryptophanEC TryptophanIC v20 TyrosineEC TyrosineIC
v21 ValineEC ValineIC v22 UreaEC UreaIC
v23 AlbuminEC AlbuminIC v24 GlucoseIC Glucose-6-phosphate
v25 Glucose-6-phosphate 2 × Glyceraldehyde-3-phosphate v26 Glyceraldehyde-3-phosphate PyruvateIC
v27 PyruvateIC Acetyl-CoA v28 Oxaloacetate + Acetyl-CoA α-Ketoglutarate
v29 α-Ketoglutarate Succinyl-CoA v30 Succinyl-CoA Fumarate
v31 Fumarate Oxaloacetate v32 AlanineIC PyruvateIC
v33 AsparagineIC AspartateIC v34 AspartateIC Oxaloacetate
v35 GlutamateIC α-Ketoglutarate v36 GlutamineIC GlutamateIC
v37 GlyineIC SerineIC v38 HistidineIC GlutamateIC
v39 IsoleucineIC Succinyl-CoA + Acetyl-CoA v40 LeucineIC 3 × Acetyl-CoA
v41 LysineIC 2 × Acetyl-CoA v42 MethionineIC Succinyl-CoA
v43 Phenylalanine IC TyrosineIC v44 SerineIC PyruvateIC
v45 ArginineIC Acetyl-CoA + Glyine IC v46 ThreonineIC GlutamateIC
v47 TyrosineIC Acetyl-CoA v48 ValineIC Succinyl-CoA
v49 TryptophanIC PyruvateIC v50 ArginineIC UreaIC
v51 AspartateIC Fumarate + ArginineIC v52 PyruvateIC LactateIC
v53 62 × AlanineIC + 24 × ArginineIC + 
17 × AsparagineIC + 36 × AspartateIC + 62 × 
GlutamateIC + 20 × GlutamineIC + 12 × 
GlycineIC + 16 × HistidineIC + 
8 × IsoleucineIC + 61 × LeucineIC + 
59 × LysineIC + 6 × MethionineIC + 
31 × PhenylalanineIC + 24 × SerineIC + 28 × 
SerineIC + 1 × TryptophanIC + 
18 × TyrosineIC + 41 × ValineIC
AlbuminIC
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Table S6.3 Dynamic formation of CYP450 products in the course of 14-day valproic acid (VPA) treatment 
with different concentrations. Absolute values are given in amol/(cell × h), determined via LC-MS. SD, 
standard deviation. 
 
  
Mean SD Mean SD Mean SD Mean SD
Untreated 29.3 1.2 57.5 2.4 49.4 3.2
0.05 mM VPA 27.8 2.6 47.7 4.0 37.6 4.8
0.15 mM VPA 26.9 2.0 41.4 2.6 31.1 3.7
0.5 mM VPA 22.7 1.8 27.5 0.4 15.6 0.9
Untreated 71.2 3.2 85.6 12.9 112.3 9.2
0.05 mM VPA 68.9 1.0 110.5 11.9 69.4 9.7
0.15 mM VPA 75.0 2.7 77.4 6.5 43.0 38.7
0.5 mM VPA 49.0 44.3 89.7 54.2 75.0 2.9
Untreated 46.6 4.4 59.6 7.5 45.9 8.4
0.05 mM VPA 47.1 5.9 62.5 4.4 34.6 5.0
0.15 mM VPA 53.8 3.1 76.8 21.3 36.8 1.6
0.5 mM VPA 52.6 14.3 85.0 7.3 36.6 2.5
Untreated 166.7 21.4 379.4 31.7 323.5 29.2
0.05 mM VPA 151.8 7.2 322.0 39.6 245.9 22.3
0.15 mM VPA 142.2 8.7 283.9 30.0 202.0 9.6
0.5 mM VPA 130.7 19.3 163.3 10.6 114.4 23.1
1.7
C
Y
P
2
B
6
C
Y
P
3
A
4
Product formation 
[amol/(cell × h)]
16.4 1.0
0 0
16.6 3.8
108.9
Day 14Day 8Day 2Day 0
C
Y
P
2
D
6
C
Y
P
1
A
2
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Table S6.4 List of altered metabolites during 14-day valproic acid (VPA) exposure. Metabolites correspond 
to highlighted metabolites in figure 6.8, i.e. those with a p-value of 0.05 or lower and an absolute log2 fold 
change of at least 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.05 mM 0.15 mM 0.5 mM 0.15 mM 0.5 mM 0.5 mM 0.05 mM 0.15 mM 0.5 mM 0.15 mM 0.5 mM 0.5 mM 0.05 mM 0.15 mM 0.5 mM 0.15 mM 0.5 mM 0.5 mM
10-Formyltetrahydrofolate X X X X X
1-(sn-Glycero-3-phospho)-1D-myo-inositol X X
2-O-a-L-Fucopyranosyl-galactose X
5-Tetradecenoic acid X X X
Caprylic acid X X X
Demethylphylloquinone X
Dihydrothymine X
Fumaric acid X X
Glutaminyl-Methionine X
Glycerol 3-phosphate X X X
Hypogeic acid X
Imidazole-4-acetaldehyde X X
Indoleacetyl glutamine X
Inosinic acid X
L-Cystathionine X X X X X
L-Glutamine X X X X
L-Histidine X
L-Malic acid X X X
LysoSM(d18:1) X X X X X X
N-Acetylglutamine X X X
NADH X X X
Norophthalmic acid X
Octanoyl-CoA X X X X
Ophthalmic acid X X X X
Pantothenic acid X
Succinyladenosine X X X
Taurine X X X X
Tetrahydroaldosterone-3-glucuronide X
Unknown139 X
Unknown152 X
Unknown17 X X X
Unknown183 X X X
Unknown191 X
Unknown192 X X X X X X X X X
Unknown193 X
Unknown201 X X
Unknown210 X X X
Unknown222 X X X X
Unknown24 X X X
Unknown242 X X X X X X
Unknown254 X X X
Unknown260 X
Unknown276 X X X
Unknown317 X X
Unknown321 X X X X X
Unknown345 X
Unknown355 X X X X
Unknown356 X X X
Unknown376 X X X X
Unknown387 X X
Unknown39 X X X
Unknown428 X
Unknown44 X
Unknown443 X X
Unknown475 X
Unknown511 X
Unknown513 X
Unknown532 X X X
Unknown555 X
Unknown574 X
Unknown589 X X
Unknown6 X X X X X
Unknown616 X X
Unknown649 X
Unknown661 X
Unknown726 X X X X X
Unknown734 X
Unknown751 X X X X X X
Valproic acid glucuronide X X X X X X X X X X
0.05 mMMetabolite
Day 2 Day 8 Day 14
Ctrl 0.05 mM
VS
Ctrl 0.05 mM Ctrl
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